woman
admit
emerg
room
complaint
abdomin
pain
gener
muscl
pain
cramp
dark
urin
last
last
five
day
well
orient
bodi
temperatur
blood
pressur
mmhg
puls
rate
system
examin
reveal
patholog
find
biochem
test
show
elev
level
alt
ul
ast
ul
ldh
ul
creatinin
mgdl
bun
mgdl
viral
hepat
leptospirosi
hepatoren
syndrom
consid
differenti
diagnosi
patient
transfer
infecti
diseas
depart
diabet
hypertens
year
take
gliclazid
mgday
lisinopril
mgday
also
take
clinic
microbiolog
infect
volum
supplement
urinari
tract
infect
frequent
site
nosocomi
infect
account
approxim
nci
catheter
risk
factor
predispos
uti
two
hundr
sixtysix
strain
catheter
patient
isol
strain
case
identifi
nci
case
identifi
commun
acquir
infect
isol
strain
found
gramneg
bacilli
aureu
candida
isol
organ
common
nci
communityacquir
infect
nosocomi
infect
higher
urolog
ward
ward
involv
abstract
object
recent
din
alter
recommend
test
betalactamas
inhibit
effect
sulbactam
presenc
constant
concentr
mgl
instead
e
coli
n
ertapenem
imipenem
meropenem
rang
k
pneumonia
n
rang
mic
object
antimicrobi
resist
nosocomi
isol
especi
intens
care
unit
icu
increas
worldwid
aim
analysi
assess
vitro
activ
meropenem
mem
eight
antibiot
gramneg
isol
paediatr
icu
method
eight
hundr
eighti
gramneg
isol
obtain
clinic
specimen
children
hospit
icu
isol
identifi
use
convent
method
minimum
inhibitori
concentr
mic
mem
imipenem
imp
piperacillin
tazobactam
taz
cefotaxim
ctx
ceftazidim
caz
cefepim
cpe
gentamicin
gm
tobramycin
tm
ciprofloxacin
cip
determin
use
nccl
agar
dilut
method
health
care
issu
public
health
pharmacoeconom
malaria
problem
afghanistan
malaria
scan
result
turkish
medic
aid
group
war
ya
ner
se
okutan
e
artinyan
b
kocazeybek
istanbul
tr
object
malaria
parasit
infect
caus
plasmodium
speci
especi
seen
tropic
subtrop
area
aim
evalu
effect
infect
afghanistan
endem
place
malaria
sever
socioeconom
lost
war
also
compar
data
one
record
war
method
blood
sampl
taken
malaria
suspect
patient
come
health
centr
establish
medic
group
istanbul
medic
faculti
afghanistan
blood
sampl
screen
use
optim
rapid
malaria
test
giemsa
stain
method
result
patient
diagnosi
malaria
patient
agent
infect
p
falciparum
patient
agent
plasmodium
speci
conclus
report
data
malaria
afghanistan
limit
studi
carri
afghan
refuge
border
countri
studi
given
data
collect
present
afghan
peopl
live
home
countri
even
war
emphas
increas
import
infect
afghanistan
malaria
endem
sever
socioeconom
damag
war
preval
salmonella
carrier
among
food
handler
hamadan
western
iran
r
yousefi
mashouf
ranjbar
hamadan
ir
object
salmonella
one
major
caus
human
diseas
relat
food
consumpt
infect
individu
recov
infect
becom
temporari
perman
carrier
harbour
organ
gallbladd
biliari
tract
rare
intestin
object
studi
preval
typhi
paratyphi
carrier
among
food
handler
method
studi
person
work
suppli
distribut
foodstuff
investig
fecal
sampl
food
handler
collect
cultur
suitabl
media
organ
identifi
relev
antisera
data
gather
questionnair
analys
use
statist
softwar
result
stool
cultur
case
posit
salmonella
speci
two
typhi
two
paratyphi
b
one
salmonella
nontyphi
posit
case
test
one
month
one
nontyphi
neg
cultur
rate
infect
conclus
result
show
preval
typhi
paratyphi
carrier
among
food
handler
hamadan
approxim
similar
third
world
countri
sinc
food
handler
carrier
high
risk
transit
organ
involv
foodborn
diseas
must
check
regularli
health
seropreval
haemophilu
influenza
type
b
children
age
year
old
region
primari
health
care
unit
antalya
turkey
object
aim
studi
determin
natur
immun
haemophilu
influenza
type
b
hib
contribut
factor
children
limit
data
seropreval
hib
turkey
method
present
studi
perform
healthi
children
age
month
live
region
primari
health
care
unit
number
antalya
total
children
select
sampl
child
vaccin
hib
probabl
factor
ask
parent
children
affect
hib
natur
immun
questionnair
form
fill
us
blood
sampl
taken
children
capsular
polysaccharid
specif
igg
antibodi
antiprp
level
determin
sera
eia
method
microgramml
accept
posit
limit
level
antiprp
igg
antibodi
depend
independ
variabl
evalu
statist
method
result
antibodi
level
lml
antibodi
level
lml
children
studi
group
signific
relationship
found
geometr
mean
titr
antibodi
year
interv
p
relationship
establish
hib
natur
immun
frequenc
upper
respiratori
tract
infect
bronchopneumonia
p
signific
relationship
found
natur
immun
age
gender
breastfeed
socioeconom
level
attend
day
care
center
number
sibl
exposur
otiti
media
sinus
p
conclus
studi
determin
natur
immun
rate
high
even
earli
age
antalya
fact
evalu
nation
wide
surveil
programm
invas
hib
diseas
nasopharyng
colonis
rate
make
decis
hib
routin
vaccin
turkey
determin
quantiti
aflatoxin
contamin
tradit
uf
chees
shiraz
iran
alborzi
b
pourabba
hanifpour
rashidi
shiraz
ir
object
aflatoxin
toxic
mold
metabolit
produc
toxigen
strain
aspergillu
speci
import
role
occurr
human
diseas
liver
cancer
chronic
hepat
cirrhosi
anim
eat
foodstuff
contain
aflatoxin
toxin
metabol
excret
aflatoxin
milk
aflatoxin
resist
thermal
inactiv
destroy
complet
pasteur
autoclav
food
process
procedur
aim
studi
evalu
quantiti
aflatoxin
contamin
uf
tradit
chees
comparison
primari
milk
contamin
shiraz
citi
iran
method
fortyeight
uf
chees
tradit
chees
milk
sampl
use
produc
chees
collect
one
chees
factori
shiraz
amount
aflatoxin
sampl
determin
elisa
test
use
ridascreen
aflatoxin
kit
rbiopharm
germani
aflatoxin
solubl
polar
compound
water
phase
centrifug
milk
sampl
methanol
phase
chees
sampl
prepar
solvent
methanol
pb
buffer
heptan
use
determin
quantiti
aflatoxin
result
thirti
per
cent
milk
sampl
contamin
maximum
toler
level
ngkg
rang
aflatoxin
contamin
uf
chees
sampl
ngkg
tradit
chees
sampl
ngkg
none
uf
tradit
chees
sampl
contamin
maximum
toler
level
accept
european
countri
ngkg
studi
show
transform
milk
uf
tradit
chees
aflotoxin
erad
whey
respect
aflatoxin
remain
respect
show
statist
differ
uf
tradit
chees
contamin
aflatoxin
conclus
although
pasteur
milk
contamin
maximum
toler
level
aflatoxin
none
chees
produc
pasteur
milk
contamin
maximum
toler
level
conclud
aflatoxin
solubl
polar
compound
gone
whey
littl
remain
chees
evalu
awar
healthcar
worker
standard
health
precaut
isol
jamshidi
jamshidi
bandar
abba
ir
object
evalu
knowledg
health
care
worker
health
precaut
associ
method
descript
studi
done
health
care
worker
work
teach
hospit
hormozgan
univers
medic
scienc
southern
iran
data
collect
give
question
includ
question
knowledg
healthcar
worker
hcw
standard
prevent
health
precaut
demograph
data
result
questionnair
analys
epi
program
find
associ
use
fisher
test
chisquar
classifi
hcw
accord
score
take
four
group
good
b
moder
c
weak
weak
result
one
hundr
ninetyon
health
care
worker
particip
program
femal
averag
age
averag
work
experi
year
health
care
worker
group
group
b
group
c
group
statist
signific
correl
score
age
sex
work
experi
signific
correl
differ
hospit
differ
ward
high
score
seen
paediatr
hospit
icu
ccu
emerg
ward
conclus
result
studi
show
awar
healthcar
worker
prevent
precaut
enough
univers
educ
program
field
necessari
crimeancongo
haemorrhag
fever
arbovir
zoonot
infect
sever
case
report
iran
measur
antibodi
level
crimeancongo
haemorrhag
fever
among
local
import
sheep
isfahan
provinc
presenc
tick
bodi
main
purpos
studi
cross
section
studi
perform
among
local
amount
import
sheep
regard
presenc
igg
antibodi
crimeancongo
haemorrhag
fever
tick
bodi
studi
made
special
help
arboviru
laboratori
iranian
pasteur
institut
local
import
sheep
seroposit
result
data
statist
meaningless
p
tick
found
bodi
surfac
local
sheep
among
import
one
total
absent
result
studi
reveal
endem
spread
cchf
sheep
isfahan
provinc
need
special
attent
prevent
infect
commun
occup
exposur
object
role
helicobact
pylori
hp
mani
gastrointestin
disord
peptic
ulcer
gastriti
intestin
metaplasia
stomach
cancer
establish
order
determin
risk
factor
infect
studi
done
method
two
hundr
thirtytwo
patient
gastrointestin
sign
studi
endoscopi
done
internist
biopsi
antrum
taken
specimen
process
shandon
tissu
processor
citadel
prepar
slide
stain
hematoxycillin
eosin
also
giemsa
two
pathologist
one
microbiologist
studi
slide
patient
blood
group
determin
patient
data
includ
age
sex
smoke
residenti
statu
clinic
sign
patholog
diagnosi
blood
group
record
analys
result
patient
femal
male
patient
women
men
show
hp
infect
frequenc
infect
femal
male
patient
age
group
age
group
year
hp
detect
first
group
second
group
rural
urban
show
hp
infect
frequent
blood
group
b
smoke
patient
patient
histori
smoke
show
infect
hp
infect
activ
gastriti
inact
gastriti
intestin
metaplasia
common
symptom
epigastr
pain
least
common
hiccup
vomit
conclus
frequenc
hp
infect
high
relat
age
sex
clinic
sign
hp
infect
person
blood
group
b
predipos
hp
smoker
high
risk
hp
infect
differ
urban
rural
studi
preval
aetiolog
outcom
septic
shock
patient
admit
obstetr
gynecolog
depart
z
shahshahan
boroomand
isfahan
ir
object
incid
sepsi
precursor
septic
shock
continu
increas
past
decad
aim
studi
evalu
outcom
aetiolog
septic
shock
iranian
patient
method
year
examin
blood
urin
uteru
discharg
cultur
patient
known
case
septic
shock
outcom
aetiolog
patient
record
result
four
hundr
patient
mean
age
rang
includ
preval
aetiolog
septic
abort
endometr
pyelonephr
chorioamnion
die
result
cultur
e
coli
klebsiella
enterobact
sp
streptococcu
sp
other
conclus
accord
studi
illeg
abort
common
caus
septic
shock
therefor
educ
effect
method
contracept
recommend
women
coinfect
salmonella
typhi
salmonella
paratyphi
giardia
lambl
travel
abroad
introduct
experienc
case
coinfect
salmonella
typhi
salmonella
paratyphi
giardia
lambl
travel
abroad
case
korean
male
year
old
travel
india
thailand
two
week
januari
first
febril
sens
day
later
travel
start
wateri
diarrhoea
time
day
week
return
republ
korea
visit
outpati
clinic
divis
infecti
diseas
hospit
drink
water
bottl
complet
cork
food
sold
side
street
india
thailand
acut
ill
look
patient
bodi
temperatur
puls
rate
respir
rate
blood
pressur
mmhg
physic
examin
shown
dehydr
tongu
decreas
skin
turgor
remark
find
laboratori
find
cbc
wbc
neutrophil
lymphocyt
monocyt
hemoglobin
gdl
platelet
chemistri
ast
iul
alt
iul
albumin
gdl
total
cholesterol
mgdl
peripher
blood
smear
malaria
neg
stool
occult
blood
posit
examin
stool
wet
smear
microcopi
discov
trophozoit
giardia
lambl
prescrib
metronidazol
mg
tid
po
patient
fever
decreas
three
day
later
forth
hospit
day
salmonella
typhi
isol
blood
cultur
ad
ciprofloxacin
mg
bid
po
patient
bodi
temperatur
normal
four
day
later
antibiot
administ
day
discharg
hospit
result
followup
stool
cultur
neg
three
day
later
high
fever
hospit
salmonella
paratyphi
isol
blood
cultur
question
salmonella
paratyphi
isol
previou
blood
stool
cultur
erad
despit
administ
ciprofloxacin
outbreak
salmonella
paratyphi
hospit
commun
eaten
admiss
discharg
prescrib
ciprofloxacin
mg
bid
po
day
later
cure
recur
conclus
although
know
correct
caus
late
onset
salmonella
paratyphi
bacteraemia
suggest
strongli
coinfect
three
pathogen
caus
foodborn
infect
travel
object
ceftobiprol
bpr
formerli
first
new
class
cephalosporin
broadspectrum
activ
toward
wide
rang
gramneg
gramposit
hospitalacquir
pathogen
includ
mrsa
pseudomona
aeruginosa
pa
common
nosocomi
pathogen
develop
high
resist
rate
variou
antibiot
studi
investig
vitro
activ
bpr
commonli
use
antipseudomon
antibiot
collect
clinic
p
aeruginosa
isol
method
total
organ
origin
hospit
europ
belgium
franc
germani
itali
spain
n
throughout
usa
n
studi
isol
nonrepeat
isol
hospit
patient
mic
bpr
ceftazidim
ciprofloxacin
imipenem
piperacillintazobactam
tobramycin
determin
broth
microdilut
accord
nccl
guidelin
bpr
breakpoint
use
mgl
suscept
mgl
intermedi
mgl
resist
result
similar
recent
report
isol
imipenem
resist
eu
usa
respect
mg
l
eu
us
respect
pa
isol
inhibit
bpr
compar
ceftazidim
two
drug
exhibit
high
degre
crossresist
conclus
addit
antimrsa
activ
spectrum
activ
bpr
toward
p
aeruginosa
resembl
ceftazidim
pharmacokinet
pharmacodynam
drug
interact
toler
import
infect
organ
antibiot
penetr
middl
ear
experiment
otiti
media
object
determin
rate
antibiot
penetr
experiment
acut
otiti
media
caus
streptococcu
pneumonia
sp
haemophilu
influenza
hi
combin
sp
hi
method
gerbil
model
otiti
media
caus
either
sp
hi
sp
plu
hi
induc
anim
sbc
treat
amoxicillin
amx
cefuroxim
cxm
erythromycin
eri
h
bacteri
challeng
antibiot
efficaci
evalu
clinic
bacteriolog
antibiot
concentr
determin
serum
healthi
anim
well
middl
ear
min
drug
administr
infect
anim
result
percentag
drug
penetr
middl
ear
anim
otiti
media
relat
inocul
organ
follow
conclus
rate
penetr
middl
ear
betalactam
antibiot
rang
approxim
anim
infect
sp
alon
combin
hi
rate
approxim
organ
involv
hi
erythromycin
rate
penetr
rang
approxim
whatev
microorgan
involv
penetr
telithromycin
nasal
mucosa
ethmoid
bone
patient
ts
kuehnel
c
schurr
k
lotter
f
kee
regensburg
object
ketolid
telithromycin
focus
spectrum
activ
respiratori
tract
pathogen
includ
penicillinand
erythromycinresist
pneumococci
well
intracellular
atyp
bacteria
aim
present
studi
investig
penetr
telithromycin
nasal
mucosa
ethmoid
bone
patient
provid
kinet
data
method
studi
design
exploratori
popul
kinet
trial
total
patient
undergo
rhinosurgeri
chronic
sinus
evalu
patient
receiv
singl
oral
dose
telithromycin
mg
sampl
blood
nasal
mucu
nasal
mucosa
ethmoid
bone
collect
surgeri
h
postdrug
administr
drug
concentr
determin
hplc
fluorimetr
detect
result
telithromycin
mean
sd
concentr
h
administr
list
tabl
achiev
concentr
gener
common
pathogen
upper
respiratori
tract
infect
pneumonia
mgl
aureu
mssa
mgl
catarrhali
mg
l
data
protekt
surveil
studi
rel
clinic
microbiolog
infect
volum
supplement
system
exposur
express
ratio
area
concentrationtim
curv
tissu
vs
plasma
nasal
mucu
nasal
mucosa
ethmoid
bone
respect
chinolon
significantli
increas
releas
clinic
vtec
vitro
object
verotoxinproduc
escherichia
coli
vtec
caus
hemolyticurem
syndrom
hu
mostli
children
children
hospitalis
intens
care
unit
given
antibiot
prophylaxi
howev
recogn
certain
antimicrobi
drug
capac
enhanc
releas
verotoxin
investig
influenc
antimicrobi
drug
use
gramneg
bacteria
clinic
vtec
vitro
clinic
vtec
strain
isol
child
suffer
hu
incub
ampicillin
sulbactam
meropenem
cefepim
piperacilin
piperacillin
tazobactam
cefotaxim
ceftazidim
gentamicin
amikacin
ciprofloxacin
trimethoprimesulfamethoxazol
use
dilut
method
h
h
incub
verotoxin
separ
presenc
verotoxin
confirm
elisa
monoclon
antibodi
use
ttest
statist
analysi
result
base
elisa
test
found
signific
increas
decreas
verotoxin
releas
h
incub
howev
h
incub
found
ciprofloxacin
p
significantli
induc
product
verotoxin
verotoxin
releas
clinic
vtec
strain
significantli
decreas
meropenem
amikacin
p
compar
clinic
vtec
strain
incub
without
antibiot
conclus
antimicrobi
drug
play
role
inhibitor
bacteri
growth
activ
product
import
virul
factor
therefor
import
isol
vtec
hu
patient
also
detect
influenc
antibiot
use
prophylaxi
hospit
verotoxin
product
isol
strain
continu
versu
intermitt
intraven
administr
antibiot
metaanalysi
randomis
control
trial
kasiak
g
sermaid
michalopoulo
e
soteriad
falaga
athen
gr
boston
usa
background
intermitt
intraven
administr
antibiot
first
line
approach
manag
sever
infect
worldwid
howev
potenti
benefit
altern
mode
administr
antibiot
includ
continu
intraven
infus
deserv
evalu
perform
metaanalysi
random
control
trial
rct
compar
effect
toxic
continu
versu
intermitt
mode
intraven
administr
variou
antibiot
method
data
metaanalysi
identifi
pubm
current
content
cochran
central
regist
control
trial
refer
relev
articl
rct
compar
continu
intermitt
intraven
administr
antibiot
regimen
examin
effect
mortal
andor
toxic
includ
analysi
experiment
trial
studi
focus
pharmacokinet
andor
pharmacodynam
paramet
trial
concern
antifung
antivir
antiparasit
agent
surgic
prophylaxi
trial
exclud
use
data
conform
standard
outcom
definit
clinic
failur
nephrotox
result
total
comparison
random
control
trial
rct
studi
alactam
aminoglycosid
vancomycin
includ
metaanalysi
public
bia
statist
signific
heterogen
observ
among
analys
studi
better
outcom
observ
continu
intraven
administr
antibiot
pool
odd
ratio
clinic
failur
comparison
rct
ci
continu
compar
intermitt
intraven
administr
regard
mortal
comparison
rct
nephrotox
comparison
rct
differ
found
pool
odd
ratio
ci
mortal
nephrotox
ci
ci
respect
compar
continu
intermitt
intraven
administr
antibiot
conclus
compar
intermitt
continu
intraven
administr
antibiot
effici
regard
clinic
effect
era
gradual
increas
resist
rate
among
pathogen
potenti
advantag
continu
intraven
administr
antibiot
sever
clinic
outcom
investig
penetr
moxifloxacin
rat
mandibular
bone
soft
tissu
object
odontogen
infect
result
submucos
infiltr
abscess
abl
penetr
facial
softtissu
bone
mix
infect
mainli
caus
facult
oblig
anaerob
base
vitro
activ
new
antibiot
moxifloxacin
mxf
seem
suit
antibiot
therapi
odontogen
infect
aim
experiment
studi
determin
level
mxf
plasma
soft
tissu
masset
mandibl
method
fortynin
male
fast
albino
wistar
rat
age
week
weigh
g
use
throughout
studi
dose
mgkg
mfx
dissolv
water
administ
oral
per
gavag
blood
sampl
anim
mfx
control
obtain
h
h
h
h
h
h
h
respect
administr
rat
kill
ketalar
mgkg
im
tissu
sampl
collect
homogen
tissu
sampl
protein
precipit
sampl
analys
hplcfluoresc
detect
assay
pharmacokinet
evalu
conduct
base
noncompartment
analysi
result
mfx
concentr
lower
limit
quantit
measur
h
h
administr
exposur
term
auc
amount
lg
hl
plasma
lg
hkg
mandibl
lg
hkg
masset
concentrationtim
curv
tissu
plateaushap
compar
plasma
calcul
auc
ratio
tissu
plasma
masset
plasma
mandibl
plasma
conclus
administr
antibiot
consid
import
part
therapi
andor
surgic
procedur
maxillofaci
area
good
penetr
bone
muscl
tissu
demonstr
wistar
rat
mxf
might
option
clinic
applic
base
experiment
data
control
studi
evalu
clinic
efficaci
mxf
also
compar
antibiot
pharmacokinet
pharmacodynam
aspect
high
dose
oral
levofloxacin
therapi
bone
infect
p
vial
f
pea
l
scudel
f
pavan
crapi
londero
f
cristini
furlanut
udin
object
assess
pharmacokinet
pharmacodynam
aspect
high
dose
oral
levofloxacin
therapi
bone
infect
due
fulli
suscept
organ
method
patient
microbiolog
document
bone
infect
treat
institut
oral
levofloxacin
includ
present
analysi
two
regimen
routin
use
accord
age
bodi
weight
renal
function
mg
bid
mg
qd
accord
differ
isol
activ
antibiot
administ
patient
underw
weekli
clinic
biochem
plasma
therapeut
drug
monitor
tdm
dosag
adjust
made
accord
plasma
level
maintain
optim
exposur
outcom
assess
week
treatment
week
disciti
least
month
end
treatment
result
fifteen
patient
includ
mean
age
year
sd
male
mean
weight
kg
sd
median
creatinin
clearanc
mlmin
rang
pt
prosthet
joint
infect
posttraumat
ostheomyel
ptom
spondilodis
septic
arthriti
infect
monomicrobi
case
mssa
con
e
faecali
e
coli
k
ozaena
polymicrobi
con
paeruginosa
mssa
mrsa
one
isol
mrsa
levofloxacinsuscept
avail
mic
isol
rang
mcgml
mean
administ
dosag
mgkgdaili
sd
averag
c
min
c
max
overal
treatment
mcgml
respect
averag
c
max
mic
ratio
five
patient
punctual
mic
median
treatment
durat
day
rang
month
follow
end
treatment
pt
deem
cure
clinic
c
reactiv
protein
normal
patient
levofloxacin
fail
prosthet
joint
infect
infect
prosthesi
remov
ptom
drug
withdraw
necessari
due
advers
event
pt
experienc
mild
arthralgi
conclus
experi
tdm
tailor
high
daili
dose
oral
levofloxacin
enabl
adequ
plasma
level
high
cure
rate
signific
advers
event
throughout
longterm
treatment
plasma
drug
level
monitor
exceedingli
use
tool
manag
bone
infect
suggest
dose
reduct
pt
risk
advers
event
dose
increas
pt
suboptim
expos
penetr
levofloxacin
sinus
mucosa
patient
chronic
sinus
follow
oral
administr
singl
mg
dose
f
pea
g
marioni
f
pavan
r
bottin
staffieri
furlanut
udin
padua
object
assess
levofloxacin
penetr
sinus
mucosa
patient
chronic
sinus
undergo
function
endoscop
sinus
surgeri
fess
method
seven
patient
mean
sd
age
yr
weight
kg
sex
mf
clcr
mlminkg
administ
standard
mg
singl
oral
dose
levofloxacin
h
n
h
n
h
n
surgic
intervent
intraop
mucos
tissu
blood
sampl
collect
simultan
patient
fess
intent
assess
compar
plasma
tissular
concentr
levofloxacin
levofloxacin
concentr
plasma
tissu
homogen
analys
mean
valid
hplc
method
result
levofloxacin
concentr
plasma
mcgml
tissu
homogen
mcgg
respect
h
rang
mcgml
mcgg
h
mcg
ml
mcgg
h
rang
mcgml
mcgg
tissuetoplasma
ratio
levofloxacin
differ
sampl
time
rang
conclus
preliminari
find
suggest
singl
mg
oral
dose
levofloxacin
may
ensur
therapeut
effect
concentr
sinus
mucosa
patient
chronic
sinus
note
consid
fluoroquinolon
exhibit
concentrationdepend
bactericid
activ
optim
exposur
may
achiev
peaktom
ratio
achiev
data
enabl
conclud
singl
mg
oral
dose
levofloxacin
may
ensur
effect
exposur
sinus
mucosa
bacteri
pathogen
mic
mcgml
valu
lower
pathogen
usual
respons
bacteri
sinus
accordingli
pharmacokinet
data
consist
levofloxacin
mg
daili
effect
antibiot
treatment
bacteri
sinus
situat
mimic
viral
hepat
statin
induc
rhabdomyolysi
fluvastatin
mgday
hypercholesterolemia
year
chang
simvastatin
mgday
last
two
month
doctor
biochem
test
reveal
serum
cpk
ul
dilut
serum
sampl
myoglobin
ngml
viral
hepat
panel
leptospira
microagglutin
test
neg
renal
function
rapidli
deterior
diagnos
statin
rhabdomyolysi
underw
hemodialysi
patient
slowli
improv
recov
hemodialysi
discontinu
statin
drug
incid
rhabdomyolysi
statin
monotherapi
report
patient
take
high
dose
statin
unawar
side
effect
patient
take
statin
inform
side
effect
drug
rational
higher
dose
levofloxacin
treatment
seriou
infect
j
kahn
n
davi
raritan
usa
backgroundobject
advanc
medic
care
continu
associ
improv
surviv
rate
better
patient
qualiti
life
consequ
develop
increas
vulner
seriou
infect
due
tradit
pathogen
commens
rel
avirul
organ
may
resist
multipl
antimicrobi
agent
new
antibacteri
agent
horizon
one
strategi
deal
threat
maxim
util
antibacteri
drug
dose
ration
purpos
paper
summar
rational
util
higher
dose
levofloxacin
manag
seriou
infect
method
review
report
avail
data
subject
expos
daili
levofloxacin
dose
mg
result
seven
year
use
us
levofloxacin
maintain
excel
suscept
profil
drug
level
seen
infect
patient
significantli
higher
achiev
healthi
volunt
enabl
coverag
organ
higher
mic
concentrationdepend
bactericid
activ
higher
dose
levofloxacin
increas
speed
thorough
bacteri
erad
vitro
inhibit
emerg
fluoroquinolon
resist
studi
organ
clinic
trial
mg
dose
undertaken
complic
skin
skin
structur
infect
nosocomi
pneumonia
febril
neutropenia
result
least
equival
compar
agent
use
dose
communityacquir
pneumonia
acut
bacteri
exacerb
chronic
bronchiti
allow
rapid
resolut
symptom
shorten
cours
therapi
dose
healthi
volunt
mg
per
day
result
signific
alter
advers
event
profil
clinic
trial
data
show
safeti
mg
daili
similar
mg
form
conclus
levofloxacin
document
efficaci
safeti
credenti
clinic
dose
least
mg
daili
higher
dose
attract
candid
monotherapi
seriou
infect
combin
therapi
agent
carbapenem
gener
cephalosporin
addit
clinic
trial
use
approach
seem
warrant
vitro
activ
antimicrobi
agent
introduct
pseudomona
stem
consist
resist
aerobian
gramneg
non
ferment
bacilli
might
caus
variou
human
infect
frequent
agent
intrahospit
infect
purpos
investig
pseudomona
strain
sensit
meropenem
imipenem
materi
method
igo
cc
belgrad
januari
till
septemb
total
strain
pseudomona
variou
patient
materi
isol
isol
strain
sensit
meropenem
imipenem
investig
gel
diffus
techniqu
use
commerci
antimicrobi
suscept
test
disc
oxoid
result
sensit
meropenem
imipenem
regist
show
sensit
meropenem
resist
imipenem
anoth
isol
strain
resist
antibiot
subject
studi
case
sensit
meropenem
investig
sensit
imipenem
test
isol
strain
pseudomona
aeroginosa
strain
sensit
meropenem
imipenem
test
show
sensit
antibiot
sensit
meropenem
resist
either
intermediari
resist
imipenem
resist
investig
antibiot
pseudomona
speci
sensit
meropenem
imipenem
investig
sensit
antibiot
show
sensit
meropenem
resist
imipenem
isol
strain
show
resist
investig
antibiot
conclus
isol
pseudomona
strain
demonstr
high
resist
imipenem
investig
period
pseudomona
strain
resist
meropenem
isol
first
time
ever
consid
karbapenem
drug
choic
treatment
multiresist
strain
appear
high
resist
point
necess
ration
use
bacteri
caus
nosocomi
infect
associ
short
long
termcathet
studi
effect
antibiot
saureu
vancomycin
gramneg
bacilli
effect
antibiot
amikacin
e
coli
tobramycin
p
mirabili
cefotaxim
k
pneumonia
ceftazidim
p
vulgari
e
cloaca
high
level
antimicrobi
resist
notic
among
p
aeruginosa
activ
antibiot
amikacin
esbl
product
nearli
ncl
commun
acquir
infect
highli
preval
among
isol
p
mirabili
follow
e
coli
isol
show
esbl
activ
rough
comparison
suscept
result
etest
ceftazidim
strip
disc
diffus
agar
dilut
method
detect
suscept
test
organ
antibiot
use
regard
plasmid
profil
seem
particular
associ
plasmid
content
esbl
activ
isol
nosocomi
strain
e
coli
p
mirabili
explain
interspeci
relationship
object
bacteraemia
repres
seriou
complic
hospit
patient
problem
therapi
bacteraemia
increas
emerg
antibiot
resist
aim
studi
monitor
preval
pathogen
trend
resist
bacteria
isol
blood
method
six
univers
clinic
andor
region
hospit
particip
studi
total
isol
collect
microbiolog
diagnosi
perform
accord
standard
method
particip
laboratori
antimicrobi
resist
estim
disc
diffus
method
nccl
result
preval
organ
coagulas
neg
staphylococci
con
staphylococcu
aureu
among
gramneg
bacteria
escherichia
coli
klebsiella
pneumonia
pseudomona
aeruginosa
follow
enterococci
enterobact
spp
acinetobact
spp
con
aureu
suscept
vancomycin
resist
oxacillin
observ
con
aureu
isol
enterococcu
spp
isol
fulli
suscept
vancomycin
teicoplanin
resist
amoxicillinclavulant
increas
among
e
coli
ciprofloxacinresist
k
pneumonia
isol
increas
despit
ciprofloxacin
togeth
carbapenem
suscept
effect
drug
k
pneumonia
effect
antibiot
p
aeruginosa
meropenem
amikacin
piperacillintazobactam
resist
ceftazidim
increas
among
p
aeruginosa
imipenem
retain
activ
enterobact
spp
isol
consider
increas
resist
ciprofloxacin
resist
meropenem
amikacin
ampicillinsulbactam
cefoperazonsulbactam
acinetobact
spp
rel
low
conclus
staphylococci
ie
con
aureu
identifi
frequent
causal
agent
bacteraemia
studi
period
signific
rise
resist
observ
ciprofloxacin
enterobact
spp
e
coli
k
pneumonia
consider
still
good
activ
carbapenem
gramneg
effici
vancomycin
teicoplanin
gramposit
bacteria
surveil
antibiot
resist
provid
data
effici
antimicrobi
given
local
import
part
measur
maintain
good
antibiot
activ
compar
vitro
activ
ertapenem
esblproduc
e
coli
k
pneumonia
isol
spain
j
r
hernandez
l
romero
c
velasco
l
martinezmartinez
pascual
sevil
e
object
studi
vitro
activ
ertapenem
esblproduc
e
coli
k
pneumonia
isol
spain
method
e
coli
k
pneumonia
isol
spanish
multicentr
studi
perform
hospit
univers
hospit
virgen
macarena
sevil
includ
esbl
product
antimicrobi
suscept
betalactam
betalactam
betalactamas
inhibitor
ciprofloxacin
aminoglycosid
cotrimoxazol
determin
microdilut
nccl
guidelin
ertapenem
activ
analys
accord
clonal
relationship
reppcr
esbltyp
pcr
esblgen
sequenc
acquisit
infect
commun
nosocomi
result
vitro
activ
ertapenem
follow
graphic
isol
suscept
carbapenem
resist
resist
intermedi
isol
esblproduc
e
coli
k
pneumonia
piperacillintazobactam
ciprofloxacin
cotrimoxazol
amikacin
gentamicin
tobramycin
respect
signific
differ
detect
among
clone
found
ertapenem
equal
activ
esbl
famili
shv
tem
ctxm
evalu
four
e
coli
one
k
pneumonia
isol
mic
ertapenem
lgml
still
suscept
rang
exclud
isol
come
hospitalis
patient
differ
activ
observ
accord
origin
infect
conclus
ertapenem
show
excel
invitro
activ
esblproduc
e
coli
k
pneumonia
ertapenem
activ
similar
imipenem
meropenem
higher
antimicrobi
test
differ
activ
observ
accord
geograph
origin
clonal
relationship
type
esbl
effect
betalactamaseinhibitor
concentr
vitro
test
result
piperacillin
tazobactam
piperacillinsulbactam
previous
mgl
present
studi
perform
assess
effect
chang
mic
distribut
e
coli
piperacillinsulbactam
ps
compar
piperacillin
tazobactam
pt
tazobactam
test
concentr
mgl
method
invitro
activ
piperacillin
without
tazobactam
sulbactam
respect
e
coli
n
leipzig
n
berlin
test
mean
microdilut
mic
determin
recommend
din
use
fix
concentr
mgl
tazobactam
well
mgl
sulbactam
result
basi
mic
breakpoint
accord
din
superior
pt
ps
maxim
piperacillinresist
e
coli
minim
piperacillinintermedi
e
coli
recent
recommend
reduct
fix
sulbactam
concentr
mgl
suscept
test
lead
reduc
suscept
piperacillinintermedi
e
coli
result
follow
tabl
conclus
recent
recommend
mgl
fix
concentr
sulbactam
test
procedur
show
invitro
activ
pt
exceed
ps
piperacillinresist
also
piperacillinintermedi
e
coli
result
credibl
stronger
inhibit
lactamas
tazobactam
comparison
sulbactam
inhibit
microbi
adhes
presenc
immun
compound
human
cell
cultur
model
object
compar
evalu
influenc
commerci
prepar
normal
human
immunoglobulin
russia
intraglobin
pentaglobin
biotest
germani
clinic
strain
aureu
adhes
human
embryon
skin
fibroblast
cultur
clinic
isol
aureu
highest
adhes
capac
select
model
coincub
target
cell
cultur
inoculum
prepar
baselin
concentr
cfuml
h
grown
meatpepton
agar
antiadhes
activ
normal
human
immunoglobulin
nhi
intraglobin
pentaglobin
baselin
concentr
lgml
assess
estim
influenc
agent
investig
bacteri
adhes
process
perform
mention
model
coincub
microorgan
targetcel
cultur
well
use
h
preincub
agent
test
also
experi
held
presenc
protein
staphylococcu
cell
wall
well
clostridi
collagenasum
anim
hyaluronidasum
intens
bacteri
adhes
antiadhes
properti
use
compound
express
follow
indic
index
adhes
ia
calcul
mean
number
attach
microb
per
one
eukaryot
cell
percent
affect
cell
monolay
ac
microbi
contamin
monolay
mc
obtain
product
percent
inhibit
bacteri
adhes
ii
calcul
figur
ia
respect
control
result
prepar
reveal
less
signific
inher
antiadhes
activ
vitro
becam
appar
reduct
indic
character
colon
targetcel
effect
prove
prepar
hour
preincub
clinic
isol
aureu
protect
fibroblast
bacteri
adhes
case
conclus
protect
effect
nhi
intraglobin
disappear
addit
protein
collagenasum
hyaluronidasum
nutrient
medium
remain
pentaglobin
accord
specif
polymer
structur
prospect
form
well
content
igm
pentaglobin
possess
much
antiadhes
activ
presenc
protein
collagenasum
hyaluronidasum
presenc
protein
enzym
igm
make
antiadhes
activ
pentaglobin
irrevers
edta
ethylenediamin
tetraacet
acid
enhanc
activ
tetracyclin
p
aeruginosa
increas
drug
accumul
sudano
roccaro
ar
blanco
catania
object
work
investig
potenti
effect
edta
tetracyclin
versu
resist
p
aeruginosa
strain
method
first
assess
mic
determin
effect
edtatetracyclin
associ
two
tetracyclin
resist
p
aeruginosa
strain
next
fluoresc
microscopi
evalu
accumul
tetracyclin
insid
bacteri
cell
presenc
edta
moreov
preexpos
cell
edta
success
wash
tetracyclin
evalu
differ
tetracyclin
accumul
presenc
edta
could
due
effect
bacteri
cell
wall
result
data
show
edta
submic
concentr
abl
reduc
mic
tetracyclin
fluoresc
microscopi
show
cell
presenc
edta
accumul
much
tetracyclin
insid
respect
cell
directli
expos
tetracyclin
alon
also
respect
cell
pre
treat
edta
success
expos
drug
conclus
thu
argu
edta
abl
improv
tetracyclin
mic
resist
p
aeruginosa
strain
permeabil
extern
cell
wall
increas
way
bacteri
tetracyclin
accumul
perhap
interf
drug
extrus
machineri
abstract
discontinu
routin
suscept
test
perform
special
laboratori
therefor
data
activ
substanc
limit
potenc
resist
develop
vancomycin
metronidazol
known
linezolid
new
antimicrob
agent
activ
gramposit
bacteria
method
select
resist
mutant
atcc
strain
mic
mgl
metronidazol
vancomycin
linezolid
perform
supplement
agar
plate
contain
increas
amount
antimicrobi
bacteria
collect
five
agar
plate
h
growth
collect
centrifug
pellet
resuspend
expos
next
higher
antimicrobi
concentr
agar
plate
result
repeat
procedur
sever
time
gener
bacteria
metronidazol
vancomycin
linezolid
gener
respect
bacteria
final
expos
mgl
metronidazol
mgl
vancomycin
mgl
linezolid
use
etest
mhc
valu
mhc
mhc
mhc
mgl
could
confirm
conclus
tig
potent
compound
wide
spectrum
activ
gramposit
gramneg
problemat
bacteria
except
p
aeruginosa
could
altern
colimycin
multiresist
isol
caus
infect
icu
patient
antibiot
resist
metalloblactamas
product
carbapenemresist
pseudomona
acinetobact
object
pseudomona
aeruginosa
infect
major
caus
morbid
mortal
cystic
fibrosi
cf
patient
rate
multiresist
among
pseudomona
aeruginosa
strain
isol
cf
patient
substanti
higher
among
pseudomona
aeruginosa
strain
set
mutat
strain
character
increas
mutat
rate
mainli
due
defect
gene
involv
dna
mismatch
repair
system
previou
studi
link
high
resist
rate
cf
patient
presenc
high
portion
mutat
pseudomona
aeruginosa
strain
foundth
object
studi
investig
proport
mutat
among
multiresist
pseudomona
aeruginosa
cf
patient
germani
method
multiresist
pseudomona
aeruginosa
strain
cf
patient
collect
german
hospit
one
isol
per
patient
permit
multiresist
defin
reduc
suscept
intermedi
resist
accord
din
guidelin
least
four
follow
class
repres
imipenem
ceftazidim
piperacillin
ciprofloxacin
gentamicin
detect
mutat
perform
disk
diffus
mutat
frequenc
determin
triplic
select
rifampicin
agar
plate
previous
defin
strain
design
hypermut
mutat
frequenc
least
higher
wildtyp
strain
result
total
multiresist
pseudomona
aeruginosa
strain
collect
increas
mutat
rate
rang
eight
mutat
strain
show
reduc
suscept
five
four
mutat
strain
four
class
repres
conclus
compar
previou
studi
germani
rate
mutat
strain
also
extrem
high
among
multiresist
pseudomona
aeruginosa
isol
cf
patient
data
underlin
link
hypermut
evolut
antibiot
resist
cf
patient
object
investig
frequenc
resist
p
aeruginosa
fluoroquinolon
detect
gyra
gene
mutat
quinoloneresist
p
aeruginosa
isol
obtain
discharg
sinus
middl
extern
ear
patient
isol
strain
test
suscept
variou
antibiot
resist
ofloxacin
test
point
mutat
gyr
gene
use
singl
strand
conform
polymorph
analysi
sscp
sequenc
select
strain
result
twentyeight
isol
resist
ofloxacin
point
mutat
gyra
gene
detect
quinolon
resist
strain
sscp
howev
direct
sequenc
pcramplifi
gyra
fragment
two
clinic
isol
singl
mutat
threonin
posit
substitut
isoleucin
detect
case
cell
attach
surfac
biofilm
toler
variou
antimicrobi
agent
plankton
counterpart
biofilm
environ
cell
abil
differenti
chang
phenotyp
lead
sever
treatment
problem
mani
case
persist
chronic
infect
approach
address
issu
identifi
specif
resist
subpopul
pseudomona
aeruginosa
biofilm
indic
differenti
play
import
role
context
biofilm
establish
flowchamb
develop
respons
addit
colistin
polymyxin
monitor
confoc
scan
laser
microscopi
timelaps
record
togeth
use
livedead
stain
initi
result
indic
modif
lp
import
factor
relat
colistin
toler
develop
may
initi
cell
differenti
pmr
mutant
biofilm
result
sensit
colistinresult
indic
furthermor
regulatori
connect
composit
cell
envelop
cell
motil
twitch
swarm
way
correl
motil
toler
antimicrobi
agent
tube
biofilm
experi
set
isol
colistin
treat
non
treat
biofilm
materi
analysi
chang
happen
differenti
popul
use
micro
array
lp
analysi
epidemiolog
resist
antibiot
usag
oxacillin
follow
lincosamid
lincomycin
aminoglycosid
notic
aminoglycosid
prescrib
patient
receiv
antibiot
bodi
weight
determin
serum
creatinin
measur
patient
receiv
aminoglycosid
among
prevail
combin
gentamicin
plu
oxacillin
lincomycin
oxacillin
metronidazol
ciprofloxacin
ampicillin
plu
gentamicin
case
total
aminoglycosid
combin
therapi
administ
patient
conclus
penicillin
remain
often
prescrib
antibiot
monotherapi
combin
aminoglycosid
howev
surgeon
often
omit
safeti
recommend
administr
aminoglycosid
strategi
improv
safeti
issu
antimicrobi
therapi
surgeri
implement
prolong
region
arteri
antibiot
infus
manag
sever
acut
pancreat
bihalskyy
chooklin
perejaslov
ivankiv
granat
lviv
ukr
object
develop
purulentsept
complic
main
caus
death
patient
sever
acut
pancreat
sap
first
week
diseas
onset
adequ
antibiot
prophylact
necessari
part
manag
patient
howev
disord
microcircul
typic
necrot
pancreat
permit
achiev
therapeut
concentr
antibiot
inflam
pancrea
due
continu
region
arteri
infus
may
benefit
manag
patient
necrot
pancreat
method
ninetyfour
patient
sap
treat
patient
antibiot
ceftriaxon
gatifloxacin
imipinem
administr
arteri
patient
compil
first
group
rest
patient
control
group
result
balthazar
ranson
score
differ
group
admiss
rate
contamin
necrot
foci
compar
first
week
contamin
necrosi
note
patient
control
group
second
week
purul
complic
sap
note
control
group
one
patient
first
group
receiv
ceftriaxon
conclus
continu
intraarteri
infus
obvious
decreas
risk
contamin
necrot
foci
appli
gatifloxacin
complex
manag
sap
benefit
prevent
purul
complic
amoxicilinclavulon
resist
found
take
consider
drugsensit
observ
use
gener
practic
sensit
norfloxacin
amoxicilinclavulon
conclus
women
gp
care
uti
etiolog
factor
e
coli
fluoroquinolon
amoxicilinclavulon
acid
prefer
drug
use
gp
consid
widespectum
activ
consid
cost
drugsensit
examin
limit
antibiot
frequent
use
gp
extend
spectrum
blactamas
produc
escherichia
coli
kuwait
hospit
object
sinc
ctxm
type
blactamas
constitut
one
rapidli
spread
extendedspectrum
blactamas
esbl
famili
detect
mani
countri
world
aim
studi
genet
characteris
phenotyp
ceftazidim
suscept
cefotaxim
resist
esblproduc
klebsiella
pneumonia
isol
method
speci
identif
perform
bbl
crystal
enf
esbl
express
confirm
e
test
esbl
ctxm
gene
amplifi
pcr
use
consensu
ctxm
primer
conjug
experi
perform
use
escherichia
coli
rifampin
resist
ctxm
gene
transconjug
detect
pcr
amplifield
product
analys
rflp
assign
distinct
group
basi
rflp
profil
analys
use
specif
primer
amplifi
product
sequenc
isol
also
investig
phagetyp
genom
fingerprint
ericpcr
pfge
plasmid
profil
analysi
set
surveil
system
antimicrobi
resist
use
lowresourc
set
west
delhi
india
object
set
surveil
system
antimicrobi
resist
use
antimicrobi
commun
low
resourc
set
use
e
coli
indictor
organ
method
studi
area
km
radiu
sir
ganga
ram
hospit
new
delhi
india
microbiolog
surveil
msu
collect
case
take
antimicrobi
without
suspect
complic
uti
attend
opd
design
region
e
coli
pathogen
well
contamin
isol
identifi
use
convent
biochem
reaction
suscept
determin
use
kirbi
baur
disc
diffus
method
muller
hinton
agar
antimicrobi
use
surveil
monthli
purchas
antimicrobi
drug
privat
retail
pharmaci
collect
convert
ddd
denomin
drug
use
popul
administr
area
pharmaci
base
addit
exit
interview
prescript
audit
done
pharmaci
inform
consecut
prescript
per
month
antimicrobi
agent
data
use
present
ddd
per
total
number
patientsprescript
result
studi
period
msu
sampl
collect
e
coli
isol
strain
resist
ampicillin
resist
quinolon
tetracyclin
third
gener
cephalosporin
cotrimoxazol
ampicillin
sulbactam
purchas
data
exit
interview
data
analys
month
result
show
fluoroquinolon
frequent
sold
antimicrobi
exit
interview
data
reveal
prescriptionspatientsmonth
fluoroquinolon
penicillin
cephalosporin
macrolid
respect
conclus
extens
usag
quinolon
penicillin
reflect
antimicrobi
resist
decreas
resist
cephalexin
could
notic
studi
period
data
collect
antimicrobi
drug
use
antimicrobi
resist
e
coli
isol
antenat
case
seem
suitabl
collect
inform
resist
use
commun
valuabl
plan
target
intervent
go
project
one
year
fund
agenc
geneva
resist
telithromycin
streptococcu
pneumonia
rare
associ
reduct
bacteri
fit
dj
farrel
jg
hurdl
chopra
london
leed
uk
object
protekt
global
longitudin
studi
antibiot
suscept
bacteri
respiratori
tract
pathogensha
complet
fourth
year
object
studi
determin
global
rate
bacteri
resist
telithromycin
first
ketolid
antibiot
evalu
fit
two
telithromycinresist
streptococcu
pneumonia
isol
rel
put
isogen
telithromycinsuscept
counterpart
method
minimum
inhibitori
concentr
mic
telithromycin
determin
nccl
broth
microdilut
method
interpret
use
nccl
breakpoint
isogen
relationship
telithromycinsuscept
resist
isol
two
independ
set
determin
serotyp
multilocu
sequenc
type
rel
competit
fit
w
telithromycinresist
strain
evalu
establish
procedur
involv
mix
cultur
competit
isogen
pair
telithromycinresist
suscept
strain
result
pneumonia
isol
collect
protekt
studi
exhibit
lowlevel
resist
telithromycin
mic
mgl
highest
mic
mgl
low
rate
telithromycin
resist
observ
across
globe
rang
australasia
middl
east
north
america
central
europ
develop
resist
telithromycin
accompani
moder
reduct
w
one
strain
conclus
clinic
resist
telithromycin
among
pneumonia
rare
low
level
global
preval
around
two
set
isogen
strain
examin
resist
telithromycin
associ
moder
fit
cost
data
suggest
potenti
pneumonia
develop
clinic
relev
resist
telithromycin
may
limit
howev
studi
need
examin
mechan
telithromycin
resist
potenti
genet
adapt
might
reinstat
bacteri
fit
telithromycinresist
strain
clinic
microbiolog
infect
volum
supplement
function
shorter
durat
therapi
improv
bactericid
kill
postantibiot
effect
whilst
reduc
risk
toxic
associ
prolong
treatment
perform
prospect
audit
gentamicin
usag
institut
one
month
period
object
aim
assess
sensit
antibiot
commonli
isol
pathogen
blood
cultur
patient
admit
tertiari
care
hospit
materi
method
analys
result
posit
blood
cultur
last
year
patient
admit
ahepa
univers
hospit
focus
suscept
antibiot
identif
bacteri
isol
antibiot
suscept
perform
vitek
analyz
biomerieux
result
frequent
isol
coagulaseneg
staphylococci
cn
follow
staphylococcu
aureu
acinetobact
calcoaceticu
pseudomona
aeruginosa
e
coli
klebsiella
pneumonia
proteu
spp
klebsiella
spp
proteu
spp
isol
significantli
resist
antibiot
use
e
coli
isol
resist
follow
ampicillin
trimethoprim
sulfamethoxazol
amoxicillinclavulan
acid
aca
cefuroxim
nitrofurantoin
ciprofloxacin
cip
resist
ceftazidim
cfz
imipenem
imi
among
pseudomona
aeruginosa
isol
resist
cfz
cip
imi
tobramucin
resist
piperacillintazobactam
pt
term
site
isol
acinetobact
spp
mainli
isol
surgic
ward
staphylococcu
epidermidi
spp
clinic
acinetobact
spp
isol
examin
show
resist
ampicillinsulbactam
imi
meropenem
pt
cip
con
strain
aureu
isol
resist
oxacillin
far
glycopeptid
resist
concern
con
isol
aureu
sensit
teicoplanin
vrsa
vrse
strain
isol
conclus
one
third
aureu
isol
hospit
methicillin
resist
mrsa
compar
previou
result
observ
signific
increas
resist
rate
pseudomona
aeruginosa
antibiot
except
ceftazidim
well
acinetobact
spp
piperacillin
tazobactam
resist
antibiot
heavi
metal
differ
speci
aeromona
collect
loa
river
chile
factor
influenc
fever
communityacquir
pneumonia
r
sommer
r
rakotoarimanana
lew
la
chauxdefond
ch
object
although
fever
account
one
major
clinic
sign
communityacquir
pneumonia
cap
well
studi
diseas
method
conduct
prospect
observ
studi
involv
adult
patient
hospit
cap
diagnos
idsa
guidelin
measur
axillari
bodi
temperatur
time
day
discharg
causal
pathogen
empir
antibiot
choic
factor
could
influenc
followup
fever
investig
result
patient
requir
hospitalis
cap
present
fever
although
level
fever
decreas
age
statist
signific
mean
durat
fever
day
except
presenc
one
instanc
influenza
viru
shorten
durat
fever
differ
relat
causal
agent
multivari
analysi
show
presenc
empyema
empir
use
quinolon
trovafloxacin
prolong
durat
fever
day
ci
p
day
ci
p
respect
conclus
fever
absent
signific
proport
patient
hospitalis
cap
last
day
appropri
treat
patient
febril
period
exceed
day
presenc
empyema
activ
search
peripher
tcell
lymphoma
masquerad
cellul
blizioti
g
peppa
p
rafailidi
p
vergidi
kapask
p
papastamataki
falaga
athen
gr
object
primari
cutan
nonhodgkin
lymphoma
nhl
encompass
mani
subtyp
lymphoma
name
mycosi
fungoid
lymphoblast
lymphoma
follicular
lymphoma
diffus
larg
bcell
lymphoma
margin
zone
lymphoma
anaplast
larg
cell
lymphoma
peripher
cell
lymphoma
otherwis
specifi
howev
report
cellul
due
lymphoma
method
descript
experi
patient
peripher
tcell
lymphoma
masquerad
cellul
result
greekamerican
male
present
extens
cellul
left
subaxillari
area
patient
evalu
two
hospit
abroad
advis
receiv
antibiot
lead
appreci
improv
supraclavicular
mass
thought
clinic
enlarg
lymph
node
remov
second
hospit
biopsi
show
inflammatori
chang
without
evid
malign
biopsi
mass
left
axillari
fossa
remov
hospit
show
conclus
evid
peripher
tcell
lymphoma
conclus
signific
delay
correct
diagnosi
result
rare
manifest
lymphoma
limit
diagnost
work
includ
biopsi
remov
tissu
clinician
awar
lymphoma
may
present
typic
cellulitislik
lesion
result
report
experi
manag
man
manifest
kyrl
diseas
patient
present
skin
lesion
two
differ
type
face
upper
lower
extrem
old
lesion
larg
hyperkeratot
plaqu
burrow
without
sign
inflamm
newer
lesion
also
hyperkeratot
plaqu
clearli
sign
inflamm
patient
success
manag
combin
surgic
medic
manag
hyperkeratot
old
larg
skin
lesion
manifest
ongo
inflamm
surgic
remov
addit
antimicrobi
therapi
oral
clindamycin
administ
one
month
led
disappear
small
newer
lesion
find
ongo
inflamm
clearli
part
kyrl
diseas
recurr
observ
month
follow
conclus
although
clindamycin
may
antiinflammatori
effect
unrel
antimicrobi
action
observ
control
inflamm
gradual
regress
newer
lesion
clindamycin
suggest
microorgan
probabl
anaerob
bacteria
play
role
pathogenesi
progress
kyrl
diseas
least
initi
stage
skin
lesion
prospect
studi
neck
mass
exclud
thyroid
nodul
one
hospit
introduct
mass
neck
common
clinic
find
present
patient
age
group
differenti
diagnosi
may
extrem
broad
although
mass
due
benign
process
malign
diseas
must
overlook
therefor
import
physician
develop
system
approach
develop
work
diagnosi
manag
plan
patient
clinic
microbiolog
infect
volum
supplement
result
thirtytwo
patient
accept
evalu
find
patient
left
includ
men
women
singl
marri
less
time
neck
mass
less
one
month
month
month
month
month
mass
posit
left
side
neck
right
side
neck
side
midlin
occiput
number
mass
one
mass
mass
mass
also
size
mass
evalu
sign
symptom
common
sign
lymphadenopathi
axilar
hepatomegali
past
histori
object
purpos
studi
evalu
effect
oral
estroprogestin
hormon
replac
therapi
hrt
bacteri
vaginosi
bv
preval
postmenopaus
women
method
one
hundr
thirti
eight
women
age
year
enrol
studi
natur
termin
menstruat
least
month
prior
studi
fifti
eight
group
current
receiv
oral
hrt
tibolon
wherea
group
b
receiv
hrt
oral
transderm
least
past
six
month
vagin
speciment
collect
posterior
fornix
later
vagin
wall
diagnosi
bv
mainstay
nugent
score
method
score
consid
indic
bv
well
presenc
gram
stain
vagin
smear
mean
age
sd
women
group
averag
number
postmenopaus
year
year
rang
year
rang
year
group
b
rang
year
rang
year
respect
preval
bv
group
slightli
lower
among
women
group
b
differ
statist
signific
p
absenc
lactobacilli
vagin
smear
without
symptom
vulvovagin
found
women
group
b
women
group
high
number
lactobacillu
colon
observ
women
receiv
hrt
conclus
treatment
postmenopaus
women
tibolon
statist
signific
effect
preval
howev
seem
affect
lactobacillu
colon
vagina
alter
flora
premenopaus
profil
bacteri
pathogen
associ
acut
diarrhoea
island
crete
greec
resist
antibiot
object
present
case
syndrom
due
tick
bite
case
report
case
syndrom
possibl
due
tick
bite
present
eosinophil
cellul
syndrom
character
skin
erupt
edema
flame
figur
mark
infiltr
eosinophil
dermi
hypersensit
arthropod
bite
cutan
viral
infect
cutan
parasit
infest
toxocariasi
ascariasi
drug
hypersensit
report
etiolog
factor
sixtyyearold
woman
refer
clinic
suspect
erythema
chronicum
migran
erythema
annular
centrifugium
patient
complain
widespread
reddish
elev
sinc
month
tick
bite
lesion
first
appear
scalp
face
spread
bodi
hospit
local
hospit
skin
biopsi
consist
nonspecif
chronic
dermat
antiborrelia
igm
igg
posit
terbinafin
system
local
system
tetracyclin
amoxicillin
clavulan
administ
respons
observ
patient
hospit
clinic
initi
diagnosi
eosinophil
cellul
erythema
chronicum
migran
erythema
annular
centrifugium
dermatolog
examin
reveal
widespread
elev
erythemat
papul
plaqu
cm
diamet
form
coalesc
papul
central
spare
histopatholog
examin
punch
skin
biopsi
show
eosinophil
infiltr
dermi
flame
figur
observ
borrelia
burgdorferi
igg
posit
igm
neg
mark
eosinophilia
note
peripher
blood
sampl
total
ige
elev
mgdl
biochem
paramet
normal
sign
system
borreliosi
found
patient
treat
dapson
mgday
methylprednisolon
mgday
diagnosi
eosinophil
cellul
lesion
tend
resolv
month
therapi
complet
resolut
without
sequel
observ
month
conclus
tick
bite
report
causal
factor
well
syndrom
moreov
arthropod
born
infecti
agent
like
borrelia
burgdorferi
may
also
trigger
factor
dapson
combin
corticosteroid
may
effect
treatment
situat
role
antibiotherapi
acut
phase
infect
controversi
rabdomyolysi
complic
shigella
flexneri
acut
gastroenter
c
papaefstathi
diakaki
k
mitsoura
marioli
g
kouppari
athen
gr
object
report
case
acut
rabdomyolysi
associ
shigella
flexneri
acut
gastroenter
method
stool
specimen
cultur
appropri
media
isol
enteropathogen
bacteria
direct
smear
examin
enteropathogen
bacterium
identifi
standard
method
api
system
biomerieux
serotyp
antiserum
reagent
myoglobin
detect
biochem
method
suscept
test
carri
disc
diffus
method
case
report
male
patient
age
year
admit
hospit
acut
gastroenter
wateri
bloodi
stool
associ
abdomin
pain
myalgia
suffer
coronari
arteri
diseas
diabet
patient
pyrexi
dehydr
hypotens
blood
pressur
mmhg
gener
weak
abund
leukocyt
erythrocyt
seen
direct
smear
stool
admiss
laboratori
data
includ
wbc
count
neutrophil
ht
hb
gdl
urea
mgdl
creatinin
mgdl
glucos
mgdl
meql
na
meql
cpk
iul
normal
valu
iul
ckmb
iul
normal
valu
ldh
iul
sgot
iul
sgpt
iul
iul
albumin
gdl
myoglobinuria
clinic
laboratori
find
rabdomyolysi
diagnos
patient
treat
parenter
hydrat
ciprofloxacin
mg
tid
iv
stool
cultur
flexneri
isol
strain
resist
trimethoprimesulphamethoxazol
ampicillin
amoxycillin
clavulan
acid
tetracyclin
chloramphenicol
suscept
ciprofloxacin
cefotaxim
piperacillin
condit
show
gradual
improv
next
day
present
gradual
improv
cpk
hospit
day
iul
iul
respect
return
within
normal
sixth
hospit
day
patient
discharg
day
conclus
rabdomyolysi
complic
flexneri
gastroenter
rare
present
case
second
found
english
literatur
possibl
rabdomyolysi
must
consid
case
sever
gastroenter
prevent
time
treatment
complic
made
possibl
corynebacterium
urealyticum
encrust
cystiti
new
case
review
literatur
encrust
alkalin
cystiti
ec
unusu
process
almost
forgotten
urologist
tend
appear
complic
underli
cystopathi
ec
consist
vesic
mucos
inflamm
encrust
amonium
magnesium
phosphat
urothelium
genesi
requir
preexist
mucos
damag
urinari
infect
urolith
microorgan
alkalin
urin
man
victim
traffic
accid
multipl
injuri
admit
icu
hospit
urinari
catheteris
perfom
day
hematuria
abdomin
pain
urin
sampl
collect
corynebacterium
urealyticum
grown
urin
foci
malakoplakia
found
area
encrust
endoscop
excis
antibiot
treatment
teicoplanin
ciprofloxacin
fulfil
day
day
treatment
endoscop
resect
bladder
wall
achiev
bacteriolog
data
case
encrust
cystiti
report
past
year
propos
literatur
review
therapeut
option
commun
clinic
microbiolog
infect
volum
supplement
risk
high
risk
fine
group
howev
pneumonia
significantli
common
sever
increas
h
influenza
show
cluster
group
pneumonia
common
less
sever
case
object
group
b
streptococci
gb
caus
lifethreaten
infect
neonat
infant
pregnant
possibl
caus
invas
infect
especi
immunocompromis
adult
gb
arthriti
rare
describ
immunocompet
adult
usual
associ
risk
factor
neoplasm
cirrhosi
diabet
present
gb
arthriti
immunocompet
male
patient
suscept
test
perform
disc
diffus
method
accord
nccl
strain
resist
aminoglycosid
antibiot
therapi
chang
intraven
penicillin
whole
bodi
bone
scan
reveal
arthriti
right
acetabulum
day
later
patient
present
increas
mobil
right
hip
final
recov
without
sequela
conclus
case
report
tri
increas
awar
clinician
gb
potenti
caus
septic
arthriti
although
gb
diseas
frequent
adult
aspleniaorgan
function
chronic
liver
diseas
diabet
congest
heart
failur
although
urinari
tract
infect
pneumonia
soft
tissu
infect
commonest
present
gb
underestim
differenti
diagnosi
septic
arthriti
even
patient
without
predispos
factor
sever
complic
patient
brucella
melitensi
infect
brucellosi
present
varieti
symptom
affect
virtual
everi
organ
tissu
bodi
report
complic
patient
brucellosi
diagnos
treat
hospit
period
year
complic
clinic
signific
lead
diagnost
therapeut
dilemma
complic
lead
diagnost
dilemma
broad
list
differenti
diagnosi
includ
skin
rash
patient
orchitisepipidym
patient
sever
pancytopenia
patient
singl
lineag
cytpenia
anoth
final
stiff
neck
csf
pleocytosi
one
patienttherapeut
dilemma
emerg
patient
develop
arthriti
spondyl
sacroilei
spondyl
right
ankl
arthriti
respect
receiv
treatment
brucellosi
final
detail
diagnost
work
patient
present
recurr
fever
arthriti
treatment
brucellosi
week
diagnos
endocard
artifici
aortic
valv
success
manag
requir
prolong
treatment
combin
antibiot
conclus
diagnosi
treatment
brucellosi
usual
simpl
howev
success
manag
complic
sever
may
requir
detail
diagnost
work
prolong
treatment
method
materi
analys
record
patient
clinic
materi
recent
year
present
posttraumat
patient
sever
ga
infect
soft
tissu
cellul
stss
patient
develop
infecti
complic
follow
injuri
case
requir
quick
aggress
surgic
procedureslarg
incis
remov
necrot
tissu
one
patient
need
multipl
surgic
intervent
three
patient
improv
spite
sever
cours
infect
one
patient
die
two
patient
suffer
head
injuri
two
patient
injuri
extrem
complic
extend
tissu
necrosi
amput
limb
necessari
cours
infect
rapidli
progress
fever
extens
soft
tissu
necrosi
mark
system
toxic
case
requir
broad
spectrum
antimicrobi
therapypati
treat
lincosamid
mainli
clindamycin
given
intraven
larg
dose
mgday
patient
microbiolog
procedur
perform
cultur
wound
blood
obtain
sent
routin
anareob
cultur
direct
microscop
examin
suitabl
diagnost
materi
exsud
wound
fragment
necrot
tissu
conclus
ga
infect
sever
life
threaten
accord
find
clindamycin
high
dose
improv
prognosi
drug
choic
streptococc
cellul
stss
demograph
microbiolog
featur
urinari
tract
infect
young
adult
patient
clinic
microbiolog
infect
volum
supplement
vs
p
e
coli
show
similar
resist
rate
male
femal
ampicillin
cotrimoxazol
nitrofurantoin
ciprofloxacin
isol
rate
e
coli
lower
vs
p
ns
women
treat
antimicrobi
month
prior
enrol
previou
treatment
resist
rate
e
coli
antimicrobi
previous
treat
non
treat
women
follow
respect
cotrimoxazol
vs
p
ampicillin
vs
p
ns
ciprofloxacin
vs
p
ns
nitrofurantoin
vs
p
ns
conclus
young
adult
pt
year
age
e
coli
caus
agent
uti
frequent
femal
male
men
microorgan
expeci
pseudomona
play
signific
role
femal
previou
antimicrobi
treatment
increas
risk
e
coli
resist
ampicillin
cotrimozazol
complic
acut
brucellosi
among
adult
diyarbakir
turkey
object
seriou
respiratori
infect
due
p
aeruginosa
b
cepacia
consist
major
problem
life
cystic
fibrosi
cf
patient
greec
b
cepacia
isol
cf
consid
rather
rare
aim
studi
investig
presenc
b
cepacia
respiratori
infect
cf
patient
chest
diseas
hospit
athen
method
select
medium
b
cepacia
agar
oxoid
use
addit
convent
media
quantit
cultur
sputum
sampl
cf
patient
admit
hospit
period
identif
method
includ
api
api
ne
vitek
biomerieux
gram
oxidas
isol
also
molecularli
identifi
initi
multiplex
pcr
order
identifi
two
bacteri
speci
p
aeruginosa
p
cepacia
multiplex
pcr
includ
primer
specif
bp
fragment
ribosom
gene
identifi
five
main
gemovar
b
cepacia
includ
multiplex
pcr
univers
bacteri
primer
pair
target
rrna
act
intern
control
bp
sampl
give
result
andor
bp
fragment
test
identif
bacteri
strain
specif
pcr
reca
gene
pcr
use
assay
discrimin
b
cepacia
complex
b
cepacia
like
microorgan
result
none
isol
identifi
belong
b
cepacia
complex
either
select
medium
pcr
high
level
correspond
note
select
b
cepacia
medium
molecular
identif
isol
conclus
evid
b
cepacia
particip
cf
respiratori
infect
rather
unusu
greec
influenc
proper
antimicrobi
prescrib
outcom
acut
sinus
object
aim
studi
evalu
correl
antimicrobi
prescrib
outpati
adult
acut
sinus
outcom
diseas
method
case
histori
outpati
diagnosi
consecut
select
outpati
depart
region
russia
retrospect
analysi
classifi
use
atccod
collect
data
analys
special
design
softwar
data
iac
smolensk
russia
outcom
classifi
cure
improv
hospit
prescript
addit
patient
age
frequenc
sinu
punctur
sp
factor
potenti
influenc
outcom
also
analys
age
compar
wilkoksonmannwhitney
test
outcom
frequenc
sp
treatment
differ
compar
use
weight
pairwis
fisher
criterion
result
total
case
histori
outpati
age
male
femal
averag
age
year
analys
popular
use
initi
monotherapi
includ
ampicillin
amp
amoxicillin
amx
amoxicillinclavulan
amc
erythromycin
eri
midecamycin
mid
gentamicin
gen
lincomycin
lin
doxycyclin
dox
ciprofloxacin
cip
cotrimoxazol
ctx
prescrib
patient
group
similar
accord
age
amx
group
associ
signific
less
frequenc
sp
lin
cip
gen
p
mid
amc
p
group
initi
prescript
cip
lin
found
higher
rate
sp
compar
amp
eri
dox
p
rate
treatment
success
failur
present
tabl
treatment
amx
statist
success
p
except
amc
mid
signific
differ
outcom
group
except
mid
better
outcom
cip
dox
p
conclus
proper
prescrib
amx
initi
treatment
led
better
outcom
amx
startup
therapi
associ
less
frequent
sp
amoxicillin
gentamicin
ampicillin
gentamicin
ciprofloxacin
gentamicin
frequent
prescrib
combin
vs
ampicillin
cotrimoxazol
gentamicin
cotrimoxazol
ampicillin
gentamicin
case
administ
oral
vs
intramuscularli
vs
intraven
rout
indic
conclus
numer
use
cap
treatment
well
prescrib
habit
improv
increas
rate
amoxicillin
amoxicillinclavulan
acid
decreas
gentamicin
cotrimoxazol
usag
observ
low
rate
macrolid
usag
unaccept
larg
number
ciprofloxacin
cefazolin
prescript
note
clinic
microbiolog
infect
volum
supplement
event
clinic
signific
occur
day
hospit
patient
develop
pneumonia
due
staphylococcu
aureu
pseudomona
aeruginosa
strain
manag
intraven
antimicrobi
agent
includ
vancomycin
gentamicin
piperacillintazobactam
led
clinic
improv
howev
day
abovement
isol
grew
cultur
bronchial
secret
specimen
gentamicin
discontinu
intraven
ciprofloxacin
rifampin
start
day
patient
develop
extens
maculopapular
rash
trunk
extrem
addit
ocular
perior
swell
observ
antimicrobi
agent
discontinu
day
develop
bacteraemia
due
klebsiella
pneumonia
strain
intraven
gentamicin
start
discontinu
one
day
later
due
flare
rash
final
day
blood
specimen
cultur
grew
mdr
acinetobact
baumannii
strain
sensit
colistin
continu
intraven
infus
regimen
colistin
unit
per
hour
initi
clinic
condit
patient
gradual
improv
rash
gradual
diminish
conclus
continu
intraven
administr
colistin
may
associ
fewer
hypersensit
advers
reaction
may
effect
tradit
intermitt
way
infus
colonis
antimicrobi
resist
tracheal
aspir
hospitalis
patient
intens
care
unit
tertiari
medic
care
centr
kosova
result
period
studi
set
total
blood
cultur
posit
microbi
growth
repres
case
neonat
bacteraemia
total
case
total
number
isol
member
enterobacteriacea
serratia
klesiella
enterobact
spp
common
caus
bacteraemia
coagulas
neg
posit
staphylococci
also
frequent
isol
chang
pattern
caus
pathogen
observ
studi
member
three
lead
genera
enterobacteriacea
antibiot
suscept
test
show
high
level
resist
among
common
pathogen
resistac
aztreonam
imipenem
ciprofloxacin
piperacillintazobactam
less
frequent
encount
staphylococcu
resist
antistaphylococc
antibiot
due
hyperproduct
penicillinas
enzym
also
high
isol
remain
sensit
vancomycin
conclus
gramneg
bacteria
especi
member
enterobacteriacea
import
caus
bacteraemia
neonat
intens
care
unit
although
isol
remain
sensit
new
antibiot
emerg
resist
strain
exclud
futur
reason
new
strategi
continu
surveil
requir
monitor
chang
epidemiolog
pathogen
antibiot
suscept
antibiot
use
need
overcom
increas
incid
resist
convent
drug
phagocyt
activ
human
peripher
blood
polymorphnuclear
leucocyt
methicillinsensit
resist
coagulaseneg
staphylococci
object
two
type
white
blood
cell
polymorphnuclear
pmn
monocyt
import
resist
infect
phagocyt
play
signific
part
first
line
defenc
bacteria
virus
fungi
human
host
object
aim
studi
assess
frequenc
colon
nasopharynx
gramneg
rod
patient
lung
cancer
undergo
thorac
surgeri
routin
receiv
antimicrobi
prophylaxi
piperacillin
cefuroxim
alon
combin
amikacin
antimicrobi
agent
suscept
isol
strain
also
defin
method
sixtythre
patient
resect
lung
cancer
includ
studi
throat
nasal
specimen
taken
two
time
day
hospit
admiss
examin
fourth
day
surgeri
examin
ii
sampl
routin
cultur
aerob
condit
strain
identifi
use
api
api
suscept
select
antimicrobi
agent
detect
disc
diffus
method
accord
nccl
recommend
result
strain
gramneg
rod
belong
enterobacteriacea
famili
nonfer
rod
found
sampl
patient
examin
patient
examin
ii
doubl
increas
frequenc
bacteria
mucou
membran
nasopharynx
examin
ii
observ
v
test
p
strain
enterobacteriacea
highli
suscept
antimicrobi
agent
wherea
nonfer
rod
classifi
multidrug
resist
organ
among
antibiot
use
studi
cefepim
ticarcillinclavulon
acid
activ
vitro
isol
gramneg
rod
found
strain
produc
extendedspectrum
blactamas
strainsinduc
blactamas
conclus
hospit
patient
lung
cancer
undergo
thorac
surgeri
preoper
prophylaxi
qualit
quantit
chang
gramneg
rod
colon
nasopharynx
observ
sampl
taken
day
surgeri
increas
preval
nonfer
rod
mostli
multidrug
resist
found
obtain
result
confirm
need
conduct
analys
microflora
upper
respiratori
tract
patient
lung
cancer
monitor
potenti
etiolog
factor
nosocomi
respiratori
tract
infect
outbreak
serratia
marcescen
bacteriuria
neurosurg
intens
care
unit
tertiari
care
teach
hospit
clinic
epidemiolog
laboratori
perspect
object
aim
studi
identifi
risk
factor
associ
develop
serratia
marcescen
bacteriuria
neurosurg
intens
care
unit
nsicu
genotyp
pathogen
order
determin
sourc
infect
environment
surveil
show
handl
urin
jug
point
sourc
contamin
genotyp
antibiogram
patient
except
two
patient
conclus
patientrel
risk
factor
identifi
rapid
identif
organ
made
alter
method
handl
urin
jug
provid
focu
heighten
surveil
infect
control
measur
empir
therapi
termin
outbreak
spondylodisc
facet
joint
steroid
inject
falaga
blizioti
mavrogeni
antoni
p
papagelopoulo
athen
gr
background
report
infect
follow
facet
joint
inject
rare
includ
paraspin
epidur
abscess
format
septic
facet
joint
arthriti
method
describ
case
pseudomona
aeruginosa
spondylodisc
facet
joint
steroid
inject
result
male
present
local
orthoped
surgeon
low
back
pain
patient
neurolog
deficit
presumpt
diagnosi
degen
spondylosi
treat
nonsteroid
antiinflammatori
agent
physiotherapi
month
three
month
later
patient
worsen
back
pain
plain
radiograph
comput
tomographi
ct
magnet
reson
imag
mri
lumbar
spine
show
osteoarthr
lower
lumbar
facet
joint
facet
joint
inject
done
use
methylprednisolon
acet
bupivacain
hydrochlorid
patient
temporari
relief
symptom
day
follow
deterior
low
back
pain
acut
onset
lowgrad
fever
laboratori
investig
reveal
increas
white
blood
cell
count
erythrocyt
sediment
rate
hour
creactiv
protein
mgl
spine
infect
suspect
ciprofloxacin
administ
mg
po
four
week
howev
treatment
led
minim
improv
clinic
symptom
time
admiss
institut
main
sign
symptom
includ
low
back
pain
tender
increas
bodi
temperatur
mri
fine
needl
aspir
cultur
affect
area
confirm
diagnosi
pseudomona
aeruginosa
spondylodisc
level
patient
treat
intraven
administr
amikacin
mg
imipenem
plu
cilastatin
mg
four
week
follow
oral
administr
ciprofloxacin
week
latest
followup
month
complet
antimicrobi
therapi
mri
lumbar
spine
show
signific
narrow
intervertebr
space
sign
activ
infect
associ
facet
inject
deterior
patient
clinic
condit
addit
absenc
obviou
hematogen
mechan
infect
suggest
iatrogen
caus
spondylodisc
iatrogen
complic
includ
riskbenefit
analysi
clinician
steril
prepar
prior
procedur
stress
select
virul
factor
resist
antimicrobi
nosocomi
carrier
aureu
strain
object
detect
product
select
virul
factor
resist
antistaphylococc
therapeut
aureu
strain
caus
sepsi
wound
joint
implant
infect
compar
carrier
strain
method
aureu
strain
isol
haemocultur
strain
surgeri
wound
strain
prosthet
hip
knee
joint
infect
strain
patient
faculti
hospit
bratislava
nasal
swab
carrier
strain
product
hyaluronidas
alpha
beta
deltahaemolysisn
adher
glass
surfac
polysaccharid
extracellular
adhesin
pia
product
congor
plate
dynam
plasmacoagulas
product
test
resist
oxacillin
erythromycin
clindamycin
gentamicin
ciprofloxacin
trimethoprimsulfamethoxazol
quinupristin
dalfopristin
qd
linezolid
lnz
vancomycin
van
estim
disk
diffus
test
accord
nccl
suscept
van
confirm
etest
methicillinresist
strain
mrsa
detect
latex
agglutin
test
result
comparison
investig
group
aureu
strain
show
except
patient
strain
produc
alphahaemolysin
combin
beta
delta
haemolysin
plasmacoagulas
product
till
hour
incub
detect
major
patient
strain
among
carrier
strain
activ
strain
isol
joint
prosthes
infect
jpi
adher
glass
surfac
detect
test
strain
intens
product
pia
detect
strain
haemocultur
jpi
strain
wound
carrier
strain
strain
found
mrsa
haemocultur
wound
infect
produc
alphatoxin
pia
strain
patient
sampl
resist
gentamicin
test
strain
suscept
van
lnz
qd
conclus
patient
aureu
strain
differ
carrier
strain
rapid
product
plasmacoagulas
strain
haemocultur
prosthet
joint
infect
characterist
intens
product
pia
differenti
wound
carrier
strain
group
mrsa
found
group
haemocultur
wound
infect
strain
strain
suscept
van
lnz
qd
investig
possibl
nosocomi
urinari
tract
infect
outbreak
due
esbl
produc
e
coli
materi
patient
e
coli
strain
isol
equal
number
inpati
two
men
two
women
mean
age
year
old
hospit
infect
uti
n
immunosuppress
n
one
pyuria
leucocyt
p
f
fever
receiv
extend
spectrum
antibiot
indwel
cathet
present
four
patient
method
resist
phenotyp
perform
kirbi
bauer
microdilut
method
accord
nccl
guidelin
esbl
product
confirm
doubl
disk
test
ddt
etest
cefepimecefepimeclavulan
ab
biodisk
solna
sweden
biotyp
base
wider
ii
francisco
soria
melguizo
sa
autom
system
result
eric
ii
pcr
use
molecular
type
isol
result
although
epidemiolog
data
time
space
cluster
well
phenotyp
data
strain
show
resist
phenotyp
biotyp
consist
possibl
clonal
spread
isol
patient
molecular
type
reveal
two
four
e
coli
esbl
produc
strain
isol
patient
share
room
similar
thu
could
associ
part
outbreak
remain
two
strain
differ
molecular
pattern
conclus
studi
support
clue
classic
microbiolog
studi
coloni
morpholog
biotyp
resist
phenotyp
well
molecular
type
method
necessari
must
perform
investig
reveal
outbreak
infect
hospit
set
object
measur
incid
nosocomi
infect
microbi
isol
intern
medicin
bedunit
hospit
method
data
collect
accord
nni
protocol
use
dedic
softwar
epinfo
program
result
octob
decemb
term
patient
enrol
male
femal
median
age
total
patientday
patient
one
comorbid
infect
patient
total
case
urinari
tract
infect
uti
catheterrel
pneumonia
blood
stream
infect
bsi
central
line
catheterassoci
case
pseudomembran
coliti
deviceutil
ratio
cvc
averag
catheter
day
central
lineday
urinari
cathet
averag
catheter
day
urinari
catheterday
central
line
catheterassoci
bsi
develop
patient
expos
cvc
central
lineassoci
bsi
rate
uti
develop
patient
expos
urinari
cathet
urinari
catheterassoci
uti
rate
one
patient
die
nosocomi
pneumonia
attribut
mortal
patient
die
diagnos
nosocomi
infect
microbi
etiolog
uti
gram
neg
case
gram
posit
case
candida
albican
case
patient
show
two
contemporari
pathogen
isol
bsi
staphilococci
case
gram
neg
case
case
clinic
sepsi
conclus
studi
compar
nni
data
show
nosocomi
infect
may
problem
also
hospit
unit
usual
consid
high
risk
probabl
due
advanc
age
multipl
comorbid
patient
admit
despit
urinari
catheterutil
ratio
within
norm
observ
high
incid
uti
howev
show
approxim
decreas
period
research
epidemiolog
aspect
hospitalacquir
pneumonia
intens
care
unit
far
east
russia
result
numer
group
consist
patient
neurolog
diseas
year
children
patient
among
adult
one
male
patient
among
children
boy
children
age
patient
chronic
infect
sever
condit
main
group
risk
patient
includ
children
lethal
outcom
main
reason
lethal
outcom
adult
sever
combin
skullbrain
trauma
acut
disturb
brain
blood
circul
infecti
diseas
sever
combin
skullbrain
trauma
also
taken
lead
posit
among
children
last
year
children
die
reason
children
die
infecti
diseas
other
die
acut
disturb
brain
blood
circul
tumor
adult
children
die
trauma
first
hour
adult
children
spent
icu
day
main
caus
pathogen
hospitalacquir
pneumonia
e
gergovia
aureu
p
aeruginosa
strain
e
gergovia
resist
amikacin
ampicillin
amoxicillin
gentmycin
tobramycin
carbenicillin
cefalotin
cefalexinth
frequent
caus
pathogen
children
aureu
resist
penicillin
ceftazidim
also
sensit
cefobit
oxacillin
amoxicillin
gentomycin
lincomycin
chloramphenicol
erythromycin
doxicyclin
p
aeruginosa
take
second
place
ethiolog
structur
caus
pathogen
hospitalacquir
infect
resist
cefalexin
cefalotin
carbenicillin
tetracyclin
tobramycin
levoflaxacin
conclus
problem
registr
laboratori
result
anaerob
infect
connect
absenc
specialist
also
lead
larg
group
undiagnos
infect
complic
treatment
increas
frequenc
lethal
outcom
unusu
bacteraemiaassoci
pathogen
experi
follow
achromobact
xylosoxidan
follow
intervent
cardiolog
examin
outcom
death
pasteurella
multocida
one
patient
copd
one
patient
myelosclerosi
outcom
case
death
burkholderia
pseudomallei
patient
travel
asia
ground
pneumonia
caus
pathogen
outcom
favor
cardiobacterium
homini
patient
endocard
outcom
favor
yersinia
enterocolitica
multitransfus
patient
outcom
favor
betahaemolyt
streptococcu
group
b
one
patient
endocard
second
patient
lung
cancer
third
patient
diabet
mellitu
outcom
favor
first
two
case
death
third
betahaemolyt
streptococcu
group
intraven
drugabus
patient
patient
left
hospit
latent
outcom
unknown
serpulina
pilosicoli
critic
ill
patient
gastroenter
outcom
death
cryptococcu
neoforman
chronic
lymphocyt
leukaemia
patient
second
patient
sarcoidosi
outcom
death
first
favor
second
patient
radiobact
rhizobium
patient
myelosclerosi
outcom
death
pseudomona
testosteroni
one
patient
cardiac
valv
insuffici
second
patient
acut
abdomen
outcom
favor
first
case
death
second
given
fact
new
pathogen
emerg
caus
factor
bacteraemia
microbiolog
laboratori
alert
abl
detect
isol
identifi
clinic
microbiolog
infect
volum
supplement
method
fortytwo
patient
cystic
fibrosi
male
femal
averag
age
year
pancreat
insuffici
patient
came
monograph
unit
adult
cf
sputum
sampl
cultur
follow
standard
microbiolog
procedur
coloni
quantif
ofpbl
agar
saboureaud
chloramphenicol
agar
blood
agar
chocol
agar
chocol
agar
bacitracin
macconkey
agar
mannitol
salt
agar
gram
stain
perform
isol
identifi
convent
test
autom
system
microscan
dadebehr
antimicrobi
suscept
determin
automat
system
microscan
disk
diffus
method
accord
nccl
recommend
result
preval
infect
pseudomona
aeruginosa
isol
patient
femal
male
averag
age
yr
number
pseudomona
aeruginosa
isol
patient
studi
period
patient
also
coloniz
aspergillu
fumigatu
aureu
methicillin
sensit
aureu
methicillin
resist
haemophillu
sp
antimicrobi
suscept
obtain
shown
tabl
conclus
high
frequenc
pseudomona
aeruginosa
colon
found
patient
cystic
fibrosi
pseudomona
aeruginosa
strain
suscept
colistin
vitro
highest
resist
rate
shown
gentamicin
adhes
cathet
slime
product
staphylococcu
haemolyticu
isol
hospitalis
patient
occurr
antibiot
suscept
object
last
ten
year
studi
show
particip
coagulas
neg
staphylococci
cn
pathogen
mani
diseas
reason
grow
interest
cn
ethiolog
infecti
factor
seen
increas
number
patient
high
risk
group
use
invas
diagnost
clinic
method
expos
cn
infect
except
patient
artifici
implant
best
character
cn
pathogen
factor
abil
tissu
colon
adhes
synthet
surfac
evas
fundament
stage
pathogen
cn
infect
properti
caus
cell
wall
ingredi
teichoic
acid
also
integr
substanc
associ
bacteri
cell
extracellular
polysaccharid
slime
studi
done
haemolyticu
strain
isol
patient
hospit
surgic
unit
aim
studi
determin
pathogen
trait
haemolyticu
slime
produc
adhes
biomateri
antibiot
suscept
method
slime
product
examin
mean
two
method
accord
christiansen
adhes
haemolyticu
strain
analys
accord
richard
method
assess
valu
substrat
ttc
reduc
isolub
red
formazan
suscept
antibiot
determin
use
discdiffus
method
result
among
haemolyticu
strain
testtub
method
label
slime
produc
nonproduc
plate
method
slime
product
notic
strain
produc
slime
analys
strain
found
ttc
reduct
among
assess
strain
reduc
ttc
conclus
quit
signific
strain
abil
slime
produc
prove
mean
two
method
testtub
plate
show
high
level
ttc
reduct
formazan
analysi
resist
antibiot
relat
slime
product
demonstr
frequent
antibiot
resist
slimeproduc
strain
detail
studi
mechan
adhes
factor
cn
staphylococci
help
prevent
infect
caus
microorgan
result
ninetythre
isol
collect
patient
intens
care
unit
icu
nonicu
inpati
area
respect
remaind
either
outpati
data
avail
suscept
pattern
e
cloaca
isol
show
highest
suscept
meropenem
follow
imipenem
cefepim
tobramycin
suscept
ciprofloxacin
wherea
suscept
ceftazidim
piperacillintazobactam
meropenem
imipenem
cefepim
also
activ
compound
c
freundii
suscept
ciprofloxacin
tobramycin
respect
suscept
ceftazidim
piperacillintazobactam
rate
resist
follow
e
cloaca
ceftazidim
cefepim
imipenem
meropenem
piperacillintazobactam
ciprofloxacin
tobramycin
c
freundii
ceftazidim
cefepim
imipenem
meropenem
piperacillintazobactam
ciprofloxacin
tobramycin
two
speci
combin
suscept
ceftazidim
piperacillintazobactam
significantli
lower
p
among
isol
icu
patient
among
isol
nonicu
inpati
conclus
carbapenem
cefepim
seem
activ
antimicrobi
agent
isol
e
cloaca
c
freundii
recov
patient
hospit
locat
germani
austria
switzerland
clinic
microbiolog
infect
volum
supplement
bacteria
result
present
studi
suggest
risk
factor
vim
appear
intens
care
unit
materi
method
identifi
first
patient
male
femal
admit
newli
establish
icu
month
period
tracheobronchi
aspir
urin
cultur
obtain
everi
day
first
three
day
everi
second
day
admiss
icu
identif
perform
pasco
system
use
accord
manufactur
instruct
mic
antipseudomon
drug
except
carbapenem
determin
pasco
microdilutionsystem
appli
criteria
prescrib
nccl
suscept
imipenem
meropenem
determin
agar
disk
diffus
accord
nccl
recommend
blaimp
blavim
specif
product
amplifi
pcr
crude
dna
extract
use
publish
primer
condit
qualit
data
express
percentag
compar
chisquar
test
consid
p
statist
signific
p
valu
base
test
result
statist
analys
perform
use
logist
regress
spss
result
isol
total
multiresist
strain
p
aeruginosa
k
pneumonia
baumannii
p
aeruginosa
strain
imipenem
resist
among
nine
posit
strain
k
pneumonia
baumannii
neg
pcr
among
total
posit
p
aeruginosa
isol
collect
urin
bronchial
secret
discuss
risk
factor
vim
appear
includ
carbapenem
administr
n
fact
may
due
augment
select
gene
press
specif
drug
b
administr
sever
blactam
deriv
n
aminoglycosid
n
combin
carbapenemsaminoglycosid
n
statist
signific
result
aminoglycosid
administr
may
due
augment
select
press
integron
contain
blavim
gene
three
differ
aminoglycosid
resist
determin
carri
mobil
gene
cassett
c
long
length
icu
stay
risk
factor
posit
strain
appear
n
conclus
although
sampl
repres
pilot
studi
measur
saa
seem
interest
inflammatori
marker
brucellosi
associ
local
infect
hematopoiesi
disord
term
anemia
find
may
explain
anemia
brucellosi
involv
cytokin
product
modul
bone
marrow
hematopoet
progenitor
cell
studi
requir
order
elucid
enigmat
complic
access
qualiti
infect
control
surveil
faecium
isol
blood
patient
pt
die
urin
pt
urinari
cathet
without
cathet
periton
fluid
pt
iv
cathet
pt
wound
pt
drainag
tube
pt
gre
faecium
infect
hospitalacquir
multivari
analysi
control
time
risk
charlson
index
co
morbid
identifi
prior
exposur
iv
cephalosporin
ci
p
antimicrobi
regimen
betalactamas
inhibitor
ci
p
urinari
cathet
ci
p
independ
predict
gre
faecium
infect
carriag
clinic
isol
also
resist
amoxicillin
macrolid
clindamycin
suscept
linezolid
vibramycin
intermedi
aminoglycosid
quinupristindalfopristin
pfge
pattern
one
clonal
relat
conclus
clonal
emerg
diffus
gre
faecium
like
result
antibiot
pressur
crosstransmiss
result
strict
recommend
regard
isol
patient
multiresist
bacteri
infect
restrict
prescript
broadspectrum
antibiot
implement
hospit
genotyp
analysi
occurr
extend
spectrum
betalactamas
introduct
variou
mechan
acquir
aureu
resist
blactam
resist
due
blactamas
preval
alter
preexist
penicillinbind
protein
pbp
acquisit
novel
pbp
insensit
blactam
also
confer
resist
methicillin
blactam
chang
outer
membran
protein
includ
product
supplement
pbp
pbp
encod
chromosom
mec
gene
meca
mecb
object
studi
resist
mechan
alactam
nosocomi
strain
aureu
method
period
year
strain
test
test
perform
follow
method
oxascreen
agar
biomerieux
mullerhinton
agar
nacl
oxacillin
mgml
detect
resist
oxacillin
mrsa
test
biomerieux
agglutin
test
detect
pbp
cefinas
disc
biomerieux
detect
blactamas
product
etest
solnasweden
detect
penicillin
oxacillin
mic
result
strain
aureu
resist
blactam
antibioticsout
latter
strain
shown
resist
due
product
blactamas
strain
shown
resist
due
alter
penicillinbind
protein
final
strain
shown
resist
due
mechan
conclus
high
percentag
nosocomi
aureu
strain
resist
blactam
studi
resist
mechan
chang
pbp
protein
frequent
computeris
surveil
nosocomi
infect
univers
hospit
result
discuss
depart
surveil
ward
round
work
time
evalu
use
logtabl
extern
qualiti
control
perform
routin
phase
week
result
nearli
complet
document
achiev
physician
andor
medic
document
offic
type
infect
rate
vap
bsi
ssi
concern
indic
oper
given
compar
nrz
data
also
data
work
time
personnel
cost
well
qualiti
assur
present
conclus
due
simpl
computer
data
assess
personnel
time
concern
surveil
low
compar
non
comput
assist
surveil
show
compar
infect
rate
nation
data
preval
extendedspectrum
betalactamas
univers
hospit
gener
ward
unit
minimum
inhibitori
concentr
mic
determin
p
aeruginosa
clinic
isol
meropenem
cefepim
amikacin
ciprofloxacin
etest
methodolog
accord
manufactur
instruct
interpret
criteria
use
describ
nccl
document
suscept
pattern
isol
icu
neutropen
patient
gener
ward
unit
determin
describ
chisquar
test
altman
appli
identifi
differ
suscept
rate
among
three
unit
type
studi
p
valu
consid
signific
result
unit
differ
among
p
aeruginosa
clinic
isol
describ
overal
resist
rate
r
meropenem
amikacin
ciprofloxacin
cefepim
higher
resist
rate
observ
icu
antimicrobi
except
amikacin
howev
differ
among
resist
rate
special
unit
signific
meropenem
p
conclus
elev
resist
rate
observ
antimicrobi
higher
overal
suscept
meropenem
meropenem
resist
rate
higher
among
icu
isol
could
due
higher
antimicrobi
use
bias
sampl
sinc
clonal
spread
overvalu
resist
clinic
isol
could
rule
far
predictor
outcom
patient
bloodstream
infect
clinic
microbiolog
infect
volum
supplement
method
antimicrobi
suscept
nine
antimicrobi
agent
clinic
isol
streptococcu
pneumonia
recov
patient
invas
clinic
signific
pneumococc
infect
studi
use
etest
disk
diffus
method
follow
nccl
guidelin
isol
n
blood
n
bronchoalveolarlavag
n
tracheal
aspir
n
cerebrospin
fluid
n
pleural
fluid
n
endophthalm
n
periton
fluid
n
sinu
aspir
n
middl
ear
fluid
n
cathet
n
fistula
specimen
serogroup
pneumococc
isol
perform
use
quellung
techniqu
staten
serum
institut
copenhagen
denmark
result
antibiot
suscept
serotyp
shown
tabl
capsular
type
pneumococc
isol
belong
type
conclus
antibiot
resist
common
pneumococc
isol
region
vaccin
formul
prevent
major
pneumococc
infect
object
clostridium
difficil
gram
posit
anaerob
sporeform
rod
present
intestin
flora
soil
circul
hospit
c
difficil
produc
differ
potenti
virul
factor
kda
enterotoxin
toxin
kda
cytotoxin
toxin
b
toxin
major
caus
enter
diseas
coliti
determin
endogen
exogen
caus
antibiot
treatment
import
endogen
caus
exogen
origin
infect
refer
orofaec
contamin
due
colonis
patient
epidem
took
place
surgeri
divis
fact
led
formul
oper
protocol
c
difficil
associ
infect
oper
protocol
start
cdc
guidelin
base
enter
isol
c
difficil
protocol
defin
hygien
procedur
adopt
case
c
difficil
associ
infect
target
protocol
prompt
identif
symptomat
patient
subsequ
applic
procedur
avoid
pathogen
transmiss
method
sinc
may
surveil
programm
activ
c
difficil
associ
infect
protocol
review
plan
case
definit
c
difficil
associ
infect
suspect
patient
diarrhoea
case
patient
investig
presenc
c
difficil
toxin
stool
one
analys
posit
divis
alert
implement
protocol
direct
epidemiolog
nurs
alert
abstract
gcontrol
chart
show
lack
statist
control
control
valu
centr
line
month
gcontol
chart
hh
bbh
sever
control
period
conclus
gcontrol
chart
found
valuabl
statist
tool
allow
quick
identif
increas
cn
contamin
rate
blood
cultur
suffici
skin
disinfect
think
bee
import
factor
minim
blood
cultur
contamin
gastric
fluid
cultur
neonat
lymphoma
hematolog
malign
median
durat
isepamicin
therapi
day
lc
arm
infect
microbiolog
clinic
document
episod
episod
respect
overal
success
rate
without
modif
sc
arm
lc
arm
mean
time
defervesc
day
sc
arm
day
lc
arm
p
modif
initi
regimen
antivir
andor
antifung
rais
success
rate
sc
arm
lc
arm
without
chang
antibiot
respons
rate
sc
arm
lc
arm
patient
singleorgan
gramneg
bacteraemia
overal
sideeffect
observ
patient
sc
arm
lc
arm
intent
treat
analysi
nephrotox
rare
similar
arm
sc
lc
p
mortal
due
infect
without
hemorrhag
occur
total
patient
sc
lc
clinic
microbiolog
infect
volum
supplement
conclus
cefepim
combin
short
four
day
cours
isepamicin
seem
effect
safe
longer
durat
isepamicin
febril
highrisk
neutropen
patient
clinicalevolut
aspect
varicella
immunocompromis
patient
immunocompromis
patient
repres
high
risk
group
larg
number
viral
bacteri
infect
requir
strict
clinic
therapeut
surveil
object
studi
clinicalevolut
aspect
varicella
adult
immunocompromis
patient
method
author
studi
group
patient
clinic
infecti
diseas
timisoara
suffer
varicella
occur
known
chronic
affect
evolv
immunocompromis
field
five
patient
known
insulindepend
diabet
mellitu
patient
chronic
renal
insuffici
hemodialysi
patient
chronic
lymphat
leukaemia
patient
chronic
myelogen
leukaemia
patient
tuberculosi
one
patient
breast
cancer
one
patient
hodkin
diseas
diagnosi
varicella
base
clinicalevolut
symptom
fever
gener
itch
rash
consist
macula
papula
vesicl
affect
skin
mouth
analgenit
conjunctiva
mucosa
occur
wave
epidemiolog
element
contact
patient
suffer
varicella
herp
zoster
patient
follow
treatment
acyclovir
gday
day
c
vitamin
calcium
antihistamin
sed
adequ
diet
treatment
basic
diseas
result
durat
skin
rash
week
patient
week
patient
rash
intens
express
wave
patient
follow
complic
observ
interstiti
pneumonia
patient
acut
congest
angina
patient
mouth
candida
patient
cerebellum
ataxia
patient
viral
mening
patient
bacteri
skin
overinfect
patient
patient
erysipela
patient
bacteri
conjunct
antibiot
treatment
claritromicin
case
amoxicillin
clavulan
acid
case
cotrimoxazol
case
perform
purpos
purpos
studi
determin
associ
pct
crp
level
serum
septic
patient
hospit
intens
care
unit
last
month
hippocr
gener
hospit
method
interv
serum
specimen
examin
correspond
icu
patient
pct
valu
serum
determin
use
immunoluminometr
assay
method
liaisonbrahm
pct
take
normal
valu
ngml
crp
valu
serum
determin
use
nephelometr
method
high
sensit
reagent
dadebehr
take
normal
valu
mgl
result
sampl
patient
patholog
pct
level
rang
ngml
septic
patient
posit
blood
cultur
serum
sampl
found
high
crp
level
rang
mgl
patient
sepsi
die
conclus
studi
show
crp
level
remain
high
serum
measur
patient
pct
valu
show
fluctuat
low
high
patient
high
pct
serum
level
also
posit
blood
cultur
connect
pct
crp
serum
level
high
pct
level
remain
serum
long
time
consist
bad
prognost
factor
diseas
outcom
object
determin
use
procalcitonin
pct
neopterin
measur
inflammatori
marker
patient
diagnos
chronic
obstruct
pulmonari
diseas
copd
establish
differ
observ
pct
neopterin
level
clinic
stabl
period
acut
exacerb
process
resolut
well
copd
patient
pneumonia
result
analys
take
consider
sever
etiolog
copd
exacerb
methodolog
total
eightynin
patient
diagnos
copd
includ
studi
patient
group
follow
group
copd
patient
stabl
period
group
copd
patient
undergo
acut
exacerb
group
copd
patient
clinic
radiograph
microbiolog
diagnosi
pneumonia
addit
control
group
healthi
individu
includ
comparison
differ
group
patient
conduct
mannwhitney
test
order
evalu
use
determin
pct
neopterin
pct
measur
immunoluminometr
assay
lumitest
pct
brahm
diagnostica
neopterin
measur
enzym
immunoassay
neopterin
elisa
ibl
serum
sampl
pct
basal
level
control
group
patient
lower
ngml
median
percentil
higher
valu
obtain
copd
patient
undergo
pneumonia
median
percentil
neopterin
basal
level
control
group
patient
lower
ngml
median
percentil
higher
valu
neopterin
also
obtain
copd
patient
affect
pneumonia
addit
pct
level
higher
copd
exacerb
patient
stabl
copd
patient
howev
signific
differ
observ
compar
exacerb
sever
copd
patient
p
stabl
copd
patient
conclus
conclud
pct
neopterin
show
higher
level
copd
patient
present
pneumonia
present
clinic
exacerb
without
pneumonia
stabl
period
diseas
furthermor
correl
pct
sever
copd
observ
pneumocysti
jiroveci
carinii
pneumonia
era
pcp
prophylaxi
result
underla
diseas
pt
nhl
myeloma
hodgkin
lymphoma
cll
acut
leukaemia
aplast
anemia
cml
hcl
md
myelofibrosi
pcp
occur
pt
time
diagnosi
treatment
remiss
pt
progress
underla
diseas
pt
without
pcp
prophylaxi
steroid
treatment
pt
treat
hd
cotrimoxazol
pt
die
start
treatment
respons
pt
need
mechan
ventil
overal
mortal
pt
pcp
need
mechan
ventil
higher
pt
steroid
anamnesi
vs
mg
steroidsday
vs
count
l
vs
underla
diseas
stage
new
diagnosi
treatment
vs
mortal
higher
pt
steroid
anamnesi
vs
mg
steroidsday
vs
l
vs
neutrophil
count
l
vs
pt
mechan
ventil
vs
pt
underla
diseas
stage
new
diagnosi
progress
vs
find
higher
mortal
higher
need
mechan
ventil
group
pt
count
vs
vs
conclus
retrospect
analysi
demonstr
low
incid
pcp
group
pt
hematolog
malign
pcp
prophylaxi
commonli
use
eg
acut
leukaemia
contrast
pt
pcp
institut
pt
underla
diseas
treatment
pcp
prophylaxi
nt
routin
use
nhl
myeloma
hodgkin
lymphoma
cll
steroid
part
treatment
protocol
especi
mgday
count
l
underla
diseas
stage
new
diagnosi
progress
pt
need
pcp
prophylaxi
background
imatinib
mesyl
glivec
select
inhibitor
bcrabl
tyrosin
kinas
deregul
express
involv
pathogenesi
chronic
myeloid
leukaemia
cml
report
case
periton
tuberculosi
patient
global
lymphopenia
follow
fourmonth
treatment
imatinib
newli
diagnos
cml
case
report
swiss
male
diagnos
bcrabl
posit
cml
chronic
phase
complain
four
month
imatinib
therapi
abdomin
pain
lack
appetit
lost
weight
nausea
abdomin
ctscan
reveal
homogen
hepatosplenomegalia
diffus
infiltr
mesenter
fat
asciti
asciti
inflammatori
predomin
lymphocyt
remain
steril
cultur
symptomatolog
attribut
advers
effect
imatinib
treatment
interrupt
one
month
later
admit
worsen
symptom
explor
laparoscopi
display
extens
chronic
granulomat
periton
periton
tuberculosi
diagnos
posit
mycobacterium
tuberculosi
pcr
periton
biopsi
chest
xray
strictli
normal
admiss
present
global
lymphopenia
cellmm
cellmm
discuss
case
rais
two
point
atyp
present
tuberculosi
nonexpos
patient
global
lymphopenia
hivneg
patient
best
knowledg
first
report
infect
suggest
immun
compromis
imatinib
treatment
imatinib
known
induc
cytopenia
moreov
two
recent
studi
shown
imatinib
inhibit
activ
prolifer
tcell
vitro
delayedtyp
hypersensit
vivo
cwynarski
et
al
dietz
et
al
suggest
imatinib
might
affect
immun
could
lead
higher
expect
incid
opportunist
infect
epidemiolog
data
yet
avail
support
hypothesi
note
tuberculosi
induc
transient
lymphopenia
hivseroneg
patient
patient
cml
risk
infect
due
possibl
dysfunct
immun
respons
conclus
studi
imatinib
effect
immun
incid
opportunist
infect
perform
check
cell
count
patient
imatinib
treatment
could
consid
identif
lactic
acid
bacteria
isol
blood
sampl
suscept
antibiot
strain
lactobacillu
rhamnosu
lactobacillu
paracasei
ssp
paracasei
lactobacillu
salivariu
ssp
salivariu
lactobacillu
fermentum
leuconostoc
mesenteroid
leuconostoc
lacti
pediococcu
pentosaceu
gtg
fingerprint
whole
cell
protein
profil
analysi
confirm
identif
furthermor
identifi
four
strain
biochem
classifi
genu
level
lactobacillu
sakei
ssp
carnosu
lactobacillu
curvatu
leuconostoc
pseudomesenteroid
weissella
confusa
investig
strain
resist
vancomycin
teicoplanin
metronidazol
cotrimoxazol
suscept
cefotaxim
imipenem
gentamicin
ciprofloxacin
variabl
conclus
lactobacillu
rhamnosu
leuconostoc
mesenteroid
common
lab
speci
isol
blood
sampl
although
isol
lab
blood
sampl
rare
clinic
signific
taken
account
treatment
decis
especi
isol
pure
cultur
steril
site
risk
factor
bacteri
infect
multipl
myeloma
treat
vincristineadriamycindexamethason
schedul
zaharof
r
koutri
g
svouka
k
kanaki
n
kostako
c
flevari
c
petrogiannopoulo
halandri
athen
gr
object
evalu
bacteri
infect
bi
patient
multipl
myeloma
mm
treat
vincristineadriamycindexamethason
vad
schedul
last
year
depart
design
method
sixtyf
patient
studi
vad
cycl
vad
given
continu
intraven
infus
cii
hospit
patient
characterist
patient
vad
schedul
retrospect
analys
detect
correl
incid
bi
result
analyz
vad
cycl
found
profound
hypogammaglobulinemia
p
posttreat
neutropenia
p
associ
higher
risk
infect
renal
function
impair
significantli
correl
bi
risk
multivari
p
analysi
evalu
first
month
therapi
character
significantli
higher
incid
bi
later
period
p
continu
schedul
p
profound
hypogammaglobulinemia
p
associ
tendenc
higher
risk
infect
high
probabl
ciirel
infect
demonstr
depend
frequent
develop
nosocomi
infect
conclus
patient
profound
hypogammaglobulinemia
receiv
vad
first
line
treatment
major
risk
bi
complet
third
month
therapi
patient
requir
antibacteri
prophylaxi
intraven
immunoglobulin
could
appropri
effect
object
fuerth
describ
member
rapid
grow
mycobacterium
chelona
complex
clinic
signific
optim
therapeut
regimen
still
remain
unclear
method
report
case
year
old
woman
cathet
relat
dissemin
infect
due
fuerth
follow
bone
marrow
transplant
due
aplast
anemia
result
fuerth
could
cultiv
april
two
blood
cultur
high
number
central
venou
cathet
therapi
start
use
imipenem
clarithromycin
follow
month
sign
infect
could
observ
patient
develop
dissemin
purpl
colour
infiltr
skin
initi
regard
cutan
gvhd
septemb
skin
biopsi
reveal
larg
amount
mycobacteria
could
also
subsequ
identifi
fuerth
accord
suscept
test
result
therapi
linezolid
start
next
three
week
lesion
improv
steril
upon
followup
biopsi
cultur
ultim
patient
succumb
due
chronic
transplantassoci
complic
conclus
member
rapid
grow
mycobacteria
fuerth
abl
caus
catheterrel
dissemin
infect
sever
immunocompromis
patient
linezolid
vitro
activ
mani
mycobacteria
effect
led
result
rapid
improv
mycobacteri
skin
infiltr
steril
blood
cultur
skin
biopsi
massiv
pericardi
effus
due
salmonella
enteritidi
patient
rheumatoid
arthriti
cefl
gund
b
erkol
n
dagdelen
koca
tr
object
although
pericardi
involv
frequent
patient
rheumatoid
arthriti
ra
rare
symptomat
cours
mostli
benign
selflimit
also
septic
pericard
extrem
uncommon
case
report
describ
patient
ra
develop
massiv
pericardi
effus
due
salmonella
method
patient
old
man
suffer
ra
two
year
lowdos
corticosteroid
methotrex
treatment
last
four
month
present
palpit
retrostern
pain
physic
examin
cardiopulmonari
distress
erythrocyt
sediment
rate
mmh
leukocyt
count
echocardigraph
examin
reveal
minim
pericardi
fluid
collect
consid
due
ra
dose
corticosteroid
increas
howev
amount
fluid
increas
period
fever
observ
pericardiocentesi
perform
ml
purul
fluid
drain
pericardi
fluid
cultiv
bactec
system
passag
endo
blood
agar
plate
conclus
studi
suggest
high
percentag
vaccin
children
nonimmun
year
need
revaccin
serotyp
salmonella
isol
strain
northern
greec
antimicrobi
resist
rate
poulou
f
markou
p
rozi
serr
gr
object
salmonella
enterica
one
main
caus
diarrhoea
world
wide
studi
present
serotyp
salmonella
isol
diarrheal
patient
year
hospit
northern
greec
determin
antimicrobi
resist
rate
method
period
total
stool
specimen
diarrheal
patient
cultur
identif
isol
strain
made
convent
microbiolog
method
determin
antibiot
suscept
ampicillin
amp
ampicillinsulbactam
sam
tetracyclin
te
chloramphenicol
cl
ciprofloxacin
cip
ceftriaxon
cro
trimethoprimsulfamethoxazol
sxt
perform
use
auto
scan
dade
boehr
disc
diffus
method
kirbi
bauer
use
necessari
accord
nccl
recommend
serotyp
perform
monospecif
antisera
slide
agglutin
method
result
total
salmonella
strain
isol
deriv
adult
major
children
also
season
distribut
salmonella
case
peak
summer
month
preval
serotyp
enteritidi
g
follow
typhimurium
goldcoast
w
blockley
thompson
strain
suscept
antibiot
test
three
strain
typhimurium
goldcoast
resist
amp
sam
cl
te
one
strain
enteritidi
resist
te
medic
case
histori
reveal
two
interest
incid
famili
infect
one
enteritidi
isol
five
member
famili
eaten
infect
meat
second
case
typhimurium
isol
two
infant
close
contact
grandfath
found
chtonic
carrier
strain
conclus
salmonella
enteritidi
predomin
serotyp
children
suscept
adult
salmonellosi
although
region
resist
rate
low
comparison
countri
ration
use
antibiot
continu
surveil
essenti
order
prevent
dissemin
resist
salmonella
strain
object
opioid
includ
morphin
believ
respons
mani
system
effect
drug
abus
involv
immun
system
opioid
increas
suscept
infect
effect
acut
administr
morphin
system
infect
evalu
studi
method
propag
titer
bk
cell
line
three
group
balbc
mice
receiv
mgkg
mgkg
pb
posit
control
subcutan
h
ip
inject
condit
group
mice
receiv
mgkg
morphin
neg
control
surviv
rate
follow
day
cytotox
activ
nk
cell
use
mtt
assay
result
surviv
analysi
demonstr
compar
control
group
administr
mg
morphin
significantli
reduc
innat
immun
infect
nk
cell
activ
reduc
morphinetr
group
comparison
salinetr
one
result
show
advers
effect
morphin
innat
immun
taken
result
enhanc
rate
mortal
infect
mice
object
disord
polymorphonuclear
leukocyt
pmnl
phagocytos
intracellular
kill
activ
play
vital
role
pathogenesi
diabet
foot
infect
high
blood
level
beta
beta
proinflammatari
cytokin
detect
initi
phase
inflamm
studi
aim
investig
chang
phagocyt
intracellular
kill
activ
pmnl
blood
level
beta
treatment
diabet
foot
infect
dfi
obtain
pretreat
period
week
treatment
period
polymorphonuclear
leukocyt
cellsml
separ
venou
blood
edta
ficollhypaqu
gradient
centrifug
pmnl
incub
candida
albican
blastospor
number
ingest
organ
per
pmnl
calcul
wound
care
ration
antibacteri
therapi
hiperbar
oxygen
therapi
constitut
treatment
protocol
beta
level
detect
three
period
elisa
quantikin
hs
r
system
inc
us
statist
analysi
perform
mannwhitney
utest
p
admit
meaning
result
twentythre
case
respond
therapi
complet
amput
perform
eight
case
respond
therapi
statist
signific
increas
phagocyt
activ
pmnl
detect
respond
group
wherea
signific
chang
intracellular
kill
activ
pmnl
due
treatment
detect
none
group
statist
signific
decreas
blood
level
beta
detect
respond
group
week
nonrespond
group
beta
level
increas
slightli
statist
signific
week
treatment
beta
level
decreas
slightli
group
statist
signific
hand
significantli
chang
beta
level
respond
nonrespond
group
week
treatment
vs
p
present
studi
confirm
increas
phagocyt
activ
pmnl
decreas
blood
level
beta
correl
well
good
clinic
prognosi
treatment
dfi
chlamydia
pneumonia
risk
factor
acut
myocardi
infarct
clinic
microbiolog
infect
volum
supplement
conclus
believ
c
pneumonia
properti
develop
chronic
infect
trigger
process
ami
risk
factor
although
direct
risk
factor
ami
preand
postop
chang
complement
complement
level
acut
append
object
cytokin
nitric
oxid
play
import
role
human
immunolog
respons
aim
studi
determin
role
immun
respons
patient
infect
echinococcu
granulosu
method
thirtytwo
patient
cystic
echinocosi
ce
studi
underw
surgeri
serum
level
tumor
necrosi
factoralpha
tnfalpha
interleukin
receptor
solubl
nitratenitr
creactiv
protein
crp
evalu
surgeri
first
day
three
month
post
oper
data
compar
obtain
healthi
volunt
result
elev
vast
major
ce
patient
increas
slight
increas
tnfalpha
level
found
limit
number
particularli
show
cyst
central
area
liver
beta
level
elev
patient
crp
nitrat
nitrat
level
also
increas
posit
correl
crp
r
p
found
confirm
link
inflamm
due
ce
activ
monocyt
patient
complet
recov
studi
paramet
level
declin
normal
level
except
one
patient
recurr
diseas
occur
interv
year
first
oper
conclus
result
suggest
differ
immunoregulatori
event
cytokin
respons
ce
may
part
relat
slight
monocytosi
ce
patient
crp
involv
host
immun
respons
e
granulosu
may
use
marker
diagnosi
monitor
ce
manag
evalu
surgic
stress
detect
fc
receptor
releas
streptococc
isol
anginosu
group
g
bancescu
r
matr
n
skaug
bancescu
bucharest
ro
bergen
n
object
oral
streptococci
especi
belong
anginosu
group
main
facult
anaerob
microorgan
involv
oral
infect
aim
studi
detect
solubl
fc
receptor
fcr
secret
streptococc
strain
anginosu
group
isol
either
singl
bacteria
associ
microorgan
pu
sampl
collect
patient
differ
pyogen
oral
maxillofaci
infect
method
strain
identifi
speci
level
use
rapid
id
strep
system
biomerieux
franc
cellfre
supernat
sampl
obtain
cultur
isol
blot
onto
nitrocellulos
membran
biorad
laboratori
use
multifiltr
apparatu
horseradish
peroxidaserabbit
antiperoxidas
complex
pap
dakoimmunoglobulin
dakopatt
denmark
use
react
bound
fcr
afterward
second
antibodi
goat
antirabbit
antibodi
conjug
horseradish
peroxidas
addit
sigma
immuno
chemic
use
detect
horseradish
peroxidas
order
visual
immun
complex
result
forti
isol
identifi
anginosu
one
three
isol
found
belong
intermediu
constellatu
speci
respect
posit
fcr
reaction
greyblu
dot
obtain
test
sampl
conclus
streptococci
anginosu
group
involv
pyogen
infect
secret
small
amount
fcr
detect
sensit
dotimmunobind
assay
pathogenesi
anim
model
includ
experiment
treatment
object
microgli
cell
behav
cell
innat
immun
brain
order
studi
pathogenesi
mening
blood
monocyt
trigger
cerebrospin
fluid
csf
sera
patient
bacteri
abacteri
mening
method
cerebrospin
fluid
blood
serum
collect
upon
admiss
nine
patient
bacteri
mening
twentyfour
patient
abacteri
mening
mononuclear
cell
isol
healthi
individu
densiti
gradient
centrifug
heparin
whole
blood
ficollhypaqu
wash
three
time
phospatebuff
salin
ph
suspend
flask
incub
one
hour
co
nonadher
cell
remov
monocyt
resuspend
plate
rpmi
fb
mm
glutamin
densiti
cellswel
minut
incub
co
sampl
csf
sampl
serum
patient
ad
differ
well
volunt
cell
subsequ
incub
hour
co
tnfa
interferonc
ifnc
measur
cultur
supernat
enzym
immunoassay
procalcitonin
pct
assay
base
immunochemoluminesc
object
aim
studi
evalu
influenc
isol
patient
gastric
ulcersguand
chronic
gastropathycgcandida
strain
gastric
secret
gastric
ulcer
heal
rat
condit
aspirinasa
oral
administr
evalu
influenc
probiot
gu
heal
method
investig
wistar
rat
equip
gastric
fistula
gu
induc
acet
acidulc
area
mm
anim
divid
group
rat
inocul
day
c
albican
cfumlig
preced
day
suppli
proteinas
ukg
ig
promot
fungal
colon
aspirinasa
mgkgig
ii
rat
receiv
candida
asa
proteinas
group
besid
lactobacillu
acidophilu
cfuml
ig
iii
rat
guinduc
given
vehiclesalineand
proteinas
anim
sacrif
day
upon
induct
ulcer
area
measur
planimetri
gastric
blood
flowgbfwa
determin
h
ga
clearanc
gastric
biopsi
taken
quantit
qualit
mycolog
investig
histopatholog
plasma
level
tnfa
gastrin
measur
rtpcr
express
ilb
tnfa
evalu
gastric
tissu
result
rat
inocul
fungi
given
asa
gastric
output
reduc
gbf
decreas
comparison
rat
given
vehiclegroup
iii
rat
group
iii
show
progress
decreas
area
gu
day
respect
contrast
ulcer
present
till
day
rat
inocul
candida
rat
given
probiot
decreas
gu
area
observ
rapidli
comparison
group
candida
colon
rat
upregul
tnfa
ilb
mrna
rise
plasmagastrin
tnfa
ilb
ifc
level
record
conclus
fungal
colon
could
achiev
rat
antisecretori
asa
treatment
fungal
infect
markedli
reduc
gastric
secret
delay
gastric
ulcer
heal
probabl
due
fail
gbf
ulcer
area
maintain
mucos
inflamm
involv
express
releas
ilb
tnfa
administr
probiot
reduc
delay
gu
heal
caus
candida
inocul
introduct
helicobact
pylori
commonli
associ
gastriti
sometim
caus
clinic
signific
infecti
diseas
gastric
peptic
ulcer
diseas
develop
diseas
depend
virul
infect
h
pylori
strain
suscept
host
environment
cofactor
cytotoxin
associ
protein
encod
caga
gene
import
virul
factor
produc
h
pylori
strain
use
virul
marker
popul
aim
studi
determin
preval
caga
gene
virul
factor
h
pylori
strain
type
iranian
gud
pud
patient
shigella
sonnei
major
caus
diarrheal
diseas
develop
well
develop
countri
epidemiolog
studi
organ
limit
lack
simpl
effect
method
compar
strain
studi
epidemiolog
marker
import
attempt
trace
sourc
infect
use
pfge
ericpcr
studi
genet
related
isol
sonnei
collect
seoul
quantit
illustr
relationship
within
larg
bodi
isol
comput
gener
dendrogram
use
determin
number
isol
pulsotyp
dice
coeffici
similar
isol
shigella
sonnei
isol
patient
seoul
pfge
experi
band
similar
divid
group
af
band
pattern
xbai
digest
produc
fragment
size
rang
kb
isol
outbreak
show
ident
pfge
pattern
differ
outbreak
strain
sporad
strain
show
ident
differ
pfge
pattern
ericpcr
techniqu
success
type
isol
examin
produc
band
bp
size
rang
suscept
strain
chloramphenicol
amikacin
cefoxitin
preval
respect
case
multipl
antibiot
resist
pattern
preval
pattern
nasmsxtt
follow
amnasmsxttict
outbreak
infect
aim
bacteri
type
provid
laboratori
evid
epidemiolog
relat
isol
also
genet
relat
isol
outbreak
show
ident
pfge
pattern
differ
outbreak
strain
sporad
strain
show
ident
differ
pfge
pattern
found
pfge
ericpcr
highest
discriminatori
power
differenti
strain
sonnei
ericpcr
fingerprint
particularli
use
simplic
repres
less
time
consum
procedur
conclud
possibl
typic
clinic
laboratori
analyz
larg
amount
pfge
inform
shigella
isol
obtain
control
condit
data
analysi
enhanc
surveil
capabl
give
indic
work
variou
aspect
bacteri
pathogen
speci
inactiv
mraz
mraw
gene
dcw
cluster
salmonella
enterica
serovar
typhimurium
versatil
adapt
bacteri
pathogen
well
complex
varieti
antimicrobi
resist
mechan
even
last
gener
antibiot
actual
use
caus
seriou
health
problem
develop
countri
reemerg
infecti
diseas
consid
total
erad
work
group
tri
discov
new
antibacteri
target
highli
specific
select
essenti
surviv
pathogen
bacteri
studi
model
salmonella
enterica
serovar
typhimuruium
stm
present
import
virul
factor
capac
replic
intracellularli
epitheli
cell
necessari
develop
complex
molecular
mechan
improv
penetr
intracellular
surviv
replic
host
cell
focus
bacteri
divis
process
specif
mraz
mraw
gene
locat
begin
divis
cell
wall
cluster
tri
determin
potenti
charact
gene
like
use
target
design
therapeut
strategi
allow
limit
infect
avoid
acquisit
antimicrobi
resist
mechan
sinc
pathogen
stm
given
capac
penetr
nonphagocit
host
cell
design
delet
mutant
stm
mraz
mraw
gene
impli
process
cellular
divis
mrazwmut
obtain
use
simpl
pcr
homolog
recombin
techniqu
first
use
set
ntprimer
amplifi
chloramphenicol
resist
gene
flank
frt
region
flp
recognit
target
follow
homolog
region
gene
adjac
mraz
mraw
gene
use
pcr
product
transform
compet
stm
cell
contain
low
number
copi
temperatur
sensit
vector
express
red
recombinas
phage
lambda
control
arabinos
induc
promot
afterward
select
chloramphenicol
resist
mutant
final
antibiot
resist
gene
elimin
use
plasmid
show
ampicillin
chloramphenicol
resist
temperaturesensit
replic
thermal
induct
recombinas
flp
synthesi
subject
mutant
sever
test
like
vitro
intracellular
infect
test
use
nonphagocit
celllin
hela
nih
nrk
parallel
test
use
mous
model
order
determin
kinet
valu
intracellular
prolifer
carri
identif
pathogen
caus
outbreak
streptococcu
sui
toxic
shock
syndrom
meningoceph
swine
human
jq
tang
cj
wang
hb
guo
xz
pan
nanj
rc
object
reveal
relationship
pathogen
toxic
shock
syndrom
meningoceph
outbreak
pig
human
east
china
method
epidemiolog
survey
isol
identif
pathogen
bacteria
perform
result
charact
diseas
quick
onset
seriou
symptom
short
cours
high
mortal
main
clinic
manifest
diseas
high
fever
sometim
nausea
vomit
diarrhoea
might
develop
myositi
fasciti
dic
multipl
organ
failur
shock
usual
die
day
among
patient
manifest
clinic
streptococc
toxic
shock
syndrom
stss
streptococc
meningoceph
syndrom
mortal
respect
bacterium
strain
isol
blood
cerebrospin
fluid
specimen
diseas
pig
patient
identifi
streptococcu
sui
base
biochem
reaction
rrna
gene
sequenc
analysi
isol
pig
human
also
show
indistinguish
antibiot
pulsefield
gel
electrophoresi
pattern
conclus
pathogen
isol
blood
patient
pig
identifi
swine
streptococci
suggest
outbreak
streptococcu
sui
sepsi
spread
pig
human
realtim
pcr
screen
women
termruptur
membran
carriag
group
b
streptococcu
object
evalu
light
cycler
pcr
assay
detect
group
b
streptococcu
gb
carriag
women
termruptur
membran
comparison
convent
cultur
method
low
vagin
swab
obtain
pregnant
women
present
term
ruptur
membran
incub
h
brainheart
infus
broth
dna
extract
instagen
matrix
biorad
realtim
pcr
amplif
detect
cfb
target
perform
lightcycl
roch
sampl
process
parallel
convent
cultur
hsa
islam
plate
confirm
gb
isol
latex
agglutin
result
twenti
sampl
posit
gb
convent
cultur
wherea
pcr
assay
detect
gb
carriag
case
although
two
pcrneg
sampl
posit
repeat
test
pcr
falseneg
result
alway
correl
low
number
target
cell
therebi
indic
problem
extract
andor
inhibit
rather
sensit
per
se
neg
posit
predict
valu
pcr
assay
respect
overal
sensit
assay
conclus
although
realtim
pcr
assay
gener
result
within
h
receipt
sampl
current
method
highlight
need
optimis
dna
extract
purif
protocol
use
clinic
set
studi
continu
address
optimis
sampl
process
dna
extract
step
today
medicin
take
advantag
latest
achiev
natur
scienc
success
employ
new
techniqu
diagnost
treatment
diseas
recent
moleculargenet
scienc
appli
field
diagnost
sexual
transmit
diseas
std
addit
convent
culturebas
serolog
method
technolog
vitro
specif
dnaamplif
polymeras
chain
reaction
pcr
molecular
method
mani
advantag
high
sensit
high
specif
option
standard
human
immunodefici
viru
hiv
member
retrovirida
famili
hiv
genom
resembl
retrovirus
typic
gag
pol
env
gene
organ
hiv
establish
perman
infect
provir
dna
integr
host
cell
genom
hiv
shown
infect
varieti
cell
includ
peripher
lymphocyt
macrophag
cell
hiv
associ
immun
system
dysfunct
respons
opportunist
infect
involv
aid
transmiss
hiv
blood
transfus
diagnosi
infect
hospit
public
health
set
continu
worldwid
concern
polyclon
monospecif
antibodi
hiv
recombin
antigen
capsid
protein
region
develop
rabbit
purifi
gel
filter
affin
chromatographi
techniqu
purifi
antibodi
conjug
horseradish
peroxidas
enzym
captur
enzym
link
immunosorb
assay
elisa
develop
detect
antigenemia
hivneg
human
sera
fail
react
develop
assay
therebi
show
specif
hiv
antigenaemia
assay
seventyf
human
posit
serum
sampl
well
human
neg
serum
sampl
test
presenc
antigen
develop
refer
assay
abbot
lab
usa
concord
sampl
test
assay
result
studi
show
develop
antigenaemia
assay
could
use
detect
hiv
infect
human
earli
appear
detect
antibodi
viru
assay
appear
highli
sensit
specif
hiv
test
also
sever
advantag
includ
rel
short
test
time
importantli
adequ
reproduc
suppli
antibodi
use
research
need
better
evalu
develop
assay
reactiv
larger
number
hiv
posit
sera
object
aim
studi
determin
procalcitonin
pct
creactiv
protein
crp
level
earli
syphili
es
case
evalu
indic
diagnosi
syphili
method
twentynin
patient
es
patient
bacteraemia
healthi
blood
donor
control
group
includ
studi
pct
level
blood
sampl
measur
monoclon
immunoluminometr
method
result
mean
pct
level
minimummaximum
found
ngml
es
group
ngml
bacteraemia
group
ngml
control
group
pct
level
es
case
statist
higher
observ
healthi
blood
donor
p
area
roc
receiv
oper
characterist
curv
use
pct
predict
earli
syphili
ci
sensit
specif
posit
predict
valu
neg
predict
valu
pct
respect
ngml
optim
concentr
consequ
pct
level
found
slightli
higher
cutoff
valu
mean
ngml
es
conclus
research
first
preliminari
studi
determin
pct
level
es
case
spite
number
casecontrol
case
result
suggest
pct
use
addit
marker
ngml
optim
serum
concentr
accord
roc
curv
convent
laboratori
test
result
fals
posit
fals
neg
nevertheless
believ
new
extend
serial
casecontrol
studi
need
support
result
microagglutin
test
complement
elisa
examin
serolog
diagnosi
legionella
infect
kw
pancer
w
gut
h
stypulkowskamisiurewicz
warsaw
pl
poland
laboratori
diagnosi
legionella
infect
gener
base
serolog
investig
bacteria
l
pneumophila
sg
frequent
caus
sever
pneumonia
less
frequent
l
pneumophila
serogroup
legionella
speci
examin
serum
sampl
use
elisa
iga
igm
igg
assay
method
choic
laboratori
detect
l
pneumophila
sg
l
pneumophila
legionella
speci
infect
microagglutin
test
usedin
studi
determin
signific
titr
serum
antibodi
l
pneumophila
serogroup
legionella
speci
base
result
examin
serum
sampl
collect
blood
donor
titr
antibodi
determin
use
antigen
prepar
inhous
refer
strain
l
pneumophila
other
legionella
statist
analysi
obtain
result
allow
determin
cutoff
titr
use
antigen
valu
cutoff
l
pneumophila
sg
l
longbacha
cutoff
l
pneumophila
sg
l
micdadei
l
jordani
cutoff
l
pneumophila
sg
l
bozemanii
l
anisa
use
cutoff
point
abl
elimin
signific
titr
due
crossreact
l
pneumophila
serogroupsdetermin
specif
serum
iga
igm
igg
antibodi
level
l
pneumophila
sg
commerci
elisa
sensit
standaris
inform
faster
microagglutin
test
howev
point
view
microagglutin
test
use
complement
test
elisa
especi
diagnosi
infect
due
l
pneumophila
serogroup
legionella
speci
serum
sampl
test
year
signific
titr
antibodi
specif
one
serogroup
l
pneumophila
found
use
mat
sera
increas
signific
level
igm
antibodi
l
pneumophila
sg
rang
iga
antibodi
determin
elisa
probabl
connect
crossreact
antigen
structur
l
pneumophila
strain
moreov
two
case
legionellosi
due
l
micdadei
diagnos
case
antibiot
chang
patient
recov
unspecif
symptom
rather
high
mortal
rate
diseas
microbiolog
diagnosi
legionella
infect
done
use
mani
supplementari
techniqu
possibl
object
aim
studi
evalu
extern
profici
test
microbiolog
laboratori
locat
tehran
suburb
identif
three
unknown
bacteria
method
survey
extern
programm
distribut
laboratori
tehran
select
microorgan
shigella
flexneri
sreptococcu
agalactia
stenotrophomona
maltophilia
flexneri
sent
agalactia
maltophilia
microbiolog
laboratori
ask
laboratori
identif
unknown
organ
perform
suscept
test
flexneri
return
answer
refer
laboratori
within
week
receipt
sampl
score
result
determin
accord
extern
survey
criteria
result
laboratori
receiv
answer
laboratori
laboratori
produc
correct
answer
identif
flexneri
receiv
score
point
laboratori
produc
incorrect
answer
identif
organ
remain
laboratori
receiv
score
point
mean
score
sd
lab
lab
produc
correct
answer
identif
maltophilia
lab
receiv
zero
score
point
remain
lab
receiv
score
point
mean
score
sd
lab
identifi
agalactia
correctli
obtain
score
point
abl
identifi
organ
therefor
receiv
score
point
ream
laboratori
obtain
score
point
mean
sore
sd
result
suscept
test
satisfi
major
laboratori
produc
correct
answer
suscept
test
flexneri
mean
score
assum
result
extern
qualiti
control
tehran
microbiolog
laboratori
accept
conclus
studi
reveal
unfortun
profici
test
microbiolog
laboratori
tehran
poor
poor
result
due
defect
reagent
l
cultur
media
inappropri
settlement
intern
qualiti
control
programm
unqualifi
technologist
method
analyt
studi
patient
gastrointestin
sign
studi
endocopi
done
biopsi
taken
antrum
specimen
process
shandon
tissu
processor
citadel
prepar
section
stain
hematoxylineosin
giemsa
slide
studi
two
pathologist
one
microbiologist
also
cc
blood
taken
determin
anti
hp
igg
elisa
method
object
campylobact
spp
recogn
major
caus
acut
bacteri
enter
develop
countri
sever
potenti
virul
factor
propos
import
factor
pathogenesi
campylobact
jejuni
eg
motil
adher
invas
toxin
product
toxin
c
jejuni
character
molecular
level
cytoleth
distend
toxin
cdt
cdt
gene
also
found
variou
gram
neg
bacteria
aim
studi
examin
whether
level
cdt
express
impact
clinic
outcom
patient
infect
c
jejuni
method
level
cdt
express
clinic
c
jejuni
isol
patient
campylobacteriosi
determin
use
hela
cell
assay
presenc
three
cdt
code
gene
cdta
cdtb
cdtc
test
isol
pcr
presenc
titr
serum
neutral
antibodi
cdt
correspond
patient
serum
also
measur
clinic
data
obtain
patient
use
standardis
questionnair
result
pcr
examin
cdt
gene
reveal
strain
wild
type
sequenc
remain
strain
major
delet
cdt
gene
three
c
jejuni
strain
undetect
level
cdt
strain
low
cdt
titr
high
titr
cdt
neutral
antibodi
found
patient
sera
level
anticdt
antibodi
correl
level
igg
igm
iga
whole
cell
heatstabl
c
jejuni
antigen
result
show
trend
low
cdt
titr
increas
risk
patient
becom
febril
neither
cdt
express
presenc
cdt
neutral
antibodi
patient
serum
correl
clinic
outcom
thu
studi
indic
cdt
use
diagnost
purpos
studi
present
patient
treat
clinic
infecti
diseas
last
two
year
exhibit
sign
mening
excit
without
neurolog
disord
normal
cytolog
biochem
find
cerebrospin
fluidth
common
diagnos
virosi
bronchopneumonia
pharyng
vertigin
syndrom
urin
infect
etc
major
patient
year
old
among
report
previou
convuls
end
even
inform
us
earlier
head
trauma
patholog
electroencephalograph
eeg
find
observ
male
femal
patient
eeg
disord
occur
mostli
day
diseas
among
patient
patholog
eeg
find
consciou
somnol
sopor
accord
locat
eeg
chang
tempor
region
domin
frontal
region
rarest
unspecif
eeg
disord
exhibit
irrit
chang
steeper
wave
specif
chang
opinion
earlier
convuls
head
trauma
patient
explain
way
react
mening
neurolog
symptom
infect
clinic
microbiolog
infect
volum
supplement
dissoci
step
result
disrupt
bind
antibodi
antigen
assay
protocol
develop
evalu
use
well
characteris
sampl
collect
hiv
infect
individu
use
rang
serolog
molecular
assay
ai
identifi
threshold
hiv
infect
probabl
occur
within
previou
day
avid
index
advantag
determin
rel
time
hiv
infect
use
one
sampl
often
case
perform
unlink
epidemiolog
investig
data
present
show
applic
assay
investig
newli
identifi
hiv
infect
comparison
result
patient
bacteri
sepsissever
sepsi
includ
bacteraemia
gramposit
bacteraemia
gramneg
bacteraemia
statist
signific
differ
either
bacterem
nonbacterem
p
gramneg
gramposit
p
bacterem
patient
regard
fever
cutoff
valu
ngml
pct
discrimin
bacterem
nonbacterem
septic
patient
p
posit
predict
valu
sensit
bacteraemia
signific
differ
pct
valu
gram
posit
gramneg
bacterem
patient
cutoff
ngml
pct
posit
predict
valu
gramneg
bacteraemia
conclus
fever
discriminatori
power
bacteraemia
septic
patient
use
pct
assess
could
help
physician
limit
number
blood
cultur
process
urogenit
mycoplasma
diagnosi
identif
sensit
test
antibiot
gulbinov
ambrasien
vilniu
kauna
lt
u
urealyticum
uu
homini
mh
speci
famili
mycoplasmatacea
smallest
bacteria
replic
cultur
medium
possess
peptidoglycan
cell
wall
tini
microorgan
found
commens
lower
genitourinari
tract
sexual
activ
men
women
moreov
caus
mani
disord
nongonococc
urithr
postpartum
fever
infertil
pelvic
inflammatori
diseas
human
speci
found
date
belong
mollicuta
class
differ
bacteria
lack
cell
wall
henc
natur
resist
alactam
well
presenc
membran
rich
sterol
obtain
adhes
eukaryot
cell
object
aim
present
studi
evalu
occurr
uu
mh
nongonococc
urethr
determin
bacteri
resist
seven
antibiot
order
determin
suitabl
treatment
strategi
method
total
patient
enrol
studi
urethr
sampl
taken
dacron
swab
place
urethra
cm
male
vagin
sampl
taken
endocerv
region
women
mycofast
evolut
detect
urogenit
mycoplasma
growth
liquid
milieu
growth
uu
mh
metabolis
urea
arginin
respect
result
colour
chang
medium
contain
phenol
red
indic
yelloworang
red
colour
chang
due
liber
ammonia
result
alkalin
ph
medium
mix
cell
granuloma
common
histolog
featur
suppur
granuloma
common
histolog
featur
afb
could
found
statist
significantli
differ
type
granuloma
tuberculoid
granuloma
common
afb
neg
group
compar
afb
posit
group
differ
statist
signific
case
afb
could
found
inflamm
tend
locat
upper
half
dermi
conclus
afb
frequent
detect
suppur
granuloma
might
locat
portion
dermi
multidrug
resist
mycobacterium
tuberculosi
centr
tunisia
ana
ferritin
ngl
region
nation
world
problem
intens
prevent
measur
must
appli
rigor
determin
mycobacterium
tuberculosi
drug
resist
mazandaran
provinc
iran
ahanjan
vahedi
nasrollahi
sari
ir
object
tuberculosi
tb
one
import
infecti
diseas
main
caus
mortal
develop
countri
drug
resist
lead
failur
treatment
follow
unafford
expens
administr
iran
plan
necessari
educ
programm
soon
possibl
erad
tuberculosi
iran
method
sputum
individu
refer
health
centr
suspect
tb
collect
steril
contain
decontamin
petroph
method
concentr
supernat
remov
collect
contain
disinfect
sediment
inocul
onto
lowensteinjensen
medium
incub
c
week
smear
prepar
collect
sampl
zeihlneelsen
stain
perform
look
presenc
mycobacterium
min
growth
medium
week
inocul
transfer
partment
mycobacteriolog
cultur
media
observ
growth
mycobacterium
tuberculosi
tb
tuberculosi
diabet
risk
realiti
viciou
combin
tuberculosi
tb
hiv
wellestablish
though
wellcontrol
unnot
meet
tb
diabet
predominantli
type
particularli
lowincom
countri
fast
transit
india
eg
adult
anoth
prestag
impair
glucosetoler
may
activ
tb
risk
activ
tb
mexico
risk
reactiv
tb
patient
increas
time
compar
increas
risk
tb
among
hivinfect
world
health
organis
preview
year
mio
may
develop
countri
remain
seen
tb
may
doubl
quadrupl
wake
epidem
case
tb
hiv
mechan
behind
increas
risk
reactiv
tb
dm
poorli
understood
present
knowledg
lack
thereof
highlight
suggest
given
futur
research
possibl
measur
control
emerg
health
problem
meningoencephalomielopolyradiculonevr
mycobacterium
tuberculosi
case
report
c
jianu
r
iubu
ciutica
clujnapoca
ro
object
tuberculosi
still
repres
public
health
problem
develop
underdevelop
countri
report
case
central
nervou
system
tuberculosi
yearold
femal
admit
hospit
fever
headach
loss
weight
progress
disabl
walk
present
fever
later
cervic
lymphadenopathi
object
neurolog
sign
coma
nuchal
rigid
kernig
sign
posit
lack
abdomin
cutan
reflex
osteotendin
reflex
paraplegia
converg
strabismu
perform
ct
brain
scan
routin
hematolog
chemic
test
chest
xray
lumbar
punctur
csf
cultur
blood
cultur
result
ct
brain
scan
reveal
cerebr
edema
object
increas
incid
tuberculosi
multidrug
resist
mdr
among
mycobacterium
tuberculosi
strain
remain
one
major
public
health
problem
poland
geograph
posit
lublin
mean
potenti
mdr
strain
former
soviet
union
countri
like
present
rapid
detect
mdr
optim
efficaci
antituberculosi
therapi
control
transmiss
aim
studi
compar
current
method
drug
suscept
test
two
molecular
assay
method
innolipa
rif
tb
appli
detect
mutat
rpob
gene
confer
rifampicin
resist
noncommerci
lowdens
macroarray
mdrtb
screen
array
detect
mutat
rpob
kat
g
inh
gene
respons
rifampicin
isoniazid
resist
respect
differenti
tuberculosi
complex
speci
confirm
use
biochem
analys
niacin
accumul
test
spoligotyp
base
polymorph
chromosom
direct
repeat
dr
locu
contain
variabl
number
short
dr
interspers
nonrepetit
spacer
result
mdr
strain
cultur
patient
pulmonari
extrapulmonari
tuberculosi
laboratori
public
hospit
subject
suscept
test
rifampicin
isoniazid
resist
ratio
method
lj
medium
strain
analys
innolipa
rif
mdrtb
screen
array
spoligotyp
phenotyp
test
establish
isol
rifampicin
isoniazid
resist
use
resist
ratio
method
gold
compar
object
evalu
perform
bactalert
biomerieux
franc
isol
mycobacteria
comparison
wensteinjensen
medium
addit
seri
studi
conduct
detect
sensit
pnitrobenzo
acid
test
differenti
mycobacterium
tuberculosi
complex
mycobacteria
social
secur
institut
sureyyapasa
chest
diseas
hospit
istanbul
method
investig
seri
differ
sampl
sputum
bronchial
aspir
pleural
fluid
bronchoalveolar
lavag
gastric
lavag
urin
periton
fluid
lenfadenopathi
drenag
recov
patient
three
major
servic
treat
naoh
decontamin
concentr
procedur
sampl
cultiv
bactalert
mp
bottl
wensteinjensen
medium
acidfast
stain
employ
smear
prepar
time
presenc
growth
bactalert
mp
bottl
monitor
record
addit
evalu
effici
bact
alert
mp
medium
rapid
differenti
mycobacteria
ad
pnb
result
among
smearposit
smearneg
specimen
mycobacteria
grew
bactalert
mp
lj
media
smearposit
sampl
bactalert
system
show
day
earlier
smear
neg
sampl
contamin
ratio
bactalert
lj
respect
total
mean
time
detect
bact
alert
mp
bottl
approxim
day
shorter
wensteinjensen
media
determin
bottl
mycobacterium
tuberculosi
complex
show
growth
late
growth
compar
bottl
contain
pnitrobenzo
acid
mycobacteria
bottl
show
type
growth
bottl
contain
pnitrobenzo
acid
mean
time
pnitrobenzo
acid
test
mycobacteria
mycobacterium
tuberculosi
complex
exceed
day
conclus
show
perform
pnitrobenzo
acid
test
bactalert
mp
bottl
sensit
rapid
thu
total
test
time
mycobacteria
system
provid
abil
meet
day
target
detect
identif
tuberculosi
complex
recommend
center
diseas
control
prevent
atlanta
ga
usa
earli
diagnosi
lung
tuberculosi
automat
system
probetec
etth
bectondickinson
result
total
sampl
posit
mtc
dna
sampl
bc
posit
neg
sampl
bc
posit
mtc
dna
neg
atyp
mycobacteria
present
case
one
cultur
contamin
elud
identif
mtc
dna
posit
bc
neg
sampl
mtc
could
demonstr
other
half
patient
ltb
therapi
start
conclus
sda
method
quickli
effici
easi
earli
diagnosi
ltb
h
overal
case
bc
posit
achiev
sensibl
compar
bc
specif
consid
techniqu
use
ltb
therapi
monitor
multidrugresist
tuberculosi
diseas
caus
mycobacterium
tuberculosi
strain
resist
least
rifampin
isoniazid
entail
extend
treatment
expens
toxic
regimen
higher
rate
treatment
failur
death
document
presenc
multidrugresist
tuberculosi
mdrtb
strain
patient
turkey
black
sea
region
januari
octob
retrospect
analys
outcom
patient
treat
untreat
test
primer
second
resist
isoniazid
rifampicin
streptomycin
ethambutol
multi
drug
resist
specimen
perform
use
bactec
system
commonli
encount
cultureposit
specimen
sputum
bal
fluid
object
tubercul
brain
abscess
tba
rare
clinic
entiti
even
endem
area
lesion
may
occur
treatment
tubercul
mening
drug
resist
well
defin
central
nervou
system
tuberculosi
case
report
yearsold
immunocompet
young
man
admit
diplopia
nausea
vomit
chang
mental
statu
patient
histori
tubercul
mening
diagnos
six
month
anoth
hospit
given
antituberculosi
treatment
isoniazid
inh
rifampicin
rf
pyrazinamid
prz
ethambutol
etb
two
month
follow
two
drug
treatment
inh
rf
four
month
comput
tomographi
ct
scan
brain
show
noncommun
hydrocephalu
patient
oper
hydrocephalu
place
ventriculoperiton
shunt
two
mount
later
patient
hospit
fever
dysfagia
left
hemiparesi
cranial
ct
scan
within
normal
howev
magnet
reson
imag
mri
examin
reveal
irregular
multilocul
peripher
contrast
enhanc
lesion
hypointens
necrot
centr
within
left
cerebellar
hemispher
extend
upper
posterior
cervic
subarachnoid
space
left
medullacerebellar
fissur
abscess
drain
surgic
oper
acid
resist
bacillu
arb
demonstr
abscess
materi
zeihlneelsen
stain
polymeras
chain
reaction
pcr
isoniazid
resist
mycobacterium
tuberculosi
grew
lowensteinjensen
cultur
medium
one
month
oper
quadryparezi
develop
cervic
mri
reveal
cervicothorac
syringomyelit
caviti
treatment
given
four
drug
inh
rf
prz
etb
month
continu
three
drug
month
patient
tubercul
mening
observ
close
complic
like
brain
abscess
isol
tuberculosi
must
test
drug
resist
pneumocysti
jiroveci
patient
pulmonari
infect
l
nimri
j
amer
irbid
jor
object
patient
acut
chronic
respiratori
problem
mainli
tuberculosi
tb
suspect
case
concern
opportunist
infect
apart
tb
pneumocysti
jiroveci
may
miss
owe
lack
diagnost
facil
aim
studi
investig
extent
p
jiroveci
pneumonia
patient
respiratori
tract
infect
especi
tb
patient
regist
smearneg
method
three
hundr
specimen
includ
bronchoalveolar
lavag
sputum
collect
patient
differ
pulmonari
infect
test
nest
pcr
p
jiroveci
tb
result
p
jiroveci
detect
patient
tb
neg
acid
fastsmear
pcr
dual
infect
tb
patient
includ
old
patient
alcohol
heavi
smoker
post
primari
tb
patient
result
suggest
might
risk
factor
pneumocysti
pneumonia
pcp
patient
pcp
somehow
differ
clinic
present
radiograph
appear
patient
tb
pcp
infect
might
overlook
due
concurr
infect
tb
make
diagnosi
difficult
conclus
use
sensit
diagnost
method
diagnosi
pcp
patient
respiratori
tract
infect
respons
treatment
recommend
suscept
test
pathogen
fungi
fluconazol
tea
camellia
sinensi
candida
albican
z
nasrolahi
tehran
ir
tea
camellia
sinensi
recent
shown
inhibit
growth
rang
bacteria
microfungi
studi
candida
albican
standard
strain
test
invitro
suscept
fluconazol
tea
contain
whole
extract
lahijan
fresh
tea
leav
black
tea
chines
green
tea
tea
polyphenol
caffein
rapid
revers
phase
hplc
method
determin
polyphenol
use
binari
gradient
system
develop
present
research
aim
determin
minimum
inhibitori
concentr
tea
extract
tea
polyphenol
caffein
concentr
mgml
cell
candida
albican
two
period
h
macrodilut
broth
test
techniqu
perform
fluconazol
use
compar
studi
found
resist
strain
fluconazol
mic
lgml
minimum
inhibitori
concentr
mfc
calcul
studi
evid
antifung
activ
polyphenol
fluconazoleresist
candida
albican
obtain
result
confirm
caffein
rather
polyphenol
produc
better
treatment
outcom
obtain
mfc
polyphenol
comparison
whole
extract
tea
better
inhibitori
effect
h
candida
albican
aspergillosi
maxilla
sinu
patient
maxillofaci
surgeri
clinic
cracow
poland
budak
dzierwa
b
bogusz
j
zapala
p
nowak
cracow
pl
object
aim
paper
analyz
occurr
aspergillosi
maxilla
sinu
among
patient
hospit
maxillofaci
surgeri
clinic
connect
estim
result
laboratoryclin
diagnost
appli
togeth
therapeut
procedur
method
subject
analysi
group
patient
chronic
inflamm
maxilla
sinu
hospit
clinic
diagnosi
aspergillosi
perform
basi
interview
object
subject
studi
radiolog
studi
midoper
estim
state
mucou
membran
insid
sinu
basi
histolog
mycolog
examin
aspir
taken
oper
maxilla
sinu
subject
mycolog
investig
diagnost
includ
direct
microscop
examin
cultur
sabouraud
agar
microcultur
estim
mic
itraconazol
voriconazol
use
etest
result
aspergillosi
maxilla
sinu
diagnos
patient
male
femal
age
respect
year
case
mycolog
examin
patient
presenc
septat
mycelium
prove
direct
prepar
one
case
presenc
aspergillu
conidiophor
also
state
person
posit
result
prepar
prove
cultur
mould
genu
aspergillu
identifi
patient
isol
recogn
aspergillu
niveu
candidu
histolog
examin
patient
presenc
foreign
bodi
also
state
lumen
sinu
numer
septat
mycelium
also
identifi
prepar
patient
treat
combin
surgic
antifung
therapi
use
itraconazol
one
patient
ambison
conclus
appli
therapeut
procedur
caus
signific
improv
local
gener
condit
patient
confirm
result
mycolog
investig
interview
took
place
along
time
surgic
oper
one
patient
invas
form
aspergillosi
observ
togeth
expand
inflamm
process
eyesocket
lower
part
front
skull
object
amphotericin
b
deoxychol
ambd
standard
therapi
system
mycos
associ
signific
advers
event
ae
includ
nephrotox
nt
object
describ
ambd
therapi
ambd
relat
ae
clinic
outcom
method
retrospect
chart
review
undertaken
academ
centr
geneva
switzerland
patient
ifi
receiv
ambd
initi
therapi
data
abstract
includ
ambd
mean
daili
dose
mdd
ae
clinicalmicrobiolog
respons
antifung
treatment
aft
mortal
nt
increas
baselin
serum
creatinin
scr
baselin
scr
upper
normal
limit
absolut
increas
mgdl
success
defin
complet
partial
clinic
respons
time
admit
hospit
outsid
croatia
treat
mix
bacteri
streptococcu
sangui
fungal
candida
albican
sepsi
tricuspid
valv
endocard
hospit
complic
pulmonari
embol
femor
thrombosi
bilater
pneumonia
requir
bilater
thorac
drainag
candida
albican
infect
treat
liposom
amphotericin
b
week
follow
oral
fluconazol
discharg
decemb
stabl
condit
given
fluconazol
mgday
methadon
mainten
therapi
case
present
patient
admit
hospit
march
two
blood
cultur
taken
outpati
set
grew
candida
albican
despit
continu
fluconazol
therapi
echocardiographi
perform
veget
cm
diamet
found
tricuspid
valv
also
thrombot
mass
cm
diamet
right
ventricl
cours
liposom
amphotericin
b
intraven
fluconazol
mgday
given
follow
oral
fluconazol
mgday
patient
becam
afebril
howev
blood
cultur
taken
may
grew
candida
albican
june
surgeri
perform
excis
veget
tricuspid
valv
right
ventricl
one
day
prior
surgeri
treatment
intraven
caspofungin
mg
day
follow
mg
day
start
candida
albican
grew
cultur
veget
suscept
fluconazol
amphotericin
b
intraven
caspofungin
given
week
follow
oral
fluconazol
mgday
follow
month
recrudesc
endocard
observ
antiretrovir
treatment
start
april
combin
stavudin
lamivudin
lopinavirritonavir
given
throughout
cours
ill
well
toler
conclus
initi
caspofungin
treatment
follow
fluconazol
mainten
therapi
addit
vegetectomi
success
treatment
candida
albican
rightsid
endocard
hiv
infect
patient
survey
preval
identif
dermatophytosi
northern
iran
iran
j
hashemi
nasrollahi
omran
tehran
tonekabon
ir
object
month
period
june
septemb
experi
patient
suspect
dermatophytosi
refer
clinic
medic
mycolog
itch
irrit
materi
method
skin
sampl
taken
scrape
patient
collect
diagnosi
confirm
direct
microscopi
carri
koh
prepar
cultur
perform
petri
dish
mycobiot
agar
dermatophyt
medium
dtm
dermatophyt
diagnosi
test
taxanom
identif
speci
thu
complet
questionnair
analysi
preval
dermatophytosi
result
result
show
total
case
suffer
dermatophytosi
diseas
confirm
microscop
examin
cultur
posit
case
patient
suffer
diseas
male
rest
femal
case
age
group
effect
diseas
lightli
higher
incid
age
group
seventi
per
cent
case
patient
live
citi
rest
case
villag
major
patient
driver
case
rest
student
case
offic
case
collar
worker
case
case
farmer
frequenc
clinic
type
accord
anatom
site
involv
dermatophytosi
groin
thu
tinea
cruri
predomin
clinic
form
ring
worm
infect
see
rest
case
case
tinea
manum
tinea
pedi
case
tinea
capiti
case
tinea
corpori
case
tinea
unguium
nineti
five
per
cent
case
tinea
barba
eighti
per
cent
tinea
capiti
ectothrix
rest
endothrix
tinea
favosa
epidermophyton
floccosum
common
etiolog
agent
case
rest
encount
dermatophytosi
includ
rubrum
case
violaceum
case
mentagrophyt
case
verrcosum
case
schoenleinii
case
sonsuden
case
cani
case
found
anthropophil
infect
case
appear
six
time
frequent
zoophil
one
case
conclus
statist
evalu
obtain
data
indic
decreas
trend
toward
frequenc
tinea
capit
grow
trend
toward
tinea
cruri
studi
highlight
common
problem
mani
area
northern
iran
suggest
measur
regard
public
health
special
person
hygien
must
undertaken
order
reduc
risk
dermatophytosi
colonis
oral
caviti
candida
speci
object
aim
studi
assess
colon
oral
caviti
otherwis
healthi
individu
oral
symptom
dri
mouth
burn
mouth
syndrom
candida
speci
determin
suscept
antimycot
drug
nystatin
nystatin
frequent
use
topic
prophylaxi
treatment
oral
candidiasi
method
studi
examin
oral
yeast
colon
particip
sampl
collect
tongu
swab
cultur
sabouraud
dextros
agar
h
isol
identifi
germ
tube
product
chlamydospor
develop
cornmeal
agar
tween
difco
detroit
usa
id
candida
identif
kit
biomerieux
marcyletoil
franc
suscept
profil
evalu
disk
diffus
method
nystatin
neosensitab
taalstrup
denmark
muellerhinton
agar
result
time
sampl
individu
posit
colon
candida
speci
isol
correspond
candida
albican
two
isol
identifi
c
kefyr
c
pseudotropicali
one
c
glabrata
isol
suscept
nystatin
conclus
candida
albican
main
candida
speci
colon
oral
caviti
nonc
albican
speci
rare
detect
sinc
isol
suscept
nystatin
safe
use
prophylaxi
oral
candidiasi
patient
oral
symptom
dri
mouth
burn
mouth
syndrom
confirm
c
dubliniensi
candida
spp
object
c
dubliniensi
cd
often
identifi
c
albican
ca
special
routin
mycolog
practic
two
speci
share
characterist
posit
produc
chlamydospor
aim
studi
distinguish
cd
candida
spp
immunocompet
immunodefici
patient
clinic
specimen
method
candida
spp
isol
test
use
algorithmtoler
osmot
resist
broth
contain
nacl
phenotyp
featur
chrom
agar
pal
agar
qualiti
control
use
c
albican
c
dubliniensi
result
one
hundr
twenti
three
strain
candida
spp
isol
genitourinari
tract
immunocompet
patient
test
cd
strain
confirm
candida
spp
oral
caviti
haematolog
patient
swab
hiv
posit
person
confirm
one
strain
cd
cd
growth
sabouraudagar
growth
broth
nacl
pal
agar
coloni
characterist
pseudohyph
root
chlamydospor
chromagar
cd
dark
bluegreen
colour
distinguish
lightblu
ca
coloni
conclus
use
algorythm
chlamydospor
format
togeth
two
method
growth
cultiv
pal
agar
present
easi
method
distinguish
c
dubliniensi
c
albican
candida
spp
clinic
laboratori
specimen
candidosi
due
candida
guilliermondii
analysi
eleven
case
object
attempt
separ
colon
infect
review
clinic
record
patient
candida
guilliermondii
identifi
clinic
specimen
method
retrospect
studi
posit
cultur
c
guilliermondii
obtain
octob
august
santa
casa
complexo
hospitalar
brazil
record
mycolog
laboratori
review
attempt
identifi
posit
cultur
c
guilliermondii
clinic
record
patient
also
review
candidemia
diagnos
peripher
posit
blood
cultur
tempor
relat
sign
symptom
histopatholog
cytopatholog
examin
show
c
guilliermondii
specimen
needl
aspir
biopsi
exclud
mucou
membran
consid
evid
invas
infect
well
posit
cultur
result
sampl
obtain
steril
procedur
normal
steril
site
result
eleven
patient
includ
studi
specimen
correspond
blood
n
asciti
fluid
n
pericardi
fluid
n
urin
n
colon
biopsi
n
esophagu
mucosa
n
patient
mainli
male
age
rang
day
year
six
patient
immunosuppress
transplant
recipi
aid
cancer
expos
invas
procedur
periton
dialysi
abdomin
surgeri
patient
candidemia
favor
respons
amphotericin
b
treatment
one
case
immunocompet
patient
receiv
antifung
therapi
two
case
present
c
guilliermondii
periton
associ
dialysi
cathet
favor
evolut
antifung
therapi
cathet
remov
conclus
seri
patient
demonstr
although
c
guilliermondii
associ
invas
diseas
presenc
may
repres
colon
even
infect
low
pathogen
mainli
immunocompet
patient
frequent
associ
c
guilliermondii
cathet
use
intraven
periton
urinari
common
candida
speci
infect
asept
techniqu
rigor
perform
process
blood
sampl
avoid
mistak
interpret
isol
c
guilliermondii
clinic
specimen
import
coexist
candida
fungi
bacteria
helicobact
pylori
object
except
well
known
role
helicobact
pylori
hp
pathogenesi
ulcer
diseas
ud
chronic
gastriti
cg
role
presenc
candida
c
fungi
stomach
evalu
problem
coexist
candida
helicobact
pylori
gastric
mucosa
influenc
ulcer
heal
cours
chronic
gastriti
explain
aim
studi
evalu
frequenc
c
patient
gastric
ulcer
gu
duoden
ulcer
du
cg
estim
frequenc
hp
gu
du
cg
evalu
frequenc
coexist
c
hp
patient
identifi
c
speci
isol
patient
gu
du
cg
evalu
influenc
hp
erad
frequenc
presenc
c
stomach
method
examin
group
patient
patient
hp
erad
therapi
age
year
dyspept
ulcer
symptom
clinic
investig
includ
clinic
histori
gastroscopi
biopsi
ureas
test
histopatholog
mycolog
evalu
hp
presenc
also
brush
smear
chang
gastric
mucosa
aspir
gastric
juic
taken
mycolog
investig
bacteriolog
investig
includ
hp
cultur
incub
co
flow
b
identif
hp
speci
evalu
ureas
catalas
oxydas
activ
mycolog
investig
examin
materi
evalu
basi
qualit
quantit
investig
identif
isol
fungi
albican
id
atb
system
bio
merieux
use
result
presenc
c
stomach
found
patient
hp
erad
therapi
respect
find
c
hp
erad
erad
patient
respect
coexist
c
hp
stomach
found
case
c
albican
frequent
isol
speci
conclus
c
hp
coexist
found
case
hp
erad
therapi
contain
proton
pump
inhibitor
antibiot
may
increas
frequenc
fungal
colon
stomach
mucosa
molecular
characteris
gtpbind
protein
gene
dermatophyt
pathogen
trichophyton
rubrum
rezai
f
nourbakhsh
f
fallahyan
tehran
ir
trichophyton
rubrum
rubrum
anthropophil
dermatophyt
infect
caus
fungu
mostli
confin
keratin
epitheli
layer
rubrum
common
caus
agent
dermatophytosi
human
skin
nail
tissu
properti
rubrum
investig
molecular
level
howev
inform
avail
regard
gtpbind
protein
dermatophyt
gtpbind
protein
regul
varieti
process
includ
sensual
percept
protein
synthesi
variou
transport
process
cell
differenti
present
studi
tri
character
gtpbind
protein
gene
dermatophyt
pathogen
rubrum
obtain
patient
dermatophytosi
cultur
appropri
condit
nucleic
acid
dna
rna
isol
obtain
myceli
mass
standard
method
pair
nt
primer
design
highli
conserv
region
gtpbind
protein
gene
eukaryot
cell
mention
primer
util
pcr
use
isol
genom
dna
well
cdna
templat
rubrum
predict
molecul
amplifi
sequenc
time
nucleotid
gene
sequenc
character
pcr
fragment
reveal
signific
homolog
gtpbind
protein
genbank
ncbi
nih
usa
still
investig
trichophyton
rubrum
rubrum
one
dermatophyt
fungi
invad
skin
human
sever
properti
fungu
investig
far
howev
studi
carri
field
molecular
biolog
fungu
present
studi
tri
identifi
vacuolar
atpas
protein
vatpas
fungu
pair
nt
primer
design
highli
conserv
region
gene
fungi
mention
primer
util
pcr
use
isol
genom
dna
well
cdna
templat
rubrum
pcr
fragment
sequenc
time
nucleotid
sequenc
new
gene
encod
polypeptid
amino
acid
nucleotid
sequenc
comparison
gene
data
bank
ncbi
nih
dna
deduc
amino
acid
sequenc
reveal
signific
homolog
vatpas
gene
protein
eukaryot
cell
molecular
character
gene
well
definit
possibl
role
physiolog
function
rubrum
still
investig
new
gene
submit
intern
genbank
ncbi
nih
usa
aspergillu
arthriti
immunocompet
patient
azap
demir
kaya
yagci
e
teke
h
riz
n
numanoglu
ankara
tr
case
aspergillu
opportunist
pathogen
caus
sever
clinic
diseas
immunosuppress
patient
wide
distribut
natur
rare
caus
diseas
immunocompet
patient
yearold
immunocompet
femal
patient
admit
hospit
one
half
month
implant
bilater
knee
prothesi
underli
diseas
complaint
fever
cough
hemoptysi
pleurit
chest
pain
dyspnea
week
oper
hospit
suspicion
pulmon
thromboembol
anticoagul
therapi
start
purulan
drainag
knee
notic
follow
polymorphonuclear
leukocyt
gramposit
cocci
seen
microscop
examin
joint
fluid
teicoplanin
treatment
begun
improv
fever
resolv
necrot
area
appear
teicoplanin
treatment
patholog
examin
necrot
materi
demonstr
fungal
hypha
cultur
grew
aspergillu
niger
amphotericin
b
start
along
debridman
patient
improv
dramat
day
amphotericin
b
therapi
knee
patient
well
without
prothesi
replac
still
good
health
three
month
discharg
conclus
prosthet
joint
infect
troublesom
complic
orthoped
surgeri
usual
gramposit
microorgan
caus
infect
descend
order
gramneg
bacilli
candida
spp
may
caus
agent
aspergillu
arthriti
rare
clinic
entiti
especi
immunocompet
patient
interest
side
case
rescument
prothesi
medic
therapi
debridman
fungaemia
yeast
portugues
univers
hospit
epidemiolog
suscept
profil
period
c
pinavaz
porto
p
fungaemia
report
caus
septicemia
intern
literatur
inher
seriou
morbid
signific
mortal
local
epidemiolog
data
problem
yet
avail
object
defin
preval
fungaemia
due
yeast
respect
risk
factor
reservoir
distribut
speci
suscept
antifung
pattern
method
yeast
isol
blood
cultur
month
univers
hospit
porto
collect
data
like
demograph
aspect
hospit
depart
presenc
central
venou
cathet
indwel
medic
devic
concomit
diseas
well
antimicrobi
therapi
collect
addit
concomit
isol
yeast
distinct
bodi
site
also
regist
nosocomi
natur
infect
investig
follow
biochem
character
isol
perform
vitek
system
suscept
pattern
antifung
like
amphotericin
b
fluconazol
itraconazol
voriconazol
caspofungin
determin
accord
nccl
protocol
result
total
blood
yeast
strain
identifi
repres
posit
blood
cultur
intern
medicin
surgic
depart
hematologyoncolog
infecti
diseas
depart
c
albican
c
parapsilosi
isol
similar
percentag
c
tropicali
c
glabrata
cryptococcu
neoforman
c
guillermondii
c
lusitanea
strain
suscept
amphotericin
b
except
c
lusitanea
isol
resist
r
fluconazol
suscept
dosedepend
sdd
r
voriconazol
mic
lgml
r
itraconazol
sdd
r
caspofungin
mic
lgml
conclus
fungaemia
due
yeast
repres
import
concern
among
us
nonalbican
speci
candida
preval
compar
intern
studi
due
fact
resist
antifung
found
signific
extent
c
krusei
show
promot
resist
oxid
stress
costadeoliveira
c
pinavaz
p
ludovico
porto
braga
p
candida
great
concern
isol
resist
antifung
c
krusei
paradigma
exampl
whose
pathogen
yet
full
understood
often
neg
mechan
like
germ
tube
format
product
enzym
like
coagulas
recent
studi
implic
role
adapt
respons
oxid
pathogenesi
reactiv
oxygen
speci
ro
produc
mainli
phagocyt
cell
host
immun
system
microbi
effect
lead
destruct
potenti
pathogen
object
studi
respons
c
krusei
oxid
stress
agent
method
blastoconidea
clinic
strain
c
krusei
strain
c
albican
stain
lgml
mitotrack
red
molecular
probe
min
expos
oxid
stress
agent
mm
h
mm
menadion
lm
plumbagin
sigma
differ
period
time
min
treatment
cell
analys
flow
cytomet
beckman
coulter
xlmcl
mitotrack
red
emit
fluoresc
enter
activ
respiratori
cell
oxid
agent
ro
strain
affect
agent
ro
show
increas
intens
fluoresc
result
c
albican
show
increas
intens
fluoresc
expos
oxid
stress
agent
increas
time
incub
convers
minor
variat
intens
fluoresc
seen
c
krusei
strain
test
conclus
c
krusei
rel
protect
agent
ro
compar
c
albican
strain
work
need
clarifi
import
role
regard
pathogen
object
determin
speci
candida
fungi
induc
respiratori
tract
infect
pulmonari
tuberculosi
tb
patient
analyz
resist
antimycot
method
cultur
inocul
onto
sabouraud
medium
chloramphenicol
microscopi
bronchoalveolar
lavag
sputum
estim
quantit
concentr
candida
spp
specimen
sampl
lung
caviti
pleural
caviti
aspir
biopsi
lung
tissu
sampl
resect
identif
isol
strain
morpholog
cornmeal
agar
candiselect
medium
testsystem
biorad
antimycot
resist
determin
use
microdilut
method
valid
nccl
refer
method
testsystem
biorad
result
studi
patient
differ
form
pulmonari
tb
inocul
clinic
sampl
reveal
strain
candida
spp
patient
group
cultur
result
confirm
posit
microscopi
clinic
sampl
detect
speci
candida
detect
rate
c
albican
strain
c
glabrata
c
krusei
c
tropicali
c
parapsilosi
c
kefyr
c
guilliermondii
c
lusitania
suscept
antimycot
fluconazol
itraconazol
amphotericin
b
ketoconazol
miconazol
test
candida
strain
strain
c
albican
c
glabrata
c
tropicali
c
krusei
c
parapsilosi
c
kefyr
c
guilliermondii
c
lusitania
resist
fluconazol
detect
studi
strain
strain
c
albican
c
glabrata
c
krusei
c
tropicali
resist
itraconazol
strain
strain
c
albican
c
glabrata
c
tropicali
also
found
strain
resist
miconazol
strain
ketoconazol
strain
strain
strain
c
lusitania
resist
amphotericin
b
conclus
pulmonari
tb
patient
administ
longterm
adequ
cours
chemotherapi
antituberculosi
drug
compos
risk
group
candidosi
consid
experiment
data
candida
clinic
strain
resist
deem
administr
specif
treatment
pulmonari
candidosi
fluconazol
itraconazol
advis
identifi
strain
determin
suscept
antimycot
candida
speci
isol
blood
steril
fluid
distribut
suscept
object
last
decad
yeast
infect
emerg
import
caus
nosocomi
infect
candida
infect
associ
signific
morbid
mortal
monitor
candida
speci
distribut
among
signific
isol
resist
requir
materi
method
consecut
strain
candida
spp
isol
blood
normal
steril
fluid
cultur
gener
hospit
athen
period
examin
isol
speciat
vitek
ii
system
biomerieux
franc
suscept
test
amphotericin
b
fluconazol
flucytosin
itraconazol
voriconazol
perform
etest
ab
biodisk
sweden
result
interpret
accord
nccl
result
total
candida
spp
strain
isol
respect
number
patient
hospit
surgeri
n
intern
medicin
n
icu
n
person
receiv
fluconazol
prophylaxi
previous
sixti
five
strain
origin
blood
steril
fluid
cultur
nine
candida
speci
identifi
c
albican
repres
common
n
follow
c
parapsilosi
n
c
glabrata
n
c
tropicali
n
howev
c
albican
isol
rate
decreas
steadili
c
glabrata
isol
rate
increas
strain
suscept
amphotericin
b
mic
mgl
singl
c
krusei
strain
flucytosin
resist
mic
mgl
resist
fluconazol
mic
mgl
itraconazol
mic
observ
strain
respect
c
glabrata
c
krusei
speci
often
resist
azol
strain
respect
c
albican
least
resist
strain
resist
voriconazol
mic
mgl
detect
among
isol
strain
c
glabrata
strain
c
parapsilosi
conclus
similarli
data
countri
result
greec
show
increas
isol
rate
speci
c
albican
blood
steril
fluid
cultur
increas
frequenc
c
glabrata
strain
resist
convent
azol
detect
voriconazol
demonstr
good
vitro
activ
candida
speci
result
ratio
isol
patient
b
capitatu
studi
period
among
clinic
isol
bc
collect
deep
site
blood
lower
respiratori
tract
steril
fluid
biopsi
abscess
recov
mucos
site
system
involv
overal
mgl
amb
fc
fz
iz
kz
vz
al
avail
bc
differ
suscept
isol
deep
mucos
site
conclus
clear
increas
rate
isol
b
capitatu
occur
second
period
studi
institut
although
establish
breakpoint
defin
antifung
suscept
bc
voriconazol
amphotericin
b
appear
activ
antifung
agent
data
show
reduc
suscept
bc
flucytosin
fluconazol
itraconazol
ketoconazol
anidulafungin
evalu
candiselect
chromogen
medium
yeast
differenti
u
nawrot
k
wlodarczyk
j
skala
apm
przondomordarska
n
nolard
wroclaw
pl
brussel
b
object
candiselect
biorad
chromogen
medium
recommend
manufactur
select
isol
yeast
direct
identif
candida
albican
presumpt
clinic
microbiolog
infect
volum
supplement
identif
c
glabrata
c
tropicali
c
krusei
identif
base
speci
specif
color
coloni
morpholog
name
pinkpurpl
c
albican
dark
turquois
smooth
c
tropicali
dark
turquois
rough
c
krusei
pale
turquois
c
glabrata
studi
evalu
perform
candiselect
identif
clinic
yeast
isol
method
total
number
strain
includ
c
albican
c
glabrata
c
krusei
c
tropicali
c
parapsilosi
c
inconspicua
c
kefyr
c
guilliermondi
c
dubliniensi
c
rugosa
c
norvegensi
c
lusitania
c
lipolytica
cerevisia
c
neoforman
p
anomala
strain
obtain
bccm
ihem
collect
clinic
isol
collect
depart
microbiolog
medic
univers
wroclaw
identifi
previous
use
standard
method
eg
test
base
rdna
restrict
fragment
length
polymorph
qualiti
control
six
typic
candida
strain
atcc
bacteri
isol
use
yeast
cultur
candiselect
medium
incub
c
day
coloni
morpholog
pigment
read
visual
everi
h
result
pinkpurpl
coloni
found
c
albican
c
dubliniensi
h
color
c
dubliniensi
coloni
becam
purplebluish
differ
c
albican
purpleviolet
pink
halo
around
color
coloni
morpholog
strain
c
tropicali
c
krusei
c
glabrata
agreement
manufactur
descript
among
remain
investig
candida
noncandida
speci
colorless
white
coloni
seldom
differ
shade
blue
green
observ
problem
discrimin
c
glabrata
c
inconspicua
c
parapsilosi
c
kefyr
c
norvegensi
sensit
specif
valu
c
albican
c
tropicali
c
krusei
c
glabrata
conclus
candiselect
could
regard
use
medium
presumpt
identif
commonli
isol
candida
speci
includ
fluconazol
resist
vitro
activ
amphotericin
b
aleuriconidia
deriv
aspergillu
terreu
c
rl
rief
mayr
innsbruck
aspergillu
terreu
uncommon
emerg
fungal
pathogen
caus
lethal
infect
often
refractori
amphotericin
b
amb
suggest
aleuriconidia
might
sourc
amb
resist
studi
use
aleuriconidia
inoculum
compar
minim
inhibitori
concentr
mic
amb
voriconazol
vrz
obtain
conidia
terreu
strain
use
broth
microdilut
method
addit
examin
vitro
suscept
hypha
deriv
aleuriconidia
conidia
terreu
mic
rang
amb
conidia
aleuriconidia
lgml
lg
ml
respect
mic
rang
vrz
conidia
aleuriconidia
lgml
lgml
respect
mic
rang
amb
hypha
conidia
aleuriconidia
lgml
lgml
mic
rang
vrz
lgml
lgml
conclus
data
confirm
amb
mic
terreu
aleuriconidia
differ
dramat
comparison
mic
obtain
conidia
vrz
significantli
activ
aleuriconidia
show
consist
lower
mic
clinic
evalu
aspergilluspcr
detect
invas
aspergillosi
immunosuppress
patient
c
rl
g
gastl
mp
dierich
petzer
innsbruck
evalu
valu
aspergillu
pcr
tool
diagnos
invas
aspergillosi
patient
risk
aspergillosi
assess
accord
european
organ
research
treatment
cancermycosi
studi
group
definit
nine
patient
proven
probabl
aspergillosi
evalu
whole
blood
sampl
prior
antifung
treatment
tissu
specimen
bronchoalveolar
lavag
fluid
investig
patient
proven
infect
sensit
pcr
lung
sampl
blood
sampl
prior
treatment
treatment
clearanc
fungal
dna
blood
associ
resolut
clinic
symptom
patient
proven
infect
consecut
posit
pcr
result
aspergillu
associ
fatal
outcom
patient
die
patient
probabl
infect
sensit
pcr
lung
fluid
blood
sampl
prior
treatment
treatment
benefit
pcr
diagnos
screen
whole
blood
limit
sampl
take
place
treatment
start
perform
aspergillu
pcr
tissu
sampl
recommend
addit
microscop
examin
cultur
techniqu
sensit
detect
fungal
infect
identif
dermatophyt
use
partial
digest
object
routin
identif
dermatophyt
timeconsum
process
depend
morpholog
form
spore
inform
mostli
pend
expertis
research
object
design
fast
easi
robust
identif
techniqu
allow
identif
speci
level
cultur
dermatophyt
method
intern
transcrib
spacer
region
pcr
follow
fragment
analysi
de
baer
et
al
shown
fast
reliabl
identif
techniqu
yeast
use
primer
univers
fungi
also
mold
dermatophyt
dermatophyt
howev
consist
varieti
speci
highli
relat
ident
therefor
ad
partial
restrict
digest
increas
discriminatori
power
result
total
speci
repres
strain
test
speci
uniqu
fingerprint
obtain
differ
speci
constant
member
speci
except
speci
minor
intraspecif
differ
obtain
speci
found
differ
fingerprint
uniqu
also
found
speci
lead
member
precis
identif
speci
level
final
number
speci
ident
fingerprint
final
identif
could
obtain
conclus
partial
digest
fragment
length
analysi
enabl
identif
dermatophyt
speci
level
speci
cluster
speci
sometim
highli
relat
method
well
observ
discrep
might
part
explain
yet
resolv
taxonomi
may
indic
exist
yet
describ
speci
need
reclassif
strain
techniqu
seen
fast
identif
techniqu
routin
encount
dermatophyt
work
especi
well
genera
arthroderma
epidermophyton
microsporon
trichophyton
speci
difficult
identifi
object
victim
sever
trauma
suscept
opportunist
fungal
infect
zygomycosi
rare
lifethreaten
infect
commonli
caus
rhizopu
speci
describ
case
child
necrot
fasciiti
caus
rhizopu
success
treat
posaconazol
po
investig
triazol
antifung
agent
vitro
activ
zygomycet
case
report
girl
sustain
bilater
haemorrhag
contus
tempor
brain
lobe
fractur
skull
left
tibia
deglov
left
leg
hit
truck
druginduc
coma
initi
control
resist
intracrani
hypertens
initi
treatment
leg
injuri
includ
almost
daili
remov
necrot
skin
muscl
tissu
hyperbar
oxygen
therapi
thirteen
day
accid
rhizopu
spp
trichosporon
oviod
cultur
multipl
wound
swab
subsequ
therapi
liposom
amphotericin
b
lamb
mgd
initi
three
day
later
sever
area
necrot
black
ulcer
suggest
invas
zygomycosi
observ
patient
show
sign
sepsi
avoid
leg
amput
suspect
sourc
infect
excis
daili
hyperbar
oxygen
treatment
given
po
oral
suspens
mgd
divid
dose
ad
lamb
therapi
po
given
via
nasogastr
tube
first
day
oral
thereaft
day
sign
sepsi
disappear
though
patient
continu
experi
fever
next
week
lamb
discontinu
day
drugassoci
toxic
anticip
necrot
fasciiti
respond
gradual
antifung
treatment
two
week
initi
po
rhizopu
longer
detect
histolog
cultur
superfici
tissu
muscl
specimen
object
cryptococcu
neoforman
import
pathogen
patient
impair
cellmedi
immun
common
caus
fungal
meningoenceph
c
neoforman
facult
intracellular
pathogen
sever
welldefin
virul
factor
includ
product
polysaccharid
capsul
melanin
growth
identif
character
enzym
produc
c
neoforman
import
potenti
role
virul
induct
host
immun
respons
epidemiolog
type
method
thirtynin
strain
includ
studi
obtain
patient
aid
patient
lymphoproliph
diseas
enzymat
profil
c
neoforman
isol
obtain
use
apizym
system
franc
wholecel
assay
inoculum
cellsml
phospholipas
activ
test
use
eggyolk
plate
method
ratio
coloni
diamet
diamet
coloni
plu
pericoloni
precipit
zone
agar
pz
correl
phospolipas
activ
result
test
strain
identifi
grubii
neoforman
varieti
standard
method
apizym
system
screen
test
activ
enzym
eleven
enzym
found
posit
signific
differ
two
group
isol
observ
activ
butyr
esteras
detect
strain
activ
capryl
esteras
lipas
leucin
arilamidas
acid
phosphatas
regist
isol
activ
follow
enzym
neg
lipas
cystin
arilamidas
trypsin
chymotrypsin
alphagalactosidas
nacetylbetaglucosaminidas
alphamannosidas
alphafucosidas
seventeen
enzymat
pattern
identifi
accord
profil
obtain
apizym
system
one
strain
isol
aid
patient
detect
phospholipas
neg
signific
differ
phospholipas
product
isol
obtain
patient
aid
lymphoproliph
diseas
mean
pz
vs
p
conclus
found
differ
enzymat
activ
strain
infect
two
differ
group
immunocompromis
patient
enzymat
activ
pathway
could
separ
relat
c
neoforman
virul
recent
demonstr
extracellular
phospholipas
activ
virul
factor
fungu
epidemiolog
antifung
sensit
result
nosocomi
infect
caus
candida
speci
patient
patient
candidemia
hospit
intens
care
unit
c
albican
promin
candida
speci
follow
c
glabrata
c
tropicali
c
parapsilosi
c
krusei
c
lusitania
c
kefyr
c
sake
c
pulcherrima
isol
sensit
amphotericin
b
mic
fluconazol
resist
c
albican
speci
respect
resist
itraconazol
found
higher
c
albican
speci
crossresist
itraconazol
determin
isol
resist
fluconazol
conclus
high
resist
azol
consid
indic
inappropri
antifung
usag
paid
attent
empir
antifung
treatment
azol
routin
use
clinician
without
differenti
infect
colonis
contamin
especi
candida
speci
isol
urinari
tract
threaten
efficaci
safeti
antifung
therapi
antifung
sensit
test
use
determin
region
antifung
sensit
pattern
follow
patient
invas
infect
like
candidemia
need
long
term
therapi
determin
resist
choos
altern
antifung
drug
unrespons
recurr
mucos
diseas
tropic
parasit
diseas
object
loiasi
nematod
parasit
infect
endem
subsaharan
western
africa
nativ
peopl
endem
area
emigr
develop
countri
often
infect
worm
report
case
conjunctiv
loiasi
young
black
male
born
guinea
case
report
patient
live
spain
last
year
complain
eye
pain
notic
pass
left
attend
ophtalmolog
emerg
care
moder
eosinophilia
present
peripher
blood
inflammatori
reaction
calabar
swell
present
surgic
medic
treatment
patient
discharg
hospit
present
time
month
latter
remain
asymptomat
result
presenc
migrat
subconjunctiv
worm
observ
remov
surgic
identifi
femal
adult
loa
loa
mm
blood
sampl
collect
daytim
lm
long
microfilaria
observ
direct
wet
smear
hematoxylin
stain
show
extern
sheath
giemsa
stain
nuclei
extend
end
tail
microfilaria
discharg
femal
worm
preserv
destil
water
laboratori
room
temperatur
day
seven
free
form
egg
present
haemonchosi
diseas
caus
haemonchu
contortu
consider
econom
import
sheep
cattl
goat
throughout
world
sever
infect
sheep
may
caus
consider
morbid
mortal
rate
even
moder
infect
lamb
may
give
rise
bodi
weight
reduct
adult
caus
variou
degre
anaemia
decreas
anim
product
control
depend
repeat
applic
anthelmint
therefor
mani
attempt
develop
vaccin
diseasein
trial
ahwaz
area
abil
experiment
vaccin
made
whole
gut
homogen
haemonchu
contortu
evalu
group
arabian
femal
lamb
immun
twice
lm
whole
gut
homogen
wgh
haemonchu
contortu
dilut
ml
pb
emulsifi
ml
freund
adjuv
group
arabian
femal
lamb
receiv
ml
pb
emulsifi
ml
adjuv
first
immun
perform
intra
muscularli
semimembran
muscl
hind
leg
booster
immun
administ
subcutan
day
day
lamb
challeng
approxim
haemonchu
contortu
thirdstag
larva
first
immun
challeng
anim
bled
interv
day
weekli
challeng
end
studi
sera
test
elisa
westernblot
lamb
necropsi
week
postchalleng
recoveri
nemetodesvaccin
lamb
show
reduct
mean
epg
reduct
mean
male
worm
number
reduct
mean
femal
worm
number
reduct
mean
total
worm
number
signific
differ
mean
optic
densiti
sera
elisa
notic
p
protein
hemonchu
contortu
gut
seper
sdspage
sera
vaccin
group
indic
high
reactiv
westernblot
clinic
featur
therapi
trichinosi
belaru
likelihood
clinic
diagnosi
enhanc
anamnest
epidemiolog
data
serolog
confirm
obtain
test
igm
elisa
patient
present
typic
clinic
pictur
trichinosi
includ
fever
periorbit
edema
myalgia
usual
affect
gastrocnemiu
muscl
eosinophilia
first
day
diseas
howev
patient
show
eosinopenia
within
first
day
correl
sever
diseas
clinic
featur
latter
patient
also
includ
myocard
neurolog
disord
respiratori
failuretreat
trichinosi
known
satisfactori
prescrib
antiparasit
therapi
attent
paid
phase
diseas
sever
eosinophyl
blood
count
approach
highli
individualis
consist
etiolog
pathogenet
symptomat
therapi
etiolog
therapi
aim
destruct
intestin
worm
prevent
develop
cyst
wall
around
larva
destruct
trichinella
larva
muscl
fiber
use
mebendazol
g
everi
h
day
etiolog
therapi
effect
incub
phase
first
day
diseas
localis
trichinella
still
remain
intestin
viceversa
therapi
mebendazol
muscular
period
diseas
less
effect
could
also
lead
exacerb
symptom
symptomat
therapi
includ
antihistamin
nonsteroid
antiinflammatori
drug
sever
invas
form
use
glucocorticosteroid
prednisolon
mgday
day
intestin
parasit
nativ
foreign
citizen
athen
twoyear
period
v
skandami
c
kotsi
c
achilleo
c
kontoucastellan
athen
gr
object
determin
incid
intestin
parasit
citizen
athen
analyz
differ
nativ
immigr
come
develop
countri
method
period
feacal
sampl
nativ
foreign
examin
hospit
laboratori
presenc
parasit
pathogen
treat
hospit
outpati
outpati
worker
examin
order
obtain
health
clearanc
certif
specimen
examin
direct
microscopi
use
wetmount
formalineth
concentr
method
result
specimen
examin
found
posit
pathogen
intestin
parasit
giardia
lamblia
enterobi
vermiculari
heterophy
heterophy
ancylostoma
duodenal
entamoeba
histolyticadispar
specimen
blastocysti
homini
detect
non
pathogen
amoeba
entamoeba
coli
iodamoeba
butschlii
incid
pathogen
parasit
greek
foreign
popul
conclus
frequenc
intestin
parasit
infect
greec
rel
low
rare
especi
recent
year
mani
immigr
come
develop
countri
introduc
new
parasit
alert
public
health
servic
critic
order
prevent
parasit
spread
carrier
healthi
popul
control
coccidiosi
poultri
kk
hayat
dera
ghazi
khan
pak
egg
adapt
gametocyt
e
tenella
vaccin
use
coccidiosi
chicken
day
five
chick
divid
four
group
administ
vaccin
oral
viz
vaccin
gametocyt
vaccin
ii
gametocyt
inactiv
vaccin
iii
gametocyt
sonic
inactiv
fourth
group
serv
control
given
normal
salin
day
immun
chick
challeng
sporul
oocyst
mix
speci
eimeria
total
bird
use
studi
bird
scarifi
chick
die
challeng
respons
day
post
vaccin
bird
subject
postmortem
lesion
score
record
maximum
bird
lesion
intestin
caeca
groupiv
bird
observ
minimum
bird
lesion
intestin
caeca
observ
groupiii
nonsignific
differ
p
lesion
score
groupi
ii
iv
lesion
score
groupiii
significantli
differ
p
groupi
ii
iv
cellular
immun
studi
cours
immun
anim
consegu
infect
entamoeba
histolytica
reedlesw
albino
rat
employ
strain
polyxen
cultur
enthistolytica
use
isol
patient
carrier
immun
rat
kill
antigen
compos
trophozoi
per
ml
medium
administ
subcutan
time
interv
week
follow
immun
rat
infect
caecum
ml
live
cultur
contain
trophozoit
day
pi
rat
appear
infect
day
pi
end
observ
infect
anim
regist
respect
control
anim
infect
day
young
rat
infect
infect
adult
veget
form
enthistolytica
found
caecum
moder
morpholog
chang
observ
hyperemia
oedema
haemorrhag
ulcer
submuc
membran
almost
experiment
anim
vascular
perivascular
mononuclear
infiltr
observ
help
migrat
inhibit
reaction
macrophag
establish
process
immun
subsegu
infect
lymphocyt
sensibl
amoeb
antigen
appear
rat
bodi
danger
observ
higher
degre
bodi
sensibil
evid
present
show
cellular
mechan
immun
great
signific
pathogenesi
amoebiasi
result
inflammatori
diseas
genit
preced
accompani
half
patient
leiomyoma
variou
combin
pelvic
inflammatori
diseas
method
casecontrol
reveal
high
risk
develop
myoma
uteru
rel
risk
occurr
paramet
attitud
chanc
patient
inflammatori
diseas
genit
bacteriolog
research
myomat
unit
reveal
associ
microb
flora
comparison
non
chang
fabric
uteru
identif
flora
carri
pcr
testifi
presenc
chlamydia
trachomati
mainli
submuc
ureaplasma
urealyticum
intermuscularsubser
myomat
unit
even
absenc
oper
underli
depart
sexual
way
pathohistolog
research
non
struck
myoma
uterus
remov
concern
endometr
combin
purul
tuboovarian
format
three
women
year
old
shown
format
reclaim
rudiment
consist
prolifer
concentr
locat
smoothlymuscular
cell
smc
around
inflammatori
infiltr
myometriumleiomyomatoz
immunohistochem
research
pcna
establish
accumul
nucleu
smc
inflammatori
mononuclear
infiltr
zone
myometrium
endometr
consid
us
trigger
myoma
uteru
conclus
opinion
uterin
fibroid
embol
ufe
prime
method
choic
treatment
myoma
uteru
case
risk
secondari
infect
degrad
unit
alloc
myomat
detritu
demand
hysterectomi
take
account
set
forth
carri
ufe
practic
use
fromilid
mg
twice
day
day
tiber
mg
twice
day
day
use
given
circuit
complex
treatment
myoma
uteru
allow
increas
effici
conserv
treatment
twice
compar
evalu
effect
urogenit
clamidiosi
treatment
antibiot
ozonotherapi
n
sarapulova
n
guryanova
kolesova
perm
ru
object
aim
studi
examin
compar
evalu
urogenit
clamidiosi
treatment
antibiot
ozonotherapi
women
childbear
age
method
two
group
women
childbear
age
year
old
urogenit
clamidiosi
investig
group
patient
treat
classic
antibiot
treatment
regimen
ii
group
got
ozonotherapi
intraven
introduct
ozon
physiolog
solut
ml
concentr
mgl
ozon
oil
use
local
estim
therapi
result
group
held
twice
month
interv
use
enzym
immunodetect
ei
diagnost
antibodi
titr
direct
immunofluoresc
di
object
direct
detect
microbi
dna
clinic
sampl
like
blood
cerebrospin
fluid
csf
requir
reliabl
dna
isol
procedur
sensit
pcr
amplif
due
low
microbi
load
clinic
sampl
respect
optim
recoveri
target
dna
extract
necessari
studi
compar
perform
dna
recoveri
autom
roch
magna
pure
total
nucleic
acid
isol
kit
mextract
manual
boom
extract
method
siextract
method
dna
recoveri
experi
conduct
pb
csf
plasma
whole
blood
replic
sampl
matrix
method
reconstruct
experi
perform
posit
control
dna
ebv
vzv
dilut
test
pcr
neg
blood
analys
pcr
also
serial
dilut
cmv
spike
cmv
neg
blood
dilut
test
analys
cmv
pcr
final
clinic
blood
sampl
test
ebv
n
cmv
n
method
result
recoveri
experi
show
reduc
recoveri
mextract
compar
siextract
matric
test
part
miss
dna
mextract
could
retriev
bind
wash
silica
matrix
dna
irretriev
posit
control
dna
show
lower
pcr
signal
mextract
compar
siextract
ebv
vzv
respect
pcr
analysi
spike
cmv
show
reduc
recoveri
loss
sensit
mextract
result
hit
rate
lowest
spike
cmv
load
wherea
siextract
obtain
object
new
therapeut
option
led
consider
improv
viral
infect
manag
also
clear
treatment
requir
care
consider
followup
monitor
viral
load
immunocompromis
patient
appli
preemptiv
diseas
manag
strategi
import
manag
opportunist
infect
prevent
diseas
order
meet
grow
clinic
demand
patient
three
sensit
assay
develop
measur
cmv
ebv
hbv
viral
dna
serum
plasma
whole
blood
method
realtim
pcr
quantit
utilis
technolog
provid
sensit
rapid
method
determin
cmv
affigen
cmv
trender
ebv
affigen
ebv
trender
hbv
affigen
hbv
trender
intern
control
ic
includ
sampl
indic
effect
inhibit
control
sampl
prepar
amplif
detect
manual
sampl
prepar
protocol
input
volum
ul
serum
plasma
whole
blood
use
result
perform
test
demonstr
affigen
cmv
trender
assay
sensit
positivityr
copi
ml
least
dynam
rang
cmv
clinic
specimen
equival
quantit
cmv
strain
shown
use
clinic
specimensaffigen
ebv
trender
assay
sensit
positivityr
copiesml
least
dynam
rang
ebv
clinic
specimen
equival
quantit
ebv
genotyp
b
shown
use
clinic
specimen
affigen
hbv
trender
assay
sensit
positivityr
uml
dynam
rang
hbv
clinic
specimen
equival
quantit
hbv
genotyp
ah
shown
use
clinic
specimen
quantit
genotyp
plasmid
normal
blood
donor
neg
hbv
serolog
crossreact
potenti
crossreact
pathogen
observ
assay
femal
infant
admit
paediatr
clinic
progress
unexplain
jaundic
light
colour
stool
symptom
began
day
admiss
examin
pediatrician
found
disten
abdomen
hepatomegali
enlarg
spleen
ultrasound
test
detect
tini
gall
bladder
hida
scan
test
radioact
dye
could
flew
billiari
system
blood
test
show
follow
pt
ptt
time
prolong
repeatedli
blood
cultur
neg
serolog
test
rule
acut
infect
b
c
e
hepat
virus
hiv
hsv
vzv
ebv
rubella
virus
toxoplasma
gondi
coxiella
burnetii
cmv
serolog
studi
base
perfom
elisa
diasorin
srl
ifa
panbio
inc
method
sera
sampl
collect
day
admiss
cmv
igg
antibodi
found
posit
elisa
test
auml
auml
auml
respect
test
sampl
cmv
igm
antibodi
found
posit
elisa
ifa
test
respect
time
pcr
analysi
carri
coba
amplicor
cmv
monitor
test
detect
cmvdna
blood
urin
sampl
first
blood
sampl
posit
copiesml
two
urin
sampl
cmv
posit
copiesml
babi
mother
cmvigg
auml
cmvigm
cmvdna
detect
blood
urin
sampl
antivir
treatment
ganciclovir
first
blood
day
urin
sampl
day
becam
neg
howev
affect
progress
damag
liver
portal
hypertens
hepat
coma
eventu
occur
conclus
cmv
perinat
congenit
infect
may
particip
etiopathogenesi
neonat
cholestasi
caus
difficult
determin
sinc
histori
matern
cmv
infect
serolog
mother
unknown
pregnanc
time
birth
time
serolog
infant
also
unknown
cmvdna
detect
month
later
enteroviru
rna
detect
rtpolymeras
chain
reaction
sixti
three
clinic
record
revis
result
isol
enteroviru
csf
posit
sampl
studi
laboratori
fortyeight
patient
male
femal
patient
year
infant
younger
one
year
enteroviru
isol
three
adult
evolut
time
hospit
admiss
less
h
case
longer
two
day
patient
hospit
requir
patient
six
discharg
h
remain
hospit
day
common
symptom
fever
headach
mening
symptom
antibiot
treatment
given
patient
case
remov
fourth
day
rest
patient
receiv
antibiot
treatment
viral
cultur
result
known
evolut
patient
favour
without
sequel
conclus
enteroviru
import
caus
viral
mening
environ
high
incid
infant
season
distribut
found
enterovirus
mening
highest
incid
record
may
june
spring
knowledg
season
distribut
diagnost
indic
help
predict
infect
month
adequ
treatment
telomeras
activ
cutan
anogenit
wart
preliminari
studi
object
evalu
telomeras
activitiy
cutaneu
anogenit
wart
method
normal
skin
genit
cutan
lesion
specimen
collect
patient
respect
telomeras
activ
detect
classic
immunohistochemstri
use
telomeras
catalyt
unit
htert
antibodi
specimen
stain
monoclon
antibodi
novocastra
result
stain
pattern
locat
basal
suprabas
locat
normal
skin
specimen
howev
telomeras
activ
basal
supra
basal
spinos
layer
detect
anogenit
wart
specimen
stain
pattern
detect
cutan
specimen
mean
telomeras
activ
specimen
anogenit
wart
cutaneu
wart
normal
skin
specimen
respect
associ
telomeras
activ
determin
anogenit
cutaneu
wart
telomeras
activ
significantli
higher
hpv
infect
group
cutaneu
anogenit
normal
skin
conclus
increas
activ
telomeras
hpv
found
studi
consist
prolif
lesion
receiv
highli
activ
antiretrovir
therapi
haart
also
hvc
infect
onset
acut
case
patient
febril
respiratori
symptom
cardiac
murmur
chest
xray
normal
nine
case
septic
embol
observ
veget
detect
twodimension
echocardiographi
tricuspid
frequent
affect
valv
case
mitral
valv
endocard
diagnos
five
case
aortic
pulmonari
valvular
insuffici
case
blood
cultur
neg
episod
three
case
polymicrobi
ie
aureu
frequent
isol
organ
episod
patient
treat
antibiot
week
need
treatment
week
therapi
depend
organ
suscept
initi
subject
empir
treat
cloxacillin
without
tobramycin
tempor
pattern
infecti
complic
hivinfect
patient
era
consequ
continu
antihiv
antimicrobi
therapi
antiretrovir
manag
indic
gabex
andor
octreotid
administr
differ
clinicallaboratori
situat
deserv
extens
control
studi
occurr
cholangiocarcinoma
aidsrel
cholang
surviv
maximum
year
surviv
thirtyon
patient
die
die
first
admiss
common
profess
driver
worker
eighti
per
cent
women
housew
one
patient
univers
graduat
heterosexu
intercours
common
rout
transmiss
blood
transfus
iv
drug
use
rout
one
male
patient
declar
men
men
sexual
relat
first
interview
detail
interview
median
count
diagnosi
min
max
mean
viral
load
diagnosi
min
max
patient
group
categori
first
admiss
commonli
detect
opportunist
infect
candid
infect
result
sustain
virolog
respons
defin
undetect
serum
hcv
rna
level
week
treatment
complet
achiev
patient
treat
interferonalfa
alon
combin
therapi
interferonalfa
ribavirin
associ
better
result
patient
still
untreat
interferonalfa
relaps
nonrespond
previou
interferonalfa
monotherapi
achiev
sustain
virolog
respons
combin
therapi
pegyl
interferon
ribavirin
use
patient
sustain
respons
achiev
one
patient
relaps
treatment
interferonalfa
ribavirin
nonrespond
combin
therapi
seriou
advers
event
necessari
reduc
dosag
even
ceas
therapi
prematur
conclus
efficaci
toler
antivir
treatment
haemophiliac
differ
patient
chronic
hepat
c
preval
hepat
b
viru
genotyp
chronic
infect
patient
e
vazquez
c
jj
picazo
madrid
e
object
hepat
b
viru
hbv
genotyp
associ
specif
pattern
liver
diseas
treatment
respons
aim
studi
determin
preval
hbv
genotyp
serum
hbvdna
level
sever
liver
diseas
chronic
infect
patient
method
total
hbv
infect
patient
enrol
male
femal
mean
age
year
rang
year
fourteen
coinfect
human
immunodefici
viru
hiv
sera
test
hbv
genotyp
revers
hybrid
line
probe
assay
innolipa
hbv
genotyp
innogenet
pcr
sensit
amplif
protocol
quantit
hbvdna
level
determin
use
coba
amplicor
monitor
kit
roch
detect
hepat
b
e
antigen
hbeag
patient
serum
sampl
also
perform
use
etiebk
enzymelink
immunosorb
assay
diasorin
result
hbv
genotyp
ag
found
genotyp
e
f
common
constitut
total
patient
popul
genotyp
b
c
g
uncommon
repres
less
one
fifteen
patient
infect
two
hbv
genotyp
hiv
coinfect
patient
genotyp
mix
g
preval
patient
detect
presenc
serum
hbeag
ten
hivinfect
associ
hbv
genotyp
mix
genotyp
g
among
patient
hbeag
neg
genotyp
f
frequent
respect
analysi
baselin
serum
hbvdna
level
hbeag
posit
patient
reveal
higher
except
two
three
mix
genotyp
genotyp
b
c
g
associ
high
level
serum
hbvdna
lower
level
serum
hbvdna
detect
patient
genotyp
neg
hbeag
conclus
data
indic
hbv
genotyp
mix
g
associ
higher
preval
hbeag
hivinfect
patient
genotyp
b
c
present
higher
serum
hbvdna
level
hbeag
neg
patient
clinic
microbiolog
infect
volum
supplement
method
rna
extract
done
serum
sampl
ivdu
chronic
hbsag
carrier
antihd
elisa
posit
twelv
pair
primer
use
amplifi
six
partial
overlap
fragment
cover
entir
hdv
genom
rtnest
pcr
pcr
product
purifi
subject
automat
cyclesequenc
procedur
edit
raw
data
accomplish
generunn
chroma
softwar
align
analysi
complet
genom
hdag
amino
acid
sequenc
carri
eleven
refer
sequenc
analys
done
clustalw
method
clustalx
softwar
subject
phylogenet
analysi
appli
neighbourjoin
model
tree
construct
result
major
patient
show
infect
genotyp
genotyp
second
common
patient
mix
type
g
polymeras
mutant
identifi
patient
mutant
observ
ymdd
variant
genotyp
mutant
detect
patient
genotyp
patient
genotyp
patient
mutat
occur
hbvdna
detect
patient
baselin
copiesml
preval
variant
viral
load
respect
follow
low
viral
load
copiesml
mutant
medium
viral
load
copiesml
mutant
high
viral
load
copiesml
mutant
conclus
genotyp
common
area
northern
greec
mutat
frequent
among
genotyp
although
appear
mutant
seem
correl
hbv
genotyp
viral
load
type
chang
propabl
relay
test
conduct
find
infect
hepat
viru
hav
genotyp
twentysix
patient
fatigu
nausea
fifteen
isol
amplifi
rtpcr
use
hav
specif
primer
compar
bp
nucleic
acid
sequenc
junction
region
genotyp
base
similar
isol
cluster
genotyp
ia
isol
separ
iiia
isol
found
genotyp
ia
sporad
japan
china
korean
strain
group
determin
geograph
region
similar
histori
patient
inform
high
relationship
endem
famili
transmiss
also
show
chang
accord
risk
age
group
follow
econom
growth
yearsold
patient
secondari
acut
viral
hepat
etiolog
diagnosi
establish
clinic
paraclin
data
serolog
marker
elisa
method
order
establish
complet
diagnosi
check
follow
syndrom
cytolit
hepatopr
billiari
retent
also
studi
paramet
age
sex
resid
period
hospit
result
total
patient
case
secondari
acut
viral
hepat
patient
infecti
mononucleosi
case
follow
patient
rubella
case
patient
cytomegaloviru
infect
case
varicella
zoster
case
patient
age
year
sex
ratio
shown
predomin
feminin
injuri
f
resid
point
view
major
children
urban
area
patient
cytolysi
syndrom
present
slight
elev
alt
n
major
case
except
one
case
infect
sever
form
hepat
billiari
retent
syndrom
hepatopr
syndrom
light
medium
case
except
patient
alreadi
mention
varicella
zoster
infect
immunodepress
person
colestat
form
chronic
case
deceas
conclus
secondari
acut
viral
hepat
present
favor
evolut
almost
case
context
viral
diseas
hepat
injuri
frequent
slight
sometim
asymptomat
diseas
gener
liver
affect
underestim
area
respons
interferonalpha
chronic
hepat
b
without
precor
mutant
strain
akhan
e
azak
karali
z
yulugkur
koca
tr
object
chronic
hepat
b
import
public
health
problem
worldwid
turkey
turkey
chronic
hepat
b
mostli
precor
mutant
strain
investig
whether
presenc
precor
mutant
affect
respons
interferonalpha
patient
chronic
hepat
b
studi
chronic
hepat
b
patient
admit
infecti
diseas
clinic
microbiolog
polyclin
last
eight
month
includ
studi
thirteen
hepat
b
e
antigenposit
hepat
b
e
antibodyneg
ten
hepat
b
e
antigenneg
hepat
b
e
antibodyposit
precor
mutant
chronic
hepat
patient
treat
natur
interferonalpha
month
treatment
patient
liver
biopsi
grade
stage
liver
diseas
liver
biopsi
show
chronic
hepat
necroinflammatori
score
cirrhosi
nobodi
interferon
therapi
serum
hbv
dna
level
criteria
begin
therapi
copiesml
precor
mutant
strain
copiesml
nonmut
strain
result
serum
hbv
dna
level
treatment
differ
two
group
p
end
treatment
serum
hbvdna
decreas
undetect
level
mutant
group
nonmut
group
decreas
serum
hbvdna
level
found
signific
z
p
mutant
group
signific
z
p
nonmut
group
six
month
treatment
percentag
case
decreas
transaminas
level
clinic
microbiolog
infect
volum
supplement
within
normal
rang
significantli
higher
mutant
group
p
nonmut
group
p
conclus
chronic
hepat
precor
mutant
strain
seem
respons
ifnalpha
reason
expect
result
may
serum
hbvdna
four
patient
nonmut
group
show
increas
spite
treatment
none
patient
mutant
group
neutrophil
oxid
metabol
children
chronic
hepat
c
wozniakowskagesicka
wisniewskaligi
p
lewkowicz
lodz
pl
grow
number
data
suggest
role
reactiv
oxygen
speci
ro
pathogenesi
chronic
type
c
hepat
activ
neutrophil
macrophag
kupffer
cell
basic
sourc
ro
cours
inflammatori
process
liver
aim
studi
assess
metabol
neutrophil
oxygen
children
chronic
hepat
c
materi
method
studi
compris
children
chronic
hepat
c
group
children
posit
serum
antihcv
antibodi
neg
hcvrna
well
normal
alt
activ
group
ii
healthi
children
group
iii
product
reactiv
oxygen
speci
neutrophil
use
method
chemiluminesc
cl
luminol
mlx
microtiti
plate
luminometr
dynex
usa
assess
estim
chemiluminesc
respons
cl
max
cl
total
neutrophil
unstimul
stimul
formylmethionylleucylphenyloalanin
fmlp
opson
zymosan
oz
phorbolmyristateacet
pma
without
prime
tumor
necrosi
factor
alpha
tnf
estim
result
cl
max
f
mlp
stimul
without
preactiv
significantli
lower
group
ii
group
iii
p
p
respect
cl
max
oz
stimul
significantli
higher
group
comparison
group
ii
p
tend
higher
group
group
iii
cl
max
pma
stimul
lower
group
compar
group
iii
p
cl
total
fmlp
stimul
lower
group
ii
p
compar
group
tend
lower
group
ii
compar
group
iii
cl
total
oz
stimul
significantli
higher
group
group
ii
p
group
iii
p
cl
max
cl
total
oz
stimul
preactiv
tnfa
significantli
lower
group
compar
group
iii
p
p
respect
sum
cours
chronic
hepat
c
children
neutrophil
preactiv
inhibit
neutrophil
releas
reactiv
oxygen
speci
occur
result
differ
mechan
observ
one
year
combin
treatment
ribavirin
intron
children
chronic
hepat
c
wozniakowskagesicka
j
kup
wisniewskaligi
lodz
pl
aim
studi
assess
effect
therapi
ifna
ribavirin
children
chronic
hepat
c
materi
method
studi
compris
children
treat
intron
administ
subcutan
dose
mu
three
time
week
ribavirin
oral
mgkg
bodi
weight
daili
forth
period
month
cours
treatment
alt
activ
haemoglobin
leucocyt
thrombocyt
determin
hcvrna
serum
perform
begin
month
therapi
result
month
combin
treatment
ifnalpha
ribavirin
elimin
hcvrna
normalis
alt
activ
observ
children
children
normalis
alt
activ
without
elimin
hcvrna
observ
six
children
respond
combin
therapi
lower
mean
activ
alt
begin
treatment
observ
children
fulli
respond
combin
therapi
compar
respond
treatment
follow
side
effect
found
treat
children
fever
headach
abdomin
pain
loss
appetit
hair
loss
myalgia
hypersomnia
children
transient
leucopenia
thrombocytopenia
anaemia
detect
conclus
full
respons
combin
therapi
hcv
rna
elimin
alt
normalis
obtain
treat
children
numer
side
effect
observ
cours
combin
therapi
caus
interrupt
treatment
object
human
herpesviru
etiolog
agent
kaposi
sarcoma
associ
diseas
primari
effus
lymphoma
castleman
diseas
bone
marrow
failur
oral
caviti
plasmablast
lymphoma
pbl
hiv
epsteinbarr
viru
ebv
known
cofactor
aidsrel
lymphoma
report
case
hiv
male
present
two
relat
neoplasm
colon
pbl
sigmoid
kaposi
sarcoma
knowledg
first
case
colon
pbl
literatur
well
first
case
two
malign
associ
case
male
histori
liquid
diarrhoea
fever
malais
known
hiv
year
previous
receiv
haart
physic
examin
normal
except
facial
lipoatrophi
small
cervic
lymphoadenopathi
cm
hemoglobin
gdl
wbc
platelet
esr
mmh
creatinin
mgdl
got
ul
gpt
ul
ldh
ul
mcgml
crp
mgdl
viral
load
copiesml
pcr
ebv
cerebrospin
fluid
posit
colonoscopi
show
purplish
lesion
sigmoid
colon
ulcer
mass
caecum
biopsi
first
one
inform
kaposi
sarcoma
second
one
pbl
bone
marrow
biopsi
show
lymphomat
infiltr
lopinavirritonavir
start
well
chop
chemotherapi
latter
stop
third
cours
due
progress
deterior
patient
develop
palsi
iii
vii
cranial
nerv
opportunist
infect
rule
spinal
tap
reveal
lymphomat
mening
involv
die
month
initi
referr
conclus
involv
pathogenesi
malign
kaposi
sarcoma
pbl
nevertheless
neither
associ
peculiar
local
pbl
right
colon
describ
extraor
site
found
nose
lung
mediastinum
stomach
testicl
bone
anorectum
diagnost
procedur
regard
infect
routin
perform
repeat
detect
describ
increas
risk
activ
kaposi
sarcoma
hypothes
extraor
pbl
might
also
relat
cofactor
similar
ebv
suggest
better
understand
mechan
infect
could
provid
prevent
treatment
strategi
prevent
treatment
neonat
herpesvirus
infect
bartosova
brno
cz
object
report
author
present
clinic
pictur
cours
therapi
use
infant
congenit
vzv
infect
infant
congenit
herp
simplex
infect
infant
cmv
infect
hospitalis
depart
paediatr
infecti
diseas
brno
within
januari
method
diagnosi
congenit
hsv
vzv
cmv
infect
establish
partli
clinic
base
typic
symptom
congenit
acquir
diseas
part
infant
even
person
anamnesi
mother
diseas
pregnanc
especi
verifi
isol
virus
skin
lesion
urin
occasion
cerebrospin
fluid
detect
vzv
hsv
cmv
dna
csf
blood
surfac
specimen
andor
detect
viral
antigen
mean
serolog
examin
result
death
hsv
vzv
studi
group
set
newborn
confirm
congenit
cmv
infect
perman
neurolog
consequ
involv
motor
psychomotor
problem
five
suffer
sensor
affect
disturb
loss
hear
strabism
conclus
earli
diagnosi
manag
congenit
perinat
infecti
neonat
import
depend
clinic
recognit
condit
unfortun
earli
diagnosi
problemat
mani
condit
nonspecif
manifest
matern
infect
asymptomat
repeat
serolog
screen
susceptibil
seroneg
women
would
requir
throughout
pregnanc
difficulti
exemplifi
neonat
herp
infect
earli
diagnos
treatment
essenti
prevent
possibl
advers
consequ
earli
initi
therapi
outmost
import
everi
case
herpesvirus
infect
treat
soon
possibl
antivir
therapi
dramat
improv
surviv
rate
object
experiment
herp
simplex
viru
type
infect
mice
parallel
occur
human
primari
infect
viral
replic
surfac
mucos
detect
period
within
h
post
infect
pi
hsv
infect
common
produc
primari
infect
also
latent
recurr
infect
follow
primari
infect
herp
simplex
viru
viru
gain
access
termini
sensori
neuron
transport
retrograd
direct
neuron
cell
bodi
sensori
ganglia
replic
spread
neuron
establish
lifelong
latent
infect
portion
neuron
method
studi
use
pcr
analysi
detect
latenc
inocul
balbc
mice
thirti
five
forti
day
intraocular
io
intraperiton
ip
challeng
differ
group
surviv
mice
euthan
trigemin
ganglia
tg
harvest
mous
tg
individu
homogen
cell
pellet
use
detect
viral
dna
pcr
analysi
tg
pellet
wash
pb
suspend
trisedta
contain
sd
protienas
k
incub
h
viral
dna
extract
pcr
perform
use
two
primer
thimidin
kinas
gene
gener
bp
product
result
show
rate
viru
latenc
io
infect
mice
significantli
higher
ip
infect
mice
conclus
primari
hsv
infect
branch
ophthalm
maxillari
mandibular
cranial
nerv
v
lead
latent
infect
nerv
cell
trigemin
ganglion
io
challeng
per
cent
latenc
comparison
ip
challeng
clinic
microbiolog
infect
volum
supplement
method
examin
hospit
patient
suspect
hcmv
infect
children
adult
blood
donor
control
group
hcmv
antigen
blood
leukocyt
detect
specif
igm
igg
antibodi
sera
wera
determin
df
eia
respect
number
blood
leukocyt
result
activ
hcmv
infect
diagnos
adult
children
antigen
detect
control
group
antigenaemia
found
case
igm
antibodi
posit
patient
igg
antibodi
posit
children
found
seroconvers
igg
control
group
igm
antibodi
neg
igg
antibodi
found
posit
children
activ
hcmv
infect
mononucleosislik
syndrom
acut
febril
infect
adult
respect
patient
mononucleosislik
syndrom
acut
febril
infect
undergo
immunosuppress
therapi
specif
sensit
antigenaemia
assay
diagnosi
activ
infect
respect
conclus
studi
antigen
assay
seem
simpl
rapid
inexpens
test
earli
diagnosi
activ
hcmv
infect
identif
two
major
human
cytomegaloviru
gb
genotyp
taiwan
object
genotyp
prefer
human
cytomegaloviru
hcmv
found
certain
geograph
area
determin
predomin
cmv
genotyp
taiwan
island
locat
southeastern
asia
perform
studi
method
use
restrict
fragment
length
polymorph
rflp
analysi
determin
subtyp
hcmv
gb
gene
encod
viral
membran
glycoprotein
total
clinic
hcmv
isol
collect
islandwid
test
determin
genotyp
result
found
two
major
cmv
gb
genotyp
paediatr
patient
mix
gb
type
unknown
type
none
belong
gb
type
reason
result
signific
differ
gb
genotyp
prefer
unclear
conclus
two
major
hcmv
gb
genotyp
gb
thpe
found
rflp
may
serv
conveni
method
genotyp
analysi
cmv
clinic
isol
igg
respons
herp
simplex
viru
type
gg
gd
recombin
protein
among
adult
children
object
recent
studi
shown
glycoprotein
glycoprotein
g
high
potenti
diagnost
reagent
reliabl
detect
typespecif
igg
purpos
studi
evalu
specif
igg
respons
among
child
adult
popul
investig
proteinspecif
pattern
low
avid
igg
reactiv
method
total
serum
sampl
adult
normal
blood
donor
serum
sampl
children
age
rang
yearsold
analys
typespecif
igg
enzym
immunoassay
russia
base
recombin
hsv
aa
protein
igg
posit
sampl
addit
test
presenc
igg
anti
anti
individu
determin
igg
avid
perform
urea
dissoci
agent
result
serum
sampl
normal
blood
donor
adult
serum
sampl
children
posit
antibodi
eia
proteinspecif
distribut
igg
activ
significantli
differ
term
igg
level
igg
avid
two
investig
group
tabl
tabl
conclus
specif
igg
respons
hsv
differ
among
variou
age
group
frequenc
lowavid
antibodi
children
significantli
exce
frequenc
lowavid
antibodi
adult
furthermor
lowavid
anti
found
predomin
children
lowavid
anti
adultsserolog
assay
base
protein
potenti
fals
neg
result
may
especi
import
primari
infect
detect
qualit
dna
pcr
earli
detect
symptomat
cmv
infect
renal
transplant
v
kanapeckien
r
valintelien
vilniu
lt
object
one
perspect
method
cmv
infect
diagnost
detect
viral
dna
polymeras
chain
reaction
pcr
actual
earli
differenti
diagnost
aris
acut
reject
crisi
cmv
clinic
syndrom
transplant
treatment
strategi
clinic
syndrom
differ
crisi
acut
reject
immunosuppress
treatment
intensifi
onset
cmv
clinic
syndromeminimis
addit
administr
specif
antivir
treatment
method
carri
prospect
laboratoryclin
studi
patient
renal
transplant
durat
month
blood
sampl
cmv
serolog
test
collect
everi
day
retrospect
way
test
dna
pcr
select
kidney
recipi
manifest
clinic
symptom
first
month
follow
transplant
repeat
serolog
test
elisa
indirect
immunofluoresc
patient
manifest
clinic
symptom
found
diagnost
increas
antibodi
titr
indic
activ
cmv
infect
cmv
clinic
syndrom
manifest
self
fever
typic
clinic
sign
determin
person
case
cmv
infect
asymptomat
posit
pcr
test
obtain
recipi
symptomat
cmv
infect
asymptomat
infect
neg
pcr
test
obtain
patient
asymptomat
infect
clinic
manifest
cmv
infect
thu
use
qualit
pcr
method
posit
neg
result
obtain
without
estim
amount
viral
nucleic
acid
symptomat
cmv
infect
earli
onset
may
identifi
case
sensit
method
though
posit
result
also
obtain
case
asymptomat
cmv
infect
therefor
specif
method
low
conclus
posit
prognost
valu
pcr
test
seek
earli
detect
symptomat
cmv
infect
requir
appropri
treatment
low
somewhat
valuabl
neg
prognost
valu
pcr
testin
presenc
neg
result
case
clinic
manifest
cmv
infect
case
specif
antivir
treatment
need
method
case
patient
admit
tertiari
care
hospit
ill
consist
cchf
posit
igm
rtpcr
test
result
two
control
per
case
select
randomli
among
live
villag
experienc
similar
ill
last
year
potenti
confound
paramet
age
year
gender
control
questionnair
fill
home
visit
region
blood
sampl
obtain
serolog
screen
specif
igg
igm
antibodiesstatist
analysi
perform
softwar
ncss
number
cruncher
statist
system
ver
dichotom
variabl
compar
chisquar
fisher
exact
test
applic
statist
comparison
alway
two
tail
result
total
case
reachabl
accordingli
control
select
among
risk
factor
compar
exposur
unset
signific
ci
case
experienc
tick
bite
mostli
describ
domest
anim
rural
area
villag
tick
exposur
data
shown
serolog
screen
case
control
signific
well
comparison
demograph
characterist
age
gender
shown
tabl
discuss
studi
demonstr
tick
bite
singl
signific
risk
factor
respons
outbreak
anim
keep
buy
sell
widespread
region
domest
anim
could
sourc
tick
exposur
howev
case
describ
certain
area
villag
thick
exposur
well
one
import
point
case
mostli
scatter
except
exampl
mostli
differ
hous
live
stock
sourc
infect
tick
would
found
cluster
hous
signific
differ
serolog
survey
case
control
support
view
well
studi
word
indic
rural
area
heavi
tick
infest
must
like
sourc
outbreak
howev
studi
region
warrant
explor
sourc
outbreak
eventu
control
high
preval
helicobact
pylori
infect
tunisia
refer
hospit
laboratori
blood
test
ask
repli
questionnair
give
blood
sampl
test
measur
antihp
antibodi
antihp
eia
quant
coba
core
ii
roch
asymptomat
volunt
blood
donor
avbd
also
includ
mean
age
yr
result
patient
includ
male
mean
age
yr
extr
patient
averag
social
stand
complain
dyspepsia
report
symptom
dyspepsia
householdth
seropreval
hp
antibodi
young
children
yr
older
children
yr
patient
yr
age
patient
older
yr
seropreval
compar
avbd
except
age
factor
gender
origin
social
stand
dyspept
symptom
influenc
hp
infect
seropreval
conclus
seropreval
hp
infect
high
mainli
asymptomat
popul
infect
increas
childhood
adolesc
reach
adult
high
preval
rais
question
whether
continu
systemat
look
hp
infect
patient
upper
gastroenterolog
disord
case
acut
melioidosi
travel
burkkolderia
pseudomallei
caus
agent
melioidosi
potenti
biolog
weapon
anthropozoonosi
endem
region
southeast
asia
northern
australia
sporad
europ
bacteraemia
melioidosi
associ
high
mortalityw
report
case
acut
melioidosi
travel
man
admit
hospit
fever
asthenia
vomit
recent
travel
bangladesh
vietnam
document
noninsulinodepend
diabet
clinic
examin
present
fever
abdomin
pain
diagnost
malaria
exclud
laboratori
investig
ct
abdomin
scan
show
hepat
splenic
abscess
diagnosi
viscer
amebiasi
discuss
although
ameb
serolog
neg
four
bloodcultur
bottl
one
aerob
bottl
posit
gramneg
bacilli
identifi
burkholderia
cepacia
vitek
good
identif
tindex
regard
doubt
diagnosi
viscer
amebiasi
unusu
suscept
isol
imipenem
new
identif
made
rnar
sequenc
identifi
burkholderia
pseudomallei
appropri
antimicrobi
treatment
prescrib
total
durat
week
ceftazidim
iv
associ
trimethoprimsulfamethoxazoldoxycyclin
clinic
outcom
favorablethi
case
emphas
possibl
misidentif
burkholderia
pseudomallei
laboratori
unfamiliar
microorgan
import
acut
diagnosi
melioidosi
treat
correctli
sever
diseas
prevent
relaps
necess
consid
diagnosi
melioidosi
travel
acut
gastroenter
caus
aeromona
jandaei
import
identif
speci
level
e
durnova
andelova
porazilova
j
kulhavi
sedlacek
ostrava
brno
cz
object
aeromonad
recent
account
new
emerg
pathogen
caus
wound
infect
septicaemia
well
gastroenter
epidemiolog
known
much
late
describ
speci
still
appear
accord
experi
identif
clinic
isol
mesophil
aeromonad
hydrophila
cavia
sobria
complex
longer
accur
proper
identif
system
even
socal
rare
speci
occur
clinic
sampl
method
isol
aeromonad
origin
mostli
stool
sampl
biochem
identif
done
plivalachema
result
assum
softwar
tnw
oxidas
posit
ferment
rod
cellular
fatti
acid
analysi
perform
mi
sherlock
midi
inc
usa
result
genu
specif
test
resist
vibriostat
agent
lg
growth
broth
cultur
addit
nacl
confirm
ensur
good
distinct
genera
vibrio
aeromona
combin
tnw
softwar
use
identif
common
aeromonad
nevertheless
due
perman
chang
taxonomi
supplementari
convent
biochem
test
recommend
routin
speci
identif
aeromona
isol
biochem
test
fatti
acid
analysi
prove
presenc
speci
complex
hydrophila
hydrophila
bestiarum
cavia
cavia
eucrenophila
media
sobria
veronii
sobria
besid
common
one
notic
also
aeromona
jandaei
isol
stool
sampl
diagnosi
acut
gastroenter
evid
vomit
wateri
dirrhoea
isol
identifi
excel
index
id
comparison
cellular
fatti
acid
profil
confirm
identif
major
also
minor
fatti
acid
jandaei
ccm
alcohol
alcohol
methyl
present
isol
conclus
enough
aeromonad
clinic
sampl
also
less
frequent
aeromona
speci
occur
region
use
appropri
identif
system
easili
warn
microbiologist
rare
speci
proper
identif
isol
provid
us
inform
whether
describ
mesophil
aeromona
speci
involv
diarrhoeal
diseaseour
project
support
iga
ministri
health
czech
republ
idcod
qfever
febril
ill
pneumonia
rural
town
balkan
tiholova
g
kamenov
sofia
bg
object
spring
increas
note
inpati
acut
fever
pneumonia
small
rural
town
balcan
diagnosi
q
fever
establish
epidem
limit
outbreak
cohort
specif
antibodi
titr
phase
ii
cburnetii
antigen
confirm
recent
infect
object
studi
establish
clinic
epidemiolog
laboratori
paramet
q
fever
part
bulgaria
draw
conclus
concern
earli
diagnosi
treatment
prevent
infect
endem
region
method
establish
diagnosi
qfever
patient
complet
physic
examin
epidemiolog
data
collect
atyp
pneumonia
document
seroconvert
consid
patient
demonstr
titr
antibodi
igg
igm
phase
ii
cburnetii
result
seroposit
case
present
acut
selflimit
ill
atyp
pneumonia
common
clinic
symptom
found
appropri
antibiot
regiment
indic
conclus
appar
reason
outbreak
inhal
infect
aerosol
larg
number
infect
domest
anim
town
may
caus
charact
fluelik
ill
pneumonia
may
impli
point
sourc
earli
diagnosi
q
fever
risk
region
help
epidemiolog
data
morbid
due
influenzalik
ill
atyp
pneumonia
condit
physician
must
treat
appropri
antibiot
serolog
confirm
diagnosi
q
fever
public
health
veterinari
municip
author
must
work
togeth
educ
popul
basic
principl
q
fever
prevent
includ
restrict
contact
peopl
cattl
improv
infect
control
place
anim
bred
discuss
appar
reason
outbreak
atyp
pneumonia
due
c
burnetii
inhal
infect
aerosolsth
larg
number
infect
domest
anim
town
may
caus
earli
diagnosi
q
fever
risk
region
help
epidemiolog
data
morbid
due
influenzalik
ill
atyp
pneumonia
condit
physician
must
treat
appropri
antibiot
serolog
confirm
diagnosi
q
fever
capsular
polysaccharid
neisseria
meningitid
group
c
induc
protect
bactericid
antibodi
human
use
vaccin
almost
two
decad
contrast
group
b
capsular
polysaccharid
vaccin
proven
essenti
nonimmunogen
reason
serogroup
b
present
major
caus
meningococc
diseas
develop
countri
combin
lack
immunogen
b
polysaccharid
necessit
develop
altern
vaccin
base
upon
outer
membran
protein
lipooligosaccharid
major
surfac
compon
outer
membran
porin
pora
class
protein
nowaday
consid
potenti
vaccin
candid
sergroup
b
n
menigitidi
strain
csbpi
obtain
collect
standard
bacteria
pasteur
institut
iran
farther
investig
cultiv
medium
meningococci
medium
accord
frantz
main
compot
lglutam
acid
lcystein
glucos
yeast
extract
cell
cultiv
membran
vesiclecontain
pora
prepar
purifi
accord
deoxychol
ultracentrifugedifferenti
techniqu
dudt
ferment
grown
bacteria
briefli
n
meningitid
csbpi
cultiv
frantz
medium
supplement
yeast
extract
dialys
l
ferment
contactflow
bv
bilthoven
unit
system
earli
stationari
phase
omvpora
extract
trisbuff
edta
wv
deoxychol
purif
done
sequenti
centrifug
step
g
min
follow
ultracentrifug
g
h
pellet
omvpora
homogen
pb
omvpora
ultrason
treat
dispers
vesicl
attach
formvarcarbon
coat
nickel
grid
prepar
step
grid
examin
ziss
cem
electron
microscop
neg
contrast
stain
electron
microscopi
size
omvproa
rang
nm
intact
vesicl
prepar
rang
vesicleprotein
concentr
measur
accord
method
lowri
et
al
sampl
analys
poli
acrylamid
gel
presenc
wv
sd
electrophoresi
protein
stain
wv
coomassi
brilliant
blue
stain
rel
amount
omvpora
determin
result
lowri
method
mg
protein
per
ml
sampl
analys
sdspage
separ
mw
calcul
immunolog
pseudomona
aeruginosa
strain
isol
patient
admit
four
tehran
hospit
use
standard
ospecif
type
sera
group
serotyp
known
pseudomona
aeruginosa
serotyp
lyophil
given
code
accord
collect
standard
bacteria
pasteur
institut
iran
csbpi
farther
investig
among
clinic
sampl
csbpi
preval
pseudomona
aeruginosa
serotyp
show
high
agglutin
titr
homolog
ospecif
type
sera
serotyp
select
extract
pseudomona
aeruginosa
major
outer
membran
vesicl
ompf
ompf
vesicl
extract
purifi
accord
deoxychol
ultracentrifugedifferenti
techniqu
puriti
molecular
weight
ompf
determin
sdspage
abil
ompf
vesicl
induc
high
titr
antibodi
rabbit
shown
sharp
antibodyantigen
precipit
line
gel
doubl
diffus
test
passiv
immun
mice
antirabbit
ompf
antisera
induc
high
level
protect
mice
postchalleng
live
pseudomona
aeruginosa
csbpi
besid
activ
immun
mice
lg
ompf
could
protect
mice
live
homolog
protect
heterolog
nativ
iranian
pseudomona
aeruginosa
serotyp
level
protect
ompf
pyrogenfre
rabbit
pyrogen
test
produc
detect
abnorm
toxic
mice
guinea
pig
moreov
ompf
show
skin
sensit
lg
inject
intradermallyth
investig
indic
purifi
ompf
csbpi
regard
safe
protect
immunogen
vaccinothrapi
pseudomona
aeruginosa
immunotyp
isol
iran
express
purif
herp
simplex
viru
type
glycoprotein
insect
cell
use
baculoviru
express
system
object
herp
simplex
viru
type
infect
mucocutan
caus
genit
infect
human
follow
establish
latent
infect
sensori
ganglia
reactiv
life
need
effect
vaccin
remain
prefer
strategi
control
infect
glycoprotein
gd
hsv
focus
subunit
vaccin
due
primari
role
induc
cellular
humor
immun
respons
herp
infect
studi
gd
express
insect
cell
use
bactobac
baculoviru
express
system
order
appli
subunit
vaccin
anim
model
method
gd
iranian
isol
amplifi
pcr
clone
pfastbac
plasmid
recombin
plasmid
transform
e
coli
cell
contain
bacmid
baculoviru
shuttl
vector
sitespecif
transposit
gene
recombin
bacmid
confirm
pcr
transfect
cell
cultur
serumfre
grace
medium
monitor
daili
observ
cytopath
effect
h
baculoviru
harvest
cell
cultur
medium
viral
stock
amplifi
reinfect
insect
cell
titrat
pfu
cell
infect
incub
ordm
c
variou
time
express
recombin
protein
interest
cell
pellet
centrifug
lyse
subject
sdspage
purif
gel
analys
western
blot
use
monoclon
antibodi
result
gd
gene
clone
confirm
sequenc
protein
product
insect
cell
shown
western
blot
analysi
result
reveal
glycosyl
nonglycosyl
form
express
insect
cell
cellassoci
protein
hour
post
infect
conclus
baculoviru
express
system
provid
correct
fold
recombin
protein
well
disulfid
bond
format
oligomer
import
posttransl
modif
consequ
express
protein
exhibit
proper
biolog
activ
function
pure
use
subunit
vaccin
anim
model
seropreval
rubella
antibodi
among
young
popul
tehran
iran
h
soleimanjahi
bamdad
f
fotouhi
chahooki
roostae
sd
siadat
tehran
ir
object
congenit
rubella
prevent
diseas
larg
control
immun
aim
studi
examin
preval
antibodi
rubella
iran
largest
mass
campaign
measl
rubella
mr
vaccin
peopl
age
rang
yearsold
method
total
serum
sampl
vaccin
collect
assay
use
hemagglutin
inhibit
test
hit
hit
consid
reliabl
index
immun
level
rv
infect
result
data
reveal
target
popul
becom
seroposit
vaccin
rubella
antibodi
mr
vaccin
conclus
rubella
infecti
viral
diseas
endem
iran
detail
epidemiolog
studi
still
need
perform
nation
immun
programm
base
result
rubella
viru
circul
among
popul
iran
recommend
select
vaccin
girl
near
age
marriag
object
one
method
approach
chronic
hepat
b
treatment
activ
tcell
immun
purpos
therapeut
vaccin
contain
hbcag
use
liveattenu
salmonella
abl
deliv
hbcag
encod
prokaryot
express
plasmid
hbcag
encod
eukaryot
express
plasmid
therefor
mention
two
type
recombin
salmonella
strain
examin
experi
mice
cell
cultur
human
monocyt
vitro
method
attenu
cya
lack
adenylatecyclas
suppressor
crp
mutant
salmonella
enteritidi
use
vechicl
hbcag
encod
prokaryot
express
plasmid
pkhbc
vector
vaccin
hbcag
encod
eukaryot
express
plasmid
dnavaccin
carri
salmonella
mice
inocul
per
rectum
suppositori
contain
cell
examin
salmonella
strain
salmonella
multipl
payer
patch
spleen
liver
lung
determin
titr
specif
anti
hbcag
antibodi
examin
cultur
human
monocyt
vitro
use
examin
interact
salmonella
strain
phagocyt
result
strain
possess
abil
multipli
payer
patch
day
contrast
salmonella
strain
strain
carri
dnavaccin
salmonella
possess
abil
multipli
parenter
lymphoid
tissu
also
induc
product
specif
anti
hbcag
antibodi
examin
interact
salmonella
strain
cultur
human
monocyt
vitro
shown
strain
free
hbcag
synthesi
possess
abil
multipli
phagocyt
object
studi
aim
evalu
anti
aureu
humor
respons
patient
treat
autovaccin
prepar
kill
aureu
strain
isol
patient
studi
perform
strain
aureu
isol
patient
chronic
inflammatori
process
throat
andor
skin
demonstr
staphylococc
aetiolog
surfac
protein
isol
laemmli
buffer
electrophoret
separ
sdspage
stain
coomassi
blue
transfer
onto
nitrocellulos
membran
immunoblot
patient
sera
obtain
two
time
point
ie
appli
autovaccin
antigen
antibodi
reaction
visual
employ
alkalin
phosphatas
method
protein
profil
individu
aureu
strain
immunoblot
result
analys
use
geldok
softwar
syngen
biotech
result
use
westernimmunoblot
igg
lass
antibodi
fund
react
aureu
surfac
protein
kda
molecular
weight
igm
class
antibodi
react
protein
molecular
weight
kda
studi
autovaccin
igm
antibodi
detect
direct
toward
individu
polypeptid
patient
igm
class
antibodi
could
detect
remain
patient
subsequ
time
point
studi
administr
autovaccin
patient
igm
class
immun
respons
found
resembl
document
remain
previous
neg
patient
time
carri
igm
antibodi
specif
toward
individu
polypeptid
far
igg
class
humor
reaction
concern
respons
compar
two
time
point
studi
obtain
result
suggest
therapeut
effect
aureu
autovaccin
relat
respect
humor
respons
clinic
microbiolog
infect
volum
supplement
infect
restrict
march
januari
ad
show
signific
correl
cilamat
factorsmal
affect
femal
infect
associ
lower
age
group
less
year
croup
laryngotracheobronch
associ
bronchiol
rsv
bronchopneumonia
pharyng
tonsil
mostli
associ
ad
infect
accord
clinic
radiolog
find
rsv
infect
distinguish
clinic
ad
infect
higher
rate
hypoxemia
retract
tachypnoea
hyperinfl
interstiti
ad
infect
distinguish
basi
conclus
studi
demonstr
prevel
three
oth
major
respiratori
virus
infect
jordanian
children
age
year
caus
hospitalz
studi
state
seasonabilti
repiratoy
virus
associt
ill
well
major
clinic
manifest
associ
viru
knowledg
local
climat
factor
togeth
characterst
pattern
virus
may
help
predict
begin
end
epidem
thu
also
help
planninig
prevent
programm
tubercul
mening
suckl
result
identifi
medium
new
case
children
per
year
compar
adult
boy
group
age
month
onset
incidi
mening
syndrom
case
conscienc
troubl
case
csf
clear
case
high
valu
protein
low
valu
glucos
chloru
tuberculosi
isol
cultur
case
directli
exam
therapi
quadrupl
associ
antitubercul
drug
favour
evolut
case
death
record
factor
bad
prognos
still
remain
littl
age
hydrocephalu
case
malnutrit
case
coma
begin
case
conclus
tubercul
mening
still
remain
diseas
high
incid
sever
evolut
suckl
despit
progress
diagnost
method
therapi
clinic
cours
urinari
tract
infect
earli
infanc
